CURRICULUM VITAE John Francis Greden, M.D.

Personal Data John F. Greden, M.D. Rachel Upjohn Professor of Psychiatry and Clinical Neurosciences Research Professor, Molecular and Behavioral Neuroscience Institute Founder and Executive Director, University of Michigan Depression Center Founding Chair, National Network of Depression Centers (NNDC) University of Michigan Medical Center Rachel Upjohn Building 4250 Plymouth Road Ann Arbor, Michigan 48109-2700 (734) 763-9629 [email protected]

Education 09/56-06/60 Rollingstone High School, Rollingstone, Minnesota 09/60-06/63 St. Mary's University of Minnesota, Winona, Minnesota (transferred to University of Minnesota) 09/63-06/67 University of Minnesota Medical School, Minneapolis (Undergraduate - Medical Science Program, B.S., 1965, M.D., 1967)

Postdoctoral Training and Military 06/67-06/68 Medicine-Pediatrics Internship, Harbor/UCLA Medical Center, 1000 West Carson Street, Torrance, California 06/68-06/69 First Year Psychiatry Residency, University of Minnesota Hospitals, Minneapolis, Minnesota (Interrupted by Military Physicians’ draft after one-year of Berry Plan deferment) 07/69-06/70 Assistant Chief, Psychiatry Out-Patient Clinic, Fort Lee, Virginia (U.S. Army) 06/70-06/72 Second and Third Year Psychiatry Residency, Department of Psychiatry, Walter Reed Army Medical Center, Washington, D.C. 06/72-06/73 Associate Director of Psychiatric Research, Department of Psychiatry, Walter Reed Army Medical Center, Washington,D.C. 06/73-06/74 Director of Psychiatric Research and Chief, Officers’ Psychiatry Inpatient Service, Department of Psychiatry, Walter Reed Army Medical Center, Washington, D.C.

Academic Appointments, University of Michigan 07/74-09/77 Assistant Professor of Psychiatry, Medical School and Chief, Acute Psychiatry Inpatient Program 1976 Acting Chief of Adult Services, Department of Psychiatry 07/76-07/77 Director, Clinical Studies Unit Inpatient Program & Interim Director, Residency Education 07/77-7/80 Director, Clinical Studies Unit for Affective Disorders Inpatient Program; Scientific Associate, Mental Health Research Institute 07/77-09/80 Associate Professor of Psychiatry, Department of Psychiatry 07/78-07/80 Director, Neural and Behavioral Sciences (NBS), Medical School 07/80-07/85 Director, Clinical Studies Unit for Affective Disorders (CSU) 09/80-Present Professor of Psychiatry, Department of Psychiatry 03/85-09/07 Chair, Department of Psychiatry

John F. Greden, M.D. Page 1 Last Revised December 2019

09/85-09/03 Senior Research Scientist, Molecular and Behavioral Neurosciences Institute (formerly Mental Health Research Institute) 09/03-Present Research Professor, Molecular and Behavioral Neurosciences Institute 09/97-Present Rachel Upjohn Professor of Psychiatry and Clinical Neurosciences 09/99-Present Founder and Executive Director, University of Michigan Comprehensive Depression Center

Academic Society Honors, Awards, Editorial Positions 1990 President, Psychiatric Research Society 1991 President, Society of Biological Psychiatry 1993-2000 Co-Editor-in-Chief, Journal of Psychiatric Research 1998-2000 Senior Administrative Editor, Scientific Publications, American College of Neuropsychopharmacology (ACNP) 1998-2000 Chair, Committee on Research Training, Council on Research, American Psychiatric Association 1998 Society of Biological Psychiatry, George N. Thompson Award 2000-2005 Chair, Council on Research, American Psychiatric Association 2001-2004 Council Member, American College of Neuropsychopharmacology (ACNP) 2002-2004 President-Elect, American Association of Chairs of Departments of Psychiatry 2004 Society of Biological Psychiatry, Contributions Committee, and Travel Award Selection Committee 2005 Special Presidential Commendation, American Psychiatric Association 2005 Distinguished Life Fellow, American Psychiatric Association 2004-2006 President, American Association of Chairs of Departments of Psychiatry 2004-2006 Chair, National Psychiatry Training Council (NIMH Council, formed to respond to IOM Task Force to develop strategies to address the shortage of Academic Psychiatrists) 2008-Present Editorial Board Member, Current Psychiatry Reports 2007-Present Founder and Chair, National Network of Depression Centers 2009-2012 Council on Communications member American Psychiatric Association 2011-2015 Carter Center/ACP Integration work group – member 2012-Present Scientific Review Board, American Foundation for Suicide Prevention (AFSP) 2012-Present Board of Directors, American Foundation for Suicide Prevention (AFSP) 2013-Present Advisory Board, Psychiatric Research Society 2011-2014 President, Board of Directors, American Foundation for Suicide Prevention (AFSP) 2014 Special Issue Editor, Current Psychiatric Reports, Depressions and Bipolar Illnesses, 8 articles 2015-2016 Board of Directors, Project 375 Foundation 2015-Present Advisory Board, Le Royal Psychiatric Institute, Ottawa, Canada

Other Honors and Awards 1960 Valedictorian, Rollingstone High School, Rollingstone, MN 1962 Beta Beta Beta, National Honor Biological Society, St. Mary's College, Winona, MN 1967 Alpha Omega Alpha (AOA), National Honor Medical Society, University of Minnesota Medical School, Minneapolis MN 1971-1972 Chief Resident, Department of Psychiatry, Walter Reed General Hospital 1974 A.E. Bennett Central Neuropsychiatric Foundation Research Award 1976 Outstanding Teacher of the Year Award, University of Michigan Medical School 1977-1979 Faculty Honorary, Galens Medical Society, University of Michigan Medical Center 1978-1979 Faculty Prefect, Galens Medical Society, University of Michigan Medical Center 1980 Ralph Patterson Memorial Award, Ohio State University, Department of Psychiatry 1980-1982 Faculty Honorary, Galens Medical Society, University of Michigan Medical Center John F. Greden, M.D. Page 2 Last Revised December 2019

1982 Nolan D.C. Lewis Visiting Scholar Award, Carrier Foundation, Belle Meade, New Jersey 1983 Outstanding Teacher of the Year Award, Department of Psychiatry, University of Michigan 1994 Best Mental Health Experts, Good Housekeeping Magazine 1997 NAMI Exemplary Psychiatrist Award 1998-Present Best Doctors in America 2001 MIRA (Mental Illness Research Association) Milestone Award 2005 Distinguished Alumnus Award of the University of Minnesota Medical School, one award annually 2011 Advancements in Health Care Award, Crain’s Health Care Heroes 2011 2012 Gerald L. Klerman Senior Investigator Award, Depression and Bipolar Support Alliance (DBSA) 2013 James T. Neubacher Award – highest honor of UM’s Council for Disability Concerns 2016 National Network of Depression Centers Building Bridges Award 2016 Special Commendation for Achievements in Mental Health from Michigan Governor Rick Snyder 2019 American Association for the Advancement of Science Fellow

Other Scientific Activities, Societies Scientific Referee Science; Archives of General Psychiatry; JAMA-Psychiatry; American Journal of Psychiatry; Psychosomatic Medicine; JAMA; Psychiatry Research; Biological Psychiatry; Psychoneuroendocrinology; Psychosomatics; Convulsive Therapy; Journal of Psychiatric Research; Life Sciences; Neuropsychopharmacology; Journal of Affective Disorders; Academic Psychiatry; Current Psychiatry Reports; Journal of Clinical Psychiatry

Editorial Boards 1986-1991 Convulsive Therapy 1992-1994 Biological Psychiatry 1998-2014 Current Psychiatry Reports 1998-1999 Neuropsychopharmacology: Fourth Generation of Progress CD-ROM Edition 2013-2014 Special Editor; Current Psychiatry Reports, Depression and Bipolar Illnesses, 8 Articles

Book Series Biological Psychiatry Hormones, Brain and Neuropsychopharmacology 1998-2004 American Psychiatric Publishing, Inc. (APPI) 2003-2004 Mind and Body 2006-Present Clinical Neuropharmacology 2008-2009 Neuropsychiatric Disorders: Faculty of 1000 Medicine 2011-Present Depression and Anxiety 2019 Springer Book Series – Invitation Pending

Consulting and Grant Review Positions 1977-1981 Research Consultant, Veterans Administration Hospital, Ann Arbor, Michigan 1980-1982 Technical Advisory Research Council, Michigan Department of Mental Health Chairman (1982- 1983) 1982-1984 Merit Review Board for Mental Health and Behavioral Sciences Study Section: Veterans Administration, Washington, D.C. 1983-1986 NIMH Study Section, Ad Hoc Member and Site Visitor, Psychopharmacological,Biological, and Physical Treatments Subcommittee (TDAB), Washington D.C. 1986-1989 NIMH Study Section, Member, Psychopharmacological, Biological,and Physician Treatments Subcommittee (TDAB), Washington, D.C. 1989-1991 Consultant, Department of Psychiatry, Beaumont Hospital, Royal Oak, Michigan John F. Greden, M.D. Page 3 Last Revised December 2019

1988-2008 Scientific Advisory Board, Eli Lilly and Company 1991-1994 Scientific Advisory Board, Abbott Laboratories 1993-1995 Scientific Advisory Board, Smith Kline Beecham 1995-1998 External Oversight Committee, UCSD Mental Health Clinical Research Center, San Diego, California 1995 Johnson and Johnson, New Brunswick, New Jersey 1997-2008 Psychiatry Advisory Council, Pfizer Corporation 1998 Advisory Board, Parke Davis Pharmaceuticals 1998-2001 Board of Directors, Mental Health Service Line, Veterans Integrated, Service Network, Region II (VISN 11) 1999-2008 Member, National Scientific Advisory Board, Pfizer Corporation 2000-Present Scientific Advisory Board, Depression Bipolar Support Alliance (DBSA), previously National Depression and Manic-Depression Bipolar Support Alliance (NDMDA) 2000-2009 Cyberonics VNS Advisory Board 2000-2011 Neuronetics Advisory Board, (TMS) 2000-2009 Novartis Pharmaceuticals Corporation 2002-2009 Wyeth Pharmaceutical Company 2003 Presentation to White House Freedom Commission for Mental Health 2004-2014 Member, Faculty of 1000 2005-2010 Center’s Internal Advisory Board, NIDA Center Application, Genetics of Behavioral Traits Modulating Drug Abuse Risk 2005-2011 rTMS Scientific Advisory Board, Neuronetics 2006-2011 Vagus Nerve Stimulation (VNS) Scientific Advisory Board, Cyberonics 2006-Present Scientific Council, American Foundation for Suicide Prevention (AFSP) 2007-Present Board Member, American Foundation for Suicide Prevention (AFSP): 2007-2009 PRIMEDIA Healthcare (The Chatham Institute) CME Advisory Board 2009-Present Vice-President, American Foundation for Suicide Prevention (AFSP) 2011-Present Scientific Advisory Board, University of Ottawa Institute of Mental Health Research 2011-2013 National Institutes of Mental Health Special Emphasis Panel – review committee 2013-Present Program Committee, National Network of Depression Centers Annual Meeting 2013-Present Janssen Pharmaceuticals (Johnson & Johnson), Advisory Board 2013-Present Allergan (formerly Naurex), Advisory Board 2014-Present Cerecor, Advisory Board 2015-Present Otsuka and Lundbeck Corporation, Advsory Board 2015-Present Neuralstem, Advisory Board 2016-Present Clinical Advisor, Workit Health 2018-Present Clinical Advisory Board, Sage Therapuetics, Inc. 2018-Present Clinical Advisory Board, Genomind, Inc. 2018-Present Executive Advisory Board, Project Healthy Minds

Grant Support Current 1. Developing and Validating a Next Generation Psychiatric Pharmacogenomics Platform. Project Grant Time Period: In Submission. Purpose: To design, develop and test a “pharmacophenomic” decision support system that will optimize therapy fo an individual patient diagnosed with depression by matching the patient’s phenotype with the best treatment strategy, including pharmacotherapy and other interventions. Role: Collaborator John F. Greden, M.D. Page 4 Last Revised December 2019

2. Combinatorial Pharmacogenomics for Major Depressive Disorder. Project Grant Time Period: 2013- Present, AssureX Health (payment of laboratory supplies for pharmacogenomic testing; no personal payment and no conflict of interest); Purpose: Precision Treatment Advancement in Mental Health. Role: Principal Investigator 3. Garrick Roemer Memorial; Project Grant #G017638; Project Grant Time Period: 01/08/2016 – 01/08/2020; Purpose: Education and outreach for student athletes. Role: Project Director 4. Development of Outreach Strategies and Innovative Mental Health Programs for Returning OEF/OIF Service Members and their Families (initial 2 yrs.); Development and Implementation of Dissemination and Sustainability Strategies for Military Mental Health Programs (continuation) The goal of the Welcome Back Veterans (WBV) initiative is to develop models for service delivery through centers, networks or collaboration across disciplines that are able to provide access to treatment, retain patients in treatment, educate and support families dealing with the effects of war, and overcome stigma, culture and attitude that form serious barriers to successful re-integration into civilian life. Role: Principal Investigator

Completed Research in Recent Past 1. Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC); National Institute of Health – NIH (PI: Brian Mickey) 11/12/2015-11/11/2016, Project Summary: The timely selection of the best treatment for patients with Major Depressive Disorder (MDD) is critical to the goal of improving treatment outcome. Due to the biological heterogeneity and variable symptom presentation, it appears unlikely that a single clinical or biological marker can guide treatment selection. Rather, a biosignature developed from a systematic exploration of clinical and biological markers would appear to be more likely to be successful. Both biosignature to maximize the selection of optimal treatment for individual patients at beginning of treatment (moderators) and biosignatures to identify indicators of eventual outcomes early in treatment (mediators) are needed. It is believed that this approach has great potential to personalize treatment and to begin to characterize the biology of treatment response. Role: Co-Investigator 2. 1 U01 MH092250-01 (PIs: McGrath, Parsey, Weissman) 09/30/2010-06/30/2014 NIH/Columbia University Biosignatures of Treatment Response in Major Depression. The goal of this project is to study biomarker signature in patients with major depression under treatment with either escitalopram or buproprion. Role: Collaborator 3. Mental Illness Research Association (PI: Greden) 8/15/2012-8/14/2013 Under the Helmet and Hat The goal of this project is to provide training and education to high school student athletes, their coaches and families, throughout Michigan, regarding mental and physical health and well-being. Role: Principal Investigator 4. NIH Recovery Act RC4 (PI: Deldin) 07/1/2010-06/30/2013 Developing a Sustainable Consumer Clearinghouse for Translational Depression and Bipolar Disorder Research. The goal of this project is to foster consumer research participation and engagement in understanding mental health research priorities related to depression, bipolar and related disorders. Role: Co-Investigator 5. 00469 University of Michigan MICHR (PIs: Peltier, Deldin & Domino) 2010-2012 NMDA Receptor Antagonism: Targets of Drug Discovery for Depression. To examine the cognitive changes associated with Ketamine administration. Role: Co-Investigator 6. The Department of Veterans Affairs (PI: Valenstein) 11/16/2010-9/30/2011; IPA Jane Leslie Spinner. To goal of the project is to provide mental health services to returning Army National Guard veterans. Role: Co-Investigator

John F. Greden, M.D. Page 5 Last Revised December 2019

7. National Institute of Health – NIH 04/01/2001 – 09/30/2009. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Major national clinical trial to identify treatment targets for depression. Role: Co-Investigator. 8. NIH-BAA-RM-04-23 (Co-PI; Clauw = PI) 10/1/2004 – 9/29/07 $725,933 Michigan Clinical Research Collaboratory: An Integrated Academic-Community Research Enterprise, a Project of the NIH Research Roadmap.The major goals of this project are to construct, test, refine, and progressively extend a common infrastructure linking three existing practice-based networks with two University of Michigan research centers, the Cardiovascular Center and the Depression Center as well as the Center for Advancement of Clinical Research. 9. NIH-NCRR C06 RR18800 : Support for the University of Michigan Comprehensive Depression Center (Greden=Project Director;) 09/15/2003-09/14/2005 $4,000,000.00 The University of Michigan Depression Center Extramural Research Facilities Construction. Provides support for the construction of research space in the new University of Michigan Depression Center, the only Depression Center in the country with NIH Research Space Support. Role: Project Director 10. Department of Veterans’ Affairs, Primary Mentor, Health Services Research and Development: Career Development Award: Screening for Mental Illness; 2002-2005; ($531,000 total award). Principal Investigator: Marcia Valenstein, M.D. 11. University of Michigan Depression Center: A Prototype for a National Network; 2002-2005; Eli Lilly and Company Foundation, Role: Project Director,; ($750,000 total award) 12. Department of Veteran’s Affairs Career Development Award (Valenstein): Role: Mentor; 03/01/2002– 02/28/2005. Health Services Research and Development: Career Development Award: Disease Management Strategies for Mental Disorders ($531,000 total award) Major goals: To develop and integrate screening procedures, adherence measures, and outcome strategies for veterans with serious mental illnesses. (Depression, Bipolar, Schizophrenia). Role: Primary Mentor for Career Development Award 13. Flinn Family Foundation 01-03 (King) 04/01/2002–07/01/2005. Role: Co-Investigator; Clinical Guidelines for the Treatment of Depressed Youth: Predictors of Treatment Adherence and Long-Term Effectiveness. Major goals: Identify predictors of treatment adherence and predictors of treatment resistant depression in youth with depressive disorders who are seeking outpatient treatment. 14. National Institute of Health, Mentor. The Clinical Associate Physician award (CAP): Serotonin Dysregulation in Adolescents with Major Depression; 2000-2004; ($144,000 total award). Principal Investigator: Neera Ghaziuddin, M.D. 15. BCBSM Foundation (King) 09/01/2001– 02/28/2004. Innovative Treatment Enhancements for Depressed Youth. Major goals: Improve the treatment of Major Depressive Disorder and its associated morbidity among children and teens by developing and evaluating innovative and feasible strategies for monitoring treatment effectiveness and enhancing treatment adherence. Role: Co-Investigator 16. Department of Veterans Affairs Career Development Award, Mentor, Geriatric Depression: Selected Confounds and Impact on Outcomes; 2001-2004; ($407,427 total award MCIT). Principal Investigator: Helen Kales, M.D. 17. NIH/University of Texas N01 MH90003 (Young) 04/1/2001–09/30/2004. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Role: Co-Investigator; Major goals: UT-SWMC establishes Regional Sites for the Sequences Treatment Alternatives for Resistant Depression (STAR D). (RUSH = P.I., University of Texas Southwestern) 18. NIH 5K24 AA00304-04 (Brower) 09/27/1999 – 08/31/2004. Role: Co-Investigator Pharmacotherapy of Alcoholism & Co morbid Insomnia ($564,405 total award). Major goals: To conduct a randomized, double-blind, parallel-group trial of gabapentin vs. placebo to prevent relapse among alcohol-dependent individuals.

John F. Greden, M.D. Page 6 Last Revised December 2019

19. World Heritage Foundation (Greden) 02/01/2002-02/28/2003. Neurobiology of Depression and Predictors of Antidepressant Response ($1,008,000 total award). Role: P.I. Major goals: To integrate clinical variables, structural magnetic resonance imaging (MRI), microarray genetics, and serotonin transporter polymorphisms to assess prediction of acute and maintenance treatment responses. Role: Principal Investigator 20. Department of Veteran’s Affairs Career Development Award (Liberzon); Role: Mentor for Career Development Award 07/01/2002-06/30/2003 Neurobiological Predictors of Stress Related Disorders after Surgery. Major goals: Examine the role of psychological and neuroendocrine abnormalities in post- operative depression and determine the stability of specific factors; whether they reliably predict the development of comorbid disorders postoperatively. Determine if the ability to terminate neuroendocrine stress response after surgery or in response to dexamethasone predicts outcome, and if this is linked to pre-stress abnormalities. 21. NARSAD - National Association for Research in Schizophrenia and Depression (Ghaziuddin, M.) Role: Mentor 07/01/1998-6/30/2003 Depression in Autism: A Family Subtype? Major goals: To develop standardized research assessments that extend our published observations that a cohort of autistic children ham comorbid depression and to characterize the clinical genetic and neurobiological features of this comorbid syndrome with the goal of developing new investigative and treatment strategies. 22. NARSAD - National Association for Research in Schizophrenia and Depression (Ghaziuddin, N.) Role: Mento07/01/1998-06/30/2002 Serotonin Dysregulation in Adolescents with Major Depression. Major goals: Assess the possible role of serotonin dysregulation in adolescents with major depressive disorder. 23. Mental Illness Research Association (Greden) 04/01/2000-03/31/2001 Reductions of Morbidity from Depression by Reversal of Brain Morphologic Changes. Role: Principal Investigator Major goals: Develop and test new strategies to improve long-term treatment adherence and help prevent recurrences. 24. Pfizer Physician-Scientist Pediatric Career Development Award, Co-Mentor, Small Area Variation in the Treatment of Attention-Deficit/ Hyperactivity Disorder; 2001-2003; ($130,000 total award). Principal Investigator: Jerry Rushton, M.D. 25. NIMH PA-00-003 (Rushton) Role: Co-Mentor for “K” Award 04/01/2002 – 03/31/2007. (Grant terminated in 2003 when Dr. Rushton relocated to University of Indiana). Primary Care Diagnosis and Treatment of Depressed Children. Major goals: Describe potential barriers to quality care initiatives in primary care practices and to design an intervention to improve care delivery for depressed youth. 26. 20052588 (Neal) 1/1/2005 – 9/30/2011 Michigan Department of Community Health Integrated Care for Medicaid Consumers; Role: Co-Investigator; The major goal of this project is to demonstrate a system for integrating the care of our most vulnerable citizens, those with a severe and persistent mental illness (SPMI), development disability and/or a substance abuse disorder 27. National Institute for Alcohol Abuse and Alcoholism (ROI AA 07217-01), Sponsor for Michael Liepman, M.D. NIDA Career Teacher Award for Substance Abuse; 1977 28. Michigan Department of Mental Health, Role: P.I.: Non-Invasive Motor Tasks for Early Identification of Tardive Dyskinesia; 1979-1984 29. National Institute of Mental Health (MH-28294), Co-Investigator, Neuroendocrine Regulation in Depression; 1979-1984 ($250,000-$400,000) 30. University of Michigan, Principal Investigator Psychomotor Regulation and Hemispheric Lateralization; 1979 ($1,500) 31. National Institute of Mental Health (MH-32736-01), Principal Investigator, Psychomotor Regulation in Affective Disorders; 1979-1985 ($130,000 annually) 32. Veterans Administration, Consultant, Dexamethasone Suppression Test and Depression in Alcoholism; 1980 Michigan Department of Mental Health, Principal Investigator, Secondary Depression Prevention Project; 1984-1985 John F. Greden, M.D. Page 7 Last Revised December 2019

33. National Institute of Mental Health (MH36168), Co-Investigator, ACTH, Beta-endorphin, and Related Peptides in Depression; 1984-1986 ($137,000 annually) 34. National Institute of Mental Health, Sponsor for Rajiv Tandon, M.D. for K-award, Muscarinic Receptor Abnormalities in Affective Illness; 1985-1990 ($314,861 total award) 35. Biomedical Research Council and Clinical Research Center, Role: P.I.; University of Michigan Medical Center, Dexamethasone Suppression Testing in Normal Subjects; 1985 ($40,000) 36. National Institute of Mental Health (40216), Principal Investigator, Hypothalamic-Pituitary-Adrenal. Dysregulation: Serial Monitoring; 1985-1988 ($270,000 annually) 37. National Institute of Mental Health (5 R01 MH 42988-02), Co-Investigator, Cellular Immunity and Depressive Illness; 1988-1989; ($141,124 annually) 38. NIAAA (National Institute for Alcohol Abuse and Alcoholism) (AA07376-02), Principal Investigator, Center Grant, 1988-1994, Alcohol and the Aged: Central Nervous System Effects; ($1,450,000 annually) 39. NIAAA (National Institute for Alcohol Abuse and Alcoholism), Co-Principal Investigator, Alcohol and Aging: Brain Changes and Clinical Implications; 1993-1998; ($1,680,000 annually) 40. NIMH (National Institute of Mental Health), Collaborator, Member, Governance Advisory Board and Research Seminar Committee, Poverty, Risk, and Mental Health; 1995-2000; ($11,000,000 total award). Principal Investigator: Sheldon Danziger, Ph.D. 41. Pfizer Pharmaceuticals, Inc., Co-Principal Investigator, Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Depression and a DSM-IV Diagnosis of Alcohol Dependence; 1996-1998; ($389,264 total award). Principal Investigator: Kirk Brower, M.D. 42. Pfizer Pharmaceuticals, Inc., Co-Principal Investigator, Double-Blind Continuation Study of Sertraline and Placebo in Subjects who have Completed Protocol No. R-0494 as Responders; 1997-1998; ($6,000). Principal Investigator: Kirk Brower, M.D. 43. Pfizer Pharmaceuticals, Inc., Co-Principal Investigator, Sleep Patterns During Treatment for Depression and Alcohol Dependence; 1997-1998; ($30,000). Principal Investigator: Kirk Brower, M.D. 44. National Association for Research in Schizophrenia and Depression, Primary Mentor (NARSAD), Depression in Autism: A Family Subtype? 1998-2000; ($56,000 total award). Principal Investigator: Mohammad Ghaziuddin, M.D. 45. University of Michigan Health System Venture Investment Fund, Co-Investigator, Screening for Depression and Substance Abuse in Pregnant Women; 1998-2000; ($227,000 total award). Principal Investigator: Sheila Marcus, M.D. 46. American Geriatrics Society/Pfizer 2001 Postdoctoral Fellowship for Research on Health Outcomes in Geriatrics, Mentor, The Effect of Race on Physicians Diagnosis and Treatment of Major Depression in the Elderly; 2001-2002; ($32,500 total award). Principal Investigator: Helen Kales, M.D. 47. BCBSM Foundation, Co-Investigator, Innovative Treatment Enhancements for Depressed Youth; 2001- 2002; ($186,249 total award). Principal Investigator: Cheryl King, M.D. 48. Blue Cross Blue Shield of Michigan Foundation, Faculty Advisor, Epidemiology of Child and Adolescent Depressive Disorders in Michigan Health Systems; 2001-2002; ($27,267 total award). Principal Investigator: Jerry Rushton, M.D. 49. Robert R. McCormick Foundation/Major League Baseball Charities (PI: Greden) P/G: N019579 07/01/2015 – 12/31/2018 Expansion, Dissemination and Sustaininteability of M-SPAN Military Mental Health Programs The overall goal of this project is the expansion, dissemination and sustainability of M- SPAN military mental health programs. We aim to: 1) develop, deliver, and evaluate a web-based program for training community clinicians to deliver Strong Military Families, an evidence-based program for military families with young children, as a cost effective, scalable dissemination strategy; 2) provide continued support to the PAVE program at 3 universities; and develop and pilot enhancements to the program to support recruitment, engagement, replicability and sustainability; and 3) conduct a

John F. Greden, M.D. Page 8 Last Revised December 2019

needs assessment to identify gaps in services for women veterans, and develop a pilot program to address these needs.Role: Principal Investigator 50. Trait Characteristics of Antidepressant Treatment Responders and Non-Responders. PI: Ryan Cardinale 10/23/2013-7/18/2018; The present study aims to identify stable clinical characteristics that may predict a patient’s response to pharmacological intervention. This study will use well-validated self-report measures of cognitive, personality, and health characteristics that will be administered to a population of patients who are participating in a larger NIMH study that aims to establish biomarkers of major depressive disorder (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care). This study will use multiple regression to assess whether the chosen measures combined are clinically useful in differentiating treatment responders from non-responders. This study may guide future research aimed at developing assessment batteries that are able to tailor an antidepressant treatment regimen to the unique characteristics of the patient to ensure that the appropriate antidepressant treatment is chosen early on. Role: Co-Investigator

Certification and Licensure Certification 1975 American Board of Psychiatry and Neurology, Diplomat

Medical Licensure Current State of Michigan Past State of California Past District of Columbia Past State of Maryland Past State of Minnesota

Military Service 1969-1974 United States Army Medical Corps RANK: Major; Army Commendation Medal in 1974

Memberships and Offices in Professional Societies Alliance for Mental Health, State of Michigan 1989-1993 Board of Directors

American Association for the Advancement of Science (AAAS) 1992-2019 Member 2019 – Present Fellow

American Association of Chairs of Departments of Psychiatry (AACDP) 1992-Present Member, Research Committee 1994-1996 Council Member 1999-2000 Co-Chair, Advocacy Committee 2000-Present Chair, Advocacy Committee 2002-2004 President-Elect 2004-2006 President 2006-2007 Past-President

American College of Neuropsychopharmacology (ACNP) John F. Greden, M.D. Page 9 Last Revised December 2019

1985-1995 Member 1989-1992 Publications Committee (Chair, 1991-92) 1994-1996 Education and Training Committee (Co-Chair, 1996) 1995-Present Fellow 1996-1997 Chair, Nominating Committee 1997 Pharmacoeconomics Task Force 1997 CD-ROM Editorial Board 1998 Member, Editor Search Committee, Neuropsychopharmacology 1998 Member, Ethics Committee 1998 Member, Nominating Committee 1998 Member, Neuropsychopharmacology Task Force for Strategic Planning 1998 Member, Task Force on Corporate Membership 1998 Member, Task Force on Ethical and Legal Issues in Clinical Research 1998-2000 Member, Task Force on the Development of Methodological Standards on Pharmacoeconomic Research 1999-2000 Senior Administrative Editor, Scientific Publications, designed to integrate the College’s Journal, Scientific Website and Textbook (“Psychopharmacology: The Fifth Generation of Progress”) 1999-2001 Program and Scientific Publications Committee 2001-2004 Council Member 2009 Liaison Committee

American College of Psychiatrists (ACP) 1988-1992 Member 1992 Fellow 2014-present Chair, Committee on Bylaws

American Foundation for Suicide Prevention (AFSP) 2006-Present Member, Scientific Council 2009-2012 Vice-President, Board of Directors 2011-Present Task Force on Development 2012-2014 President, Board of Directors 2014-Present Scientific Advisory Board

American Psychiatric Association (APA) 1985-1986 Member, Task Force to Evaluate Melancholia in Diagnostic and Statistical Manual III Revision (DSM-III R) 1987-1991 Member, Samuel G. Hibbs Award Board 1989-1991 Chair, Samuel G. Hibbs Award Board 1993-1994 Consultant, Committee on Research Training, Council on Research 1994-1996 Member, Committee on Research Training, Council on Research 1996-1997 Chair, Committee on Research Training, Council on Research 1996-2006 Co-Founder and Keynote Speaker, Annual Colloquium for Young Investigators 1996-2006 Keynote Speaker for Annual Colloquium for Young Investigators 2000-2005 Chair, Council on Research 2003-2005 Member, Joint Reference Committee 2003 Distinguished Fellow 2005-Present Member, Presidential Task Force on Mental Health on College Campuses 2005-2006 Co-Chair, Corresponding Committee on Research Training John F. Greden, M.D. Page 10 Last Revised December 2019

2005-2008 Member, Corresponding Committee on Research Training

American Psychiatric Institute for Research and Education (APIRE) 2000-2001 Member, Board of Directors 2001-2005 Member, Executive Committee, APIRE

Association of Professors of Medicine 2010-Present Member, APM Physician-Scientist Initiative

Depression and Bipolar Support Alliance (DBSA) –Formerly National Depressive and Manic Depressive Association, NDMDA) 1997-Present Member, Scientific Advisory Board

Mental Illness Research Association (MIRA), State of Michigan 1993 Founding Member 1993-Present Member

Michigan Mental Health Association 1975-Present Member

Michigan Psychiatric Society (MPS) 1974-Present Member 1981 Chairman, Committee on Research 1983-1986 Ethics Subcommittee 1989-1992 Councilor 1993-1996 Member, Fellowship Committee

National Network of Depression Centers 2007-2016 Founder and Chair 2007-Present Board of Directors and Executive Committee 2009- Present Member, Treatment Resistant Depression Task Group, Mood Outcomes Report Task Group 2013 –Present Co-Chair, Public Policy Task Force 2016 – Present Founding Chair role

The New York Academy of Science 1976-2014 Member

Psychiatric Research Society 1976-Present Member 1988-1989 Councilor 1989-1990 President-Elect 1990-1991 President 1991-1992 Past-President 2014-Present Advisory Board

Research Society on Alcoholism 1988-2000 Member

John F. Greden, M.D. Page 11 Last Revised December 2019

The Royal, University of Ottawa Institute of Mental Health Research; Ottawa, Ontario, Canada 2013-Present Scientific Advisory Board 2015-Present Selection Committee Member, The Royal-Mach-Gaensslen Prize for Mental Health Research

Society for Biological Psychiatry 1974-Present Member 1988-Present Committee on Resource Development 1989-1990 Vice-President 1990-1994 Founder and Chair, Society of Biological Psychiatry/Lilly Travel Fellowship Award Committee 1990-1991 President-Elect 1991-1992 President 1992-1997 Member, Executive Council 1997 Chair, Search Committee for Editor, Biological Psychiatry 1997 Chair, George N. Thompson Award Selection Committee 1997 Member, Ziskind-Somerfeld Award Selection Committee 1997 Member, Gold Medal Award Committee 2000-2002 Co-Chair, George N. Thompson Award Selection Committee 2004-Present Member, Contributions Committee 2006 Member, Search Committee, Editor, Biological Psychiatry 2012 George N. Thompson Award

Student Veterans of America (SVA) 2009-2013 Member, Advisory Board

The National Foundation for Mental Health 2005-2008 Member, Board of Directors

Teaching Activities Department of Psychiatry 1975-1986 Director, Residents' Journal Club 1977-1982 Coordinator and Principal Lecturer: Psychiatry Interviewing (Course for Psychiatry Residents) 1994-1996 Director, Residents' Journal Club 1995-1996 Director and Principal Lecturer History of Psychiatry (Course for HO-IV Psychiatry Residents) 1995-1996 Director and Principal Lecturer Controversies in Psychiatry (Course for HO-IV Psychiatry Residents) 1997-1999 Director and lecturer Diagnosis and Descriptive Psychiatry (Course for HO-II Psychiatry Residents) 2002-Present Annual Lecture for Residents on “Mood Disorders”

Medical School 1975-79 Lecturer, psychiatry sequence for first and second year students in “Neural and Behavioral Sciences” (NBS) and Neuroscience Sequence at University of Michigan Medical School (ranging from 6 to 27 classroom hours/year) 1977-79 Director, Neural and Behavioral Sciences (NBS) 1982-Present Lecturer, 1st and 2nd year medical student classes during Psychiatry Rotation (Depression)

Development/Philanthropy Leadership (2000-Present) As Department of Psychiatry Chair, Founder and Executive Director of the Depression Center, and Founding John F. Greden, M.D. Page 12 Last Revised December 2019

Chair of the National Network of Depression Centers, I have led Development activities that have garnered Approximately $110 million to date. Gifts have enabled construction of the Rachel Upjohn Building, housing the Depression Center and Ambulatory Psychiatry, and garnered 5 endowed Professorships.

Extramural Invited Presentations (1982 onward) 1. Invited Participant, Stifteverband fuer die Deutsche Wissenschaft-Deutsche Forschungs-Gemeinschaf (Dahlem Konferenzen on The Origins of Depression: Current Concepts and Approaches). Berlin Federal Republic of Germany. September 1982 2. Classification of Depression. The Michigan State Medical Society Annual Meeting. Dearborn, Michigan. November 1982 3. A Laboratory Test for Depression. The Michigan State Medical Society Annual Meeting. Dearborn, Michigan. November 1982 4. Applications of Psychomotor Markers in Affective Disorders. National Mental Health Association Meeting. Detroit, Michigan. 1982 5. Hypothalamic-Pituitary-Adrenal Dysregulation: Serial Assessments at Both Pituitary and Adrenal Levels. Presented at the Max Planck Institute fur Psychiatrie. Munich, Federal Republic of Germany. July 1984 6. Hypothalamic-Pituitary-Adrenal- Dysregulation and the Dexamethasone Suppression Test in CNS Diseases. Presented at the Brook Lodge Symposium on Laboratory Markers in CNS Diseases. Kalamazoo, Michigan. September 1984 7. Use of Laboratory Tests in Psychiatry. Grand Rounds Presentation. Northwestern University. Chicago, Illinois. January 1985 8. Visiting Professor, University of Michigan Family Practice Symposium. Boyne Highlands, Michigan. January 1985 9. Laboratory Tests of Depression: Is There Any Clinical Future? Grand Rounds Presentation. Henry Ford Hospital. Detroit, Michigan. April 1985 10. Neuroendocrine Testing for Depression: Any Clinical Value? Grand Rounds Presentation. Stony Brook University. Stony Brook, New York. June 1985 11. Stress in Physicians. Grand Rounds Presentation, University of Michigan Medical Center. Ann Arbor, Michigan. August 1985 12. New Laboratory Tests in Psychiatry. Invited Speaker. University of Michigan Continuing Medical Education, Towsley Center. Ann Arbor, Michigan 13. HPA Dysregulation in Depression: What Have the New Strategies Revealed? Grand Rounds Presentation. University of California, San Diego. La Jolla, California. December 1985 14. The Many Faces of Depression. Presented at Health Night Out. Sponsored by the University of Michigan Medical Center. Ann Arbor, Michigan. February 1986 15. Laboratory Tests in Psychiatry. Invited Speaker. Spring Family Practice Program. Towsley Continuing Education Center. University of Michigan Medical Center. Ann Arbor, Michigan. March 1986 16. Laboratory Tests in Psychiatry: Is There a Clinical Future? Invited Speaker, St. Johns Hospital. Detroit, Michigan. April 1986 17. The Many Faces of Depression. Presented at Health Night Out. Sponsored by the University of Michigan Medical Center. Ann Arbor, Michigan. April 1986 18. Laboratory Test in Psychiatry: What Is Their Clinical Future? Invited Speaker. The University of Chicago. Chicago, Illinois. April 1986 19. Laboratory Tests of Depression: What Is Their Clinical Future? Grand Rounds Presentation. University of Buffalo. Buffalo, New York. May 1986 20. Laboratory Test in Psychiatry: Is There a Clinical Future? Grand Rounds Presentation. Henry Ford Hospital. Detroit, Michigan. June 1986

John F. Greden, M.D. Page 13 Last Revised December 2019

21. Future Trends in Psychiatric Education. Invited Speaker. Faculty Recognition Program, Sinai Hospital. Detroit, Michigan. September 1986 22. Laboratory Tests in Psychiatry: Is There a Clinical Future? Invited Speaker, Minneapolis Veterans Medical Center. Minneapolis, Minnesota. November 1986 23. Nicotine and Caffeine: What’s New in Diagnosis and Treatment? Segment presented in television program the “Trembling Brain”, Cable Health Network. Produced by the Carrier Foundation. December 1986 24. Seasonal Affective Disorders. Invited Guest. J.P. McCarthy’s Focus Program, WJR Radio. Detroit, Michigan. January 1987 25. Brain Imaging in Psychiatry: Problems and Promises. Invited Speaker. Continuing Medical Education Lecture Series, Harper/Grace Hospitals. Detroit, Michigan. March 1987 26. Clinical and Pharmacological Management of Affective Disorders. Invited Speaker. Ninth Semi-Annual Psychiatric Conference. Oakwood Hospital. Dearborn, Michigan. April 1987 27. PET Imaging and Psychiatry: Problems and Promises. Guest Speaker. Spring Meeting, Michigan Psychiatric Society Meeting. April 1987. An Update on Common Clinical Concerns: 1) Neurological disorders masquerading as psychiatric diagnoses. 2) Psychiatric drug update. 3) Pain and depression. 4) Adolescent suicide. 5) Future directions in psychiatry. Faculty Lecturer at the 23rd Annual Northern Michigan Summer Conference. The University of Michigan Medical School. Bellaire, Michigan. June 1987 28. Clinical and Pharmacological Management of Affective Disorders. Invited Speaker. Pine Rest Hospital. Grand Rapids, Michigan. July 1987 29. Visiting Faculty for the Tri-County Medical Society. Calumet, Michigan. October 1987 30. Differential Diagnosis and Current Treatment of Depression and Anxiety. Visiting Faculty. Highland Park Hospital. Highland Park, Illinois. October 1987 31. New Developments for Depression and Mania. Invited Speaker. National Convention of the National Depressive and Manic Depressive Association. Detroit, Michigan. 1987 32. Depression: The Application of New Findings on Clinical Programs. 2) Suicide Prevention: What Have We Learned? 3) Caffeinism: Psychiatric Manifestations 4) Suicide Prevention Strategies 5) Laboratory Tests in Psychiatry. Visiting Professor. Michigan State University. East Lansing, Michigan. November 1987 33. Differential Diagnosis of Depression and Anxiety. Mead Johnson Visiting Faculty. Illinois Masonic Hospital. Chicago, Illinois. November 1987 34. The Dexamethasone Suppression Test: Update on Utility and Research Findings. Invited Speaker. Fair Oaks Hospital. Delray Beach, Florida. January 1988 35. New Developments in Depression. Invited Speaker. Conference on Clinical Training in Depressive Disorders. Sponsored by the U.S. Department of Health and Human Services, N.I.M.H., D/ART Program. Ann Arbor, Michigan. February 1988 36. Diagnosis, Classification and Etiology of Anxiety Disorders. Invited Speaker. Anxiety Disorders Symposium. Northern Indiana Education Foundation. Michigan City, Indiana. March 1988 37. Caffeinism. Invited Guest. J.P. McCarthy Focus Program. WJR Radio. Detroit, Michigan. March 1988 38. Grand Rounds Presentation. Stanford University. Stanford, California. April 1988 39. Rational Use of Psychotropic Drugs. Burns Clinic. Petoskey, Michigan. May 1988 40. Depression: A 21st Century Perspective. Invited Speaker. Detroit Rotary Club. Detroit, Michigan. June 1988 41. Affective Disorders: Diagnostic and Treatment Update. Invited Speaker. The 12th Annual Virginia Beach Update in Neuroscience. Virginia Beach, Virginia. July 1988 42. Lecturer at the 24th Annual Northern Michigan Summer Conference. The University of Michigan Medical School. Boyne City, Michigan. August 1988 43. Overview: Classification and Epidemiology of Depression. Invited Speaker. Conference on Clinical Training in Depressive Disorders. Sponsored by the U.S. Department of Health and Human Services. NIMH D/ART Program. Traverse City, Michigan. August 1988

John F. Greden, M.D. Page 14 Last Revised December 2019

44. Assessment, Treatment, and Prevention of the Suicidal Patient. Visiting Faculty. Kalamazoo Regional Hospital. Kalamazoo, Michigan. September 1988 45. Depression: Current Understanding of Mechanism of Action of the Tricyclic Antidepressants and Newer Antidepressants. Visiting Faculty. Battle Creek Adventist Hospital. Battle Creek, Michigan. September 1988 46. Schizophrenia in the 1990’s. Symposium Moderator. Ypsilanti Regional Psychiatric Hospital. Ann Arbor, Michigan. September 1988 47. Atypical Depression: Does It Exist? Can It Be Treated? Invited Speaker. Seminar on Controversies in Clinical Psychopharmacology. Minneapolis, Minnesota. October 1988 48. Use of Laboratory in the Differential Diagnosis and Treatment of Depression. Invited Speaker. Meeting on Clinical Research in Psychiatric Practice: The Use of Laboratory in Clinical Psychiatry. Seattle, Washington. October 1988 49. Atypical Depression: Recognition and Treatment. Visiting Faculty. LA County, USC Medical Center. Los Angeles, California. October 1988 50. Atypical Depression. Visiting Faculty. Martin Luther King, Jr. Medical Center. Los Angeles, California. October 1988 51. Depression: Clinical Applications of New Advances. Invited Speaker. Ypsilanti Regional Psychiatric Hospital. October 1988 52. Geriatric Depression: Diagnosis and Treatment. Invited Speaker. Michigan State University, St. Lawrence Hospital. Lansing, Michigan. November 1988 53. Grand Rounds Presentation. University of Minnesota, Department of Psychiatry. Minneapolis, Minnesota. January 1989 54. Invited Speaker. St. Paul-Ramsey Medical Center. St. Paul, Minnesota. January 1989 55. Antidepressant Overdose. Invited Speaker. St. Vincent Medical Center. Toledo, Ohio. February 1989 56. Depression in the Elderly. Invited Speaker. Birmingham, Michigan. April 1989 57. Update on Depression Management. Invited Speaker. Gunderson Clinic. La Crosse, Wisconsin. April 1989 58. Psychopharmacology for the Primary Care Physician. Invited Speaker. Wayne County Medical Society. Detroit, Michigan. May 1989 59. Recognition and Treatment of Depression: New Advances. Invited Speaker. Port Huron Hospital. Port Huron, Michigan. May 1989 60. Manic Depression: Research Update. Keynote Speaker. State Alliance for the Mentally Ill, 4th Annual Conference. Muskegon, Michigan. June 1989 61. Abuse and Overdose of Antidepressants and Anti-anxiety Drugs. Invited Speaker. Garden City Hospital. Garden City, Indiana. June 1989 62. Overview: Classification and Epidemiology of Depression. Invited Speaker. Conference on Clinical Training in Depressive Disorders. Sponsored by the U.S. Department of Health and Human Services. NIMH D/ART Program. Ann Arbor, Michigan. June 1989 63. Symposium Moderator “Anxiety and Panic Disorders”. Sponsored by Ypsilanti Regional Psychiatric Hospital. Ann Arbor, Michigan. September 1989 64. Depression. Invited Speaker. Toledo Hospital. Toledo, Ohio. September 1989 65. Management of Executive Stress. Keynote Speaker. Washtenaw Area Pharmaceutical Representatives Association. September 1989 66. Overview: Classification and Epidemiology of Depression. Invited Speaker. Conference on Clinical Training in Depressive Disorders. Sponsored by the U.S. Department of Health and Human Services. NIMH D/ART Program. Novi, Michigan. October 1989 67. Seasonal Affective Disorders. Invited Speaker. Pontiac General Hospital. Pontiac, Michigan. October 1989 68. Antidepressant Overdose. Invited Speaker. LaPorte Hospital. LaPorte, Indiana. October 1989 69. Laboratory Testing for Depressed Patients: A Clinical Update. Invited Speaker. Department of Psychiatry, Wright State University. Dayton, Ohio. October 1989 John F. Greden, M.D. Page 15 Last Revised December 2019

70. Recognition and Management of the Depressed Patient. Invited Speaker. Dayton Psychiatric Society. Dayton, Ohio. October 1989 71. Atypical Depression: New Perspectives on Etiology and Treatment. Invited Speaker. Concepts in Depression for the 90’s Program. Orlando, Florida. November 1989 72. Assessment and Treatment of Depressive Disorders. Invited Speaker. Michigan State Medical Society Annual Scientific Meeting. Dearborn, Michigan. November 1989 73. Do Psychiatrists Rely Excessively on Drugs? Invited Guest. Alpha Omega Alpha. Ann Arbor, Michigan. November 1989 74. Recognizing and Treating Depression. Invited Speaker. William Beaumont Hospital. Royal Oak, Michigan. November 1989 75. Cholinergic Hyperactivity and Negative Schizophrenic Symptoms. Edwin F. Gildea Lecturer. Department of Psychiatry, Washington University. St. Louis, Missouri. January 1990 76. Laboratory Tests for Depression: Is There expanAny Clinical Future? Invited Speaker. Department of Psychiatry, The Medical College of Pennsylvania, EPPI. Philadelphia, Pennsylvania. January 1990 77. Negative Symptoms of Schizophrenia: New Perspectives on Causes and Treatment. Invited Speaker. Department of Psychiatry, Michael Reese Hospital and Medical Center. Chicago, Illinois. February 1990 78. Recognition and Latest Treatment of Depression. Invited Speaker. Heritage Hospital. Taylor, Michigan. February 1990 79. Anxiety versus Caffeinism: A 1990’s Reappraisal. Invited Speaker. Sixteenth Annual International Symposium on Psychopharmacology. Louisville, Kentucky. March 1990 80. Manic Depressive Disorders: A Neuroscience Update. Invited Speaker. Society of Neurosurgeons Annual Meeting. Ann Arbor, Michigan. May 1990 81. Diagnosis and Treatment of Alcoholism in the Elderly Population. Invited Speaker. Multidimensional Aspects of Psychoactive Substance Abuse Program. Michigan State University College of Osteopathic Medicine. East Lansing, Michigan. June 1990 82. Clinical Applications of the Dexamethasone Suppression Test. Invited Speaker. Biological Markers of Depression: State of the Art. Department of Psychiatry, University of Liege. Liege, Belgium. June 1990 83. A New Look at Antidepressant Therapy. Invited Speaker. Margaret Montgomery Psychiatric Hospital. Westland, Michigan. September 1990 84. Clinical Neurosciences in the Medical Setting. Invited Speaker. University Health Center, Detroit Receiving Hospital. Detroit, Michigan. September 1990 85. The Suicidal Patient. Invited Speaker. Pontiac General Hospital. Pontiac, Michigan. September 1990 86. Etiology of Depression. Invited Speaker. Symposium on Depression. Ypsilanti Regional Psychiatric Hospital. Ann Arbor, Michigan. September 1990 87. Panic: Neglected Causes and Promising Treatments. Invited Speaker. Brain, Behavior and Biology Course. Minneapolis, Minnesota. October 1990 88. Rational Approach to Pharmacotherapy of Depression. Invited Speaker. Symposium “Depression: New Diagnostic Strategies, New Treatment Perspectives, Wayne State University. Dearborn, Michigan. November 1990 89. Atypical Mood Disorders. Invited Speaker. Symposium on the Challenge of Major Depression. Washington, D.C. November 1990 90. Diagnosis, Management, and Treatment of Depression. Invited Speaker. Michigan Health Care Corporation, Adult Mental Health Division. Detroit, Michigan. January 1991 91. Atypical Depression. Invited Speaker. Department of Psychiatry, Michael Reese Hospital. Chicago, Illinois. April 1991 92. Atypical Depression. Invited Speaker. Department of Psychiatry, Hines VA Hospital. Chicago, Illinois. April 1991

John F. Greden, M.D. Page 16 Last Revised December 2019

93. Atypical Depression. Invited Speaker. Department of Psychiatry, University of Illinois. Chicago, Illinois. April 1991 94. Depression: New Perspectives and Relevance for Obstetrics and Gynecology. Invited Speaker. Clinical Challenges of the 21st Century for Obstetrics and Gynecology. The University of Michigan. April 1991 95. Academic Psychiatry: Where Are We Going and How Do We Pay for It? Keynote Speaker. Annual Meeting of the Administrators in Academic Psychiatry. Orlando, Florida. April 1991 96. Atypical Depression. Invited Speaker. Medical School of the University of South Carolina. Charleston, South Carolina. April 1991 97. Use of Laboratory Studies in Psychiatry. Presented at the Annual Spring Meeting of the Michigan Psychiatric Society. Ann Arbor, Michigan. April 1991 98. A Crisis for Educators in Psychiatry Earn-As-You-Go Pressures versus Teaching. Invited Speaker. Department of Psychiatry, Temple University. Philadelphia, Pennsylvania. September 1991 99. Manic Depressive Illness in the Decade of the Brain: New Perspectives, New Treatments. Invited Speaker. Manic Depression and Depressive Association of Metropolitan Detroit. Detroit, Michigan. September 1991 100. Depression: New Breakthroughs in the Decade of the Brain. Invited Speaker. Presentation to Alumni of the University of Michigan (President’s Forum). Ann Arbor, Michigan. September 1991 101. Atypical Depression: Diagnosis and Management. Invited Speaker. Pontiac General Hospital. Pontiac, Michigan. October 1991 102. Treatment Strategies of Depression. Invited Speaker. Department of Psychiatry, Ohio State University. Columbus, Ohio. November, 1991 103. Clinical Neurosciences: Advances and Implications for Medical Practice. Invited Speaker. University of Michigan Medical School Alumni Association. Miami, Florida. February 1992 104. Depression Medication: When to Stop, When to Maintain. Invited Speaker. Michigan State University. East Lansing, Michigan. March 1992 105. Depression Medication: When to Stop, When to Maintain. Invited Speaker. Michigan State University. Kalamazoo, Michigan. April 1992 106. Biochemical Aspects of Affective Disorders. Invited Speaker. Rush Institute for Mental Well Being. Chicago, Illinois. April 1992 107. Neurobiology of Mood Disorders. Invited Speaker. Symposium on Advances in Office Psychiatry: Mood and Anxiety Disorders. Mackinac Island, Michigan. July 1992 108. Unipolar Depressions. Invited Speaker. University of Michigan Symposium on Advances in Office Psychiatry: Mood and Anxiety Disorders. Mackinac Island, Michigan. July 1992 109. Bipolar Disorders. Invited Speaker for University of Michigan Symposium on Advances in Office Psychiatry: Mood and Anxiety Disorders. Mackinac Island, Michigan. July 1992 110. Seasonal Affective Disorders. Invited Speaker for University of Michigan Symposium on Advances in Office Psychiatry: Mood and Anxiety Disorders. Mackinac Island, Michigan. July 1992 111. Depression Medication: When to Maintain, How to Stop. Invited Speaker. Kingswood Hospital. Detroit, Michigan. July 1992 112. Antidepressant Medications: When to Discontinue and How to Stop. Invited Speaker. 72nd Annual Coller Penberthy Thirlby Medical Conference. Traverse City, Michigan. July 1992 113. Stress and Depression. Invited Speaker. Women's Health and Life Forum. Ypsilanti, Michigan. September 1992 114. Short-Term Management and Long-Term Maintenance with Lithium and Neuroleptics. Invited Speaker. Bipolar Disorder: Current Progress and Future Directions in Diagnosis and Management. Amelia Island, Florida. September 1992 115. Antidepressant Medication: When to Discontinue, How to Stop. Grand Rounds Presentation. Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. Atlanta, Georgia. November 1992 John F. Greden, M.D. Page 17 Last Revised December 2019

116. Termination of Maintenance Drug Therapy. Invited Speaker. Symposium: Current Issues in Drug Therapy of Depression. Tysons Corner, Virginia. January 1993 117. Affective Disorders Through the Life Cycle. Wayne State University Conference. Detroit, Michigan. January 1993 118. Is Depression a Lifetime Disorder? Invited Speaker. Third Annual Winter Indianapolis Psychiatric Symposium. Indianapolis, Indiana. March 1993 119. Long-Term Treatment of Depression: Special Considerations. Invited Speaker. 1993 120. U.S. Depressive Disorders Update. Dearborn, Michigan. March 1993 121. Antidepressant Medications. Invited Speaker. Blue Cross-Blue Care Network. Flint, Michigan. March 1993 122. New Knowledge and Trends Influencing Care and Treatment of the Mentally Ill. Mental Health Association in Michigan, Board of Directors Meeting. Ann Arbor, Michigan. March 1993 123. Depression Medication: When to Maintain, How to Stop. Invited Speaker. 1993 124. St. Louis Psychiatric Symposium. St. Louis, Missouri. March 1993 125. Lifelong Depression and Treatment. Grand Rounds Presentation. Cleveland Clinic. Cleveland, Ohio. March 1993 126. Recognizing Depression. Invited Speaker. Michigan Chapter - Pakistani Physicians. Ann Arbor, Michigan. April 1993 127. New Agents for the Treatment of Depression. Invited Speaker. American Psychiatric Association's 146th Annual Meeting. San Francisco, California. May 1993 128. Alcohol, Drugs and Addiction: Myth and Reality. Invited Speaker. American Psychiatric Association's Annual Meeting. San Francisco, California. May 1993 129. Bipolar and Seasonal Affective Disorders. Invited Speaker. University of Michigan and the Michigan Psychiatric Society Summer Meeting. Grand Traverse, Michigan. July 1993 130. Depression Medication: When to Maintain, How to Stop. Invited Speaker. Fall Psychiatry Symposium of California Pacific Medical Center on "Recurrent Depression: A Lifetime Disorder." San Francisco, California. September 1993 131. Treatment of Recurrent Depression. Invited Speaker. Mid-Michigan Regional Medical Center. Midland, Michigan. October 1993 132. When to Stop Antidepressants. Invited Speaker. Psychopharmacology Training Program at the NYS Office of Mental Health, Bureau of Psychiatric Services. Albany, New York. October 1993 133. Atypical Depression Revisited: Do Our New Treatments Work? "Diagnostic and Therapeutic Challenges in Psychiatry. 1993. 134. Invited Speaker. University of Wisconsin-Madison. Madison, Wisconsin. October 1993 135. Depression as a Lifetime Disorder: The Issue of Maintenance Therapy. Invited Speaker. "Depression in Primary Care" Conference, University of Michigan Continuing Medical Education. Ann Arbor, Michigan. October 1993 136. Major Depression and Manic-Depression. Invited Speaker. Alliance for the Mentally Ill, Grosse Pointe Adult Community Education. Grosse Pointe, Michigan. November 1993 137. Antidepressant Medication: When to Maintain, How to Stop. Invited Speaker. Grand Rounds Presentation. University of Kansas Medical Center. Kansas City, Kansas. November 1993 138. Recurrent Depression. Invited Speaker. North Oakland Medical Center. Pontiac, Michigan. November 1993 139. Depression: Management of a Recurrent Disorder. Invited Speaker. Senior Residents' Symposium. San Diego, California. November 1993 140. Antidepressant Medication: When to Maintain, How to Stop. Invited Speaker. Hillside Hospital Grand Rounds. Brooklyn, New York. December 1993 141. Antidepressant Medication: When to Maintain, How to Stop. Invited Speaker. St. John's Episcopal Hospital Grand Rounds. Far Rockaway, New York. December 1993 142. Depression: A Lifetime Disorder. Teleconference for Pharmacists. Lansing, Michigan. December 1993 John F. Greden, M.D. Page 18 Last Revised December 2019

143. Atypical Depression Revisited: Do Our New Treatments Work? Invited Speaker. Henry Ford Hospital Grand Rounds. Detroit, Michigan. December 1993 144. Atypical Depression. Invited Speaker. Kaneohe State Hospital. Kaneohe, Hawaii. December 1993 145. Seasonal Affective Disorder. Invited Speaker. North Oakland Medical Center. Pontiac, Michigan. January 1994 146. Antidepressant Treatment Selections: Algorithms for Clinical Practice. Invited Speaker. Catherine McAuley Health System, Continuing Medical Education lecture series. Ann Arbor, Michigan. January 1994 147. Recurrent Depression: A Lifetime Disorder. Grand Rounds Presentation. University of Louisville. Louisville, Kentucky. January 1994 148. Atypical Depression. Invited Speaker. Mental Health Network's Quarterly Professional Staff Meeting. Southfield, Michigan. February 1994 149. Managing Treatment Resistant Patients: “Thick Chart Syndromes.” Invited participant in Ohio State's First Annual Psychiatry Clinical Update. Columbus, Ohio. April 1994 150. Recurrent Depression: A Lifetime Disorder. Grand Rounds Presentation. University of Florida. Gainesville, Florida. April 1994 151. Maintenance Treatment of Depression: Who Needs It? Invited Speaker. 5th Fifth International Symposium on Psychiatry. Ghent, Belgium. April 1994 152. Antidepressant Treatment-What's New? Invited Speaker. Oakwood Psychiatric Staff. Dearborn, Michigan. May 1994 153. Depression, New Perspectives for the 21st Century. Invited Speaker. Michigan Association of Physicians from India. Dearborn, Michigan. June 1994 154. Recurrent Depression and Maintenance Therapy: How Long? How Much? Why Maintain? Invited Speaker. Mercy and St. Charles Hospitals. Toledo, Ohio. June 1994 155. Depression - Long-term Treatment and Longitudinal Incidence. Invited Speaker. University of Kansas Medical Center Grand Rounds. Wichita, Kansas. August 1994 156. Antidepressant Maintenance Medications: When to Discontinue and How to Stop. Allegheny General Hospital. Pittsburgh, Pennsylvania. September 1994 157. Recurrent Depression: A Lifetime Disorder. Invited Speaker. Jackson Area Practitioners. Jackson, Michigan. September 1994 158. Atypical Depression. Invited Speaker. Grand Rounds Presentation. VA Medical Center. Minneapolis, Minnesota. September 1994 159. Recurrent Depression. Grand Rounds Presentation. Hennepin County Medical Center. Minneapolis, Minnesota. September 1994 160. Depression and Awareness in the 90's. Invited Speaker. Primary Care Physicians. Minneapolis, Minnesota. September 1994 161. Depression as a Lifetime Disorder: Implications for Clinicians. Grand Rounds Presentation. Vanderbilt University. Nashville, Tennessee. September 1994 162. Treatment Algorithm in Treatment of Depression. Invited Speaker. Wayne State University and University of Michigan Fifth Annual Psychiatric Conference. Dearborn, Michigan. October 1994 163. Depression in the Primary Care Setting. Invited Speaker. Philippine Medical Association. Southfield, Michigan. October 1994 164. Depression as a Lifetime Disorder - The Issue of Maintenance Therapy. Invited Faculty Member Depression in Primary Care Conference, University of Michigan Departments of Family Practice and Psychiatry. Southfield, Michigan. October 1994 165. Treatment of Recurrent Depression. Invited Speaker. Lakeshore CME. Muskegon, Michigan. October 1994 166. Lifelong Treatment of Depression: The Issue of Maintenance Therapy. Invited Speaker. Michigan State Medical Society Annual Meeting. Dearborn, Michigan. November 1994

John F. Greden, M.D. Page 19 Last Revised December 2019

167. Mood Disorders: Treatment Algorithms. Faculty Member for Advances in Psychiatry VI. Ann Arbor, Michigan. November 1994 168. Diagnostic and Statistical Manual Changes: What Do They Mean in Office Practice Invited Speaker. OHEP Center for Medical Education Conference. Dearborn, Michigan. December 1994 169. Seasonal Affective Disorder. The Mysterious Brain. Invited Speaker at Michigania. December 1994 170. New Agents and New Treatments (Affective Disorders). Discussant for Michigan Psychiatric Society Winter Meeting. Novi, Michigan. February 1995 171. Mysterious Brain: Implications for Physicians of the Future. Pre-Medical Students' Symposium. Ann Arbor, Michigan. March 1995 172. Health Economics. Albion College. Albion, Michigan. March 1995 173. Recurrent Depression. Psychiatry Grand Rounds Presentation, St. Lawrence Hospital, Michigan State University. Lansing, Michigan. April 1995 174. Facts about Schizophrenia, Mood Disorders, and Michigan's Research Contributions: Past, Present and Future. Invited Speaker. Oakland County Alliance for the Mentally Ill. Royal Oak, Michigan. April 1995 175. Depression in a Primary Care Setting. Invited Speaker. CME Presentation, St. Charles Hospital. Oregon, Ohio. April 1995 176. Recurrent Depression: A Lifetime Disorder. Invited Speaker. Spring/Annual Meeting, Ohio Psychiatric Association. Perrysville, Ohio. April 1995 177. The Education of Psychiatrists (Panel Discussion) and Bipolar and Unipolar Disorder (workshop). Tenth Anniversary Conference of the Alliance for the Mentally Ill of Michigan. Novi, Michigan. May 1995 178. Recurrent Depression: A Lifetime Disorder. Invited Speaker. Tenth Congress of German Psychological and Neurological Societies. Freiburg, Germany. May 1995 179. Outcome Studies in Mood Disorders: Perils and Pitfalls (Meet the Expert Program) and Antidepressant Maintenance Medications (Plenary Lectures). Invited Speaker. Lecture Tour, Hungarian Psychiatry Association. Budapest, Pecs, and Szeged, Hungary. May 1995 180. The Lifetime Disorder of Depression. Invited Speaker, Blue Care Network. Linden, Michigan. June 1995 181. Depression: New Advances, New Treatment Options, Management of Difficult Cases. Invited Speaker. Ann Arbor, Michigan. June 1995 182. Better Outcomes with Difficult Cases. Invited Speaker. CME Presentation. San Francisco, California. June 1995 183. Long-term Treatment of Depression. Invited Speaker. Long term Treatment of Depression. Invited Speaker for presentation to Saginaw area psychiatrists. Saginaw, Michigan. June 1995 184. Recognition, Diagnosis and Treatment of Depression. Geriatric Considerations. Invited Speaker. Montgomery Hospital. Livonia, Michigan. July 1995 185. Treatment Algorithms for Mood Disorders. Faculty Member for Advances in Psychiatry IV: Mood and Anxiety Disorders. Mackinac Island, Michigan. August 1995 186. Better Outcomes with Difficult Cases of Depression. Faculty Member for Advances in Psychiatry IV: Mood and Anxiety Disorders. Mackinac Island, Michigan. August 1995 187. Better Outcomes with Difficult Cases. Invited Speaker. Medical College of Ohio Journal Club meeting. Toledo, Ohio. August 1995 188. Recurrent Depression: A Lifetime Disorder. Audio Conference for Family Practice Physicians in the Midwest. September 1995 189. Maintenance Therapy for Depression. Invited Speaker. Chicago Medical School Grand Rounds. North Chicago, Illinois. October 1995 190. Lab Monitoring in Psychiatric Care. Invited Speaker. Grand Rounds Presentation, Battle Creek Health System. Battle Creek, Michigan. October 1995 191. Treatment Algorithms for Mood Disorders. Invited Speaker. Grand Rounds Presentation, Medical University of South Carolina. Charleston, South Carolina. October 1995 John F. Greden, M.D. Page 20 Last Revised December 2019

192. Relapse Following Treatment Discontinuation: Prediction and Prevention. Faculty Member. Advances in Psychiatry VII: Schizophrenia, OCD and Depression. Ann Arbor, Michigan. November 1995 193. Anxiety and Depression. Guest Faculty Member. The Mosaic of Care in the Confused Elderly Conference. Oregon, Ohio. November 1995 194. Better Outcomes for Difficult Cases of Depression. Invited Speaker. A conference presented by the Oakwood Hospital, Annapolis and Merriman Centers. Wayne, Michigan. November 1995 195. Helping Families Cope with Depressive Illnesses. Invited Speaker. Depression Education Coalition. Dearborn, Michigan. November 1995 196. Better Outcomes with Difficult Cases. Invited Faculty Member for the U.S. Psychiatric and Mental Health Congress. New York, New York. November 1995 197. Better Outcomes with Difficult Cases. Invited Speaker. Dinner meeting of the North Oakland Medical Centers. Pontiac, Michigan. January 1996 198. Depression: New Understandings, New Treatments, New Hope. Guest Faculty Member for Current Issues in Psychiatry, Sponsored by Huron Valley Center. Ypsilanti, Michigan. January 1996. 199. Solving the Problem of Refractory Depression. Invited Speaker. Northwest Ohio Psychiatric Association. Toledo, Ohio. February 1996 200. Recurrent Depression. Invited Speaker. Flint area general practice physicians. Linden, Michigan. February 1996 201. Extended Maintenance Treatment of Depression. Keynote Speaker. 125th Anniversary Congress of the Netherlands' Association of Psychiatry. Amsterdam, Netherlands. March 1996* 202. Stress and Depression. Invited discussant for the Women's Health and Life Forum. Dearborn, Michigan. May 1996 203. Depression in General Medical Settings: New Understandings, New Treatments, New Hope. Grand Rounds speaker at Hurley Medical Center. Flint, Michigan. June 1996 204. Impact of Antipsychotic Treatment on Long-Term Course of Schizophrenic Illness. Symposium presented at the Twentieth CINP Congress. Melbourne, Australia. June 1996 205. New Developments in the Treatment of Depression. Guest speaker. National Alliance for Research on Schizophrenia and Depression (NARSAD) Symposium. Dearborn, Michigan. July 1996 206. Bipolar Disorders Update. Guest Speaker. Eleventh Annual Val R. Kostrzewa Memorial Psychiatry Lecture, Saginaw Cooperative Hospitals. Saginaw, Michigan. September 1996 207. Geriatric Depression. Guest Speaker. Forest View Hospital. Grand Rapids, Michigan. September 1996 208. The "New Psychiatry." Keynote Speaker. Administrators in Academic Psychiatry Seventh Annual Fall Conference. Ann Arbor, Michigan. October 1996. 209. Women and Depression: What Have We Learned? Philippine American Association of Family Physicians- Michigan. Southfield, Michigan. October 1996 210. Depression. Blue Cross Blue Shield of Michigan Continuing Medical Education. Southfield, Michigan. January 1997 211. A Practical Approach to the Recognition and Management of Depression: Important Tools for the Primary Care Physician. Co-Med Communications. Louisville, Kentucky. March 1997 212. Antidepressant Maintenance Medications: Neglected Research Questions. Grand Rounds, Stanford University. Palo Alto, California. March 1997* 213. A Practical Approach to the Recognition and Management of Depression: Important Tools for the Primary- Care Physician. Co-Med Communications. Detroit, Michigan. April 1997 214. Antidepressant Maintenance Medications: When to Discontinue, How to Stop. Grand Rounds Presentation, Minneapolis VAMC. Minneapolis, Minnesota. June 1997 215. Antidepressant Maintenance Medications: When to Discontinue, How to Stop. Hennepin County Medical Center. Minneapolis, Minnesota. June 1997

John F. Greden, M.D. Page 21 Last Revised December 2019

216. Extended Maintenance Treatment of Depression: Guidelines for the Clinician. Anchorage Mental Health Symposium. Anchorage, Alaska. July 1997 217. Treatment of Depression. Psychiatric Resident Symposium (Advances in Mood Disorders and Schizophrenia: Diagnoses, Biology and Treatment). Palm Beach, Florida. September 1997* 218. Treatment Outcomes in the Management of Depression. Symposium in Psychiatry, sponsored by Flower Hospital. Toledo, Ohio. September 1997 219. Better Outcomes for Troubling Cases in Primary Care. Invited Faculty Member for University of Michigan Continuing Medical Education Program. The Many Faces of Depression: Recognizing and Treating Depression in Primary Care. Chicago, Illinois. September 1997* 220. Antidepressant Maintenance Treatment: Clinical Guidelines, Research Questions. Grand Rounds Presentation. Baylor College of Medicine. Houston, Texas. October 1997* 221. Improving the Long-Term Treatment of Depression and Enhancing Compliance. Tenth Annual U.S. Psychiatric & Mental Health Congress. Orlando, Florida. November 1997* 222. Mood Disorders. Michigan Association of Community Mental Health Boards (MACMHB) DSM-IV Training. Ann Arbor, Michigan. March 1998* 223. The Mysterious Brain. Invited Speaker, Rotary Club of Ann Arbor. Ann Arbor, Michigan. May 1998* 224. Key Principles of Depression. Invited Speaker. Department of Psychiatry and Glaxo Pharmaceuticals Training Conference. October 1998* 225. The Mysterious Brain. Invited Speaker, Washtenaw County Dental Society. October 1998* 226. The Mysterious Brain. Invited Speaker, Alumni Association of the University of Michigan. November 1998 227. Morbidity of Depression: Major Causes, Target Responses. Annual APA Conference. 1998* 228. The Future of Psychiatry. Keynote Speaker, Michigan Psychiatric Society. January 1999 229. Serotonin: The First Decade. Physicians Postgraduate Press, Continuing Medical Education Seminar. Atlanta, Georgia. February 1999 230. Fundamentals of Establishing a Faculty Group Practice (FGP). University Medical Associates at Syracuse. Syracuse, New York. February 1999 231. Long Term Therapy of Depression. Stanford Third Biannual Psychopharmacology Review Course. Stanford, California. March 1999 232. Integration vs. Isolation: Moving Psychiatry into the Next Millennium. Keynote Speaker. National Meeting of Administrators in Academic Psychiatry. Orlando, Florida. April 1999* 233. A Decade of Serotonin Studies: Beyond Depression. Symposium Chair and Invited Speaker. American Psychiatric Association. Washington, DC. May 1999* 234. Future Trends in Psychiatry. APA Committee for Young Investigators, Research Colloquium for Junior Investigators. Washington, DC. May 1999* 235. The Mysterious Brain. Invited Speaker. Senior Women’s Club. Ann Arbor, Michigan. June 1999 236. Why is Depression Important? Latin American Regional Neuroscience Conference. Eli Lilly and Company. Indianapolis, Indiana. July 1999* 237. New Developments in the Rapidly Changing Field of Depression. Grand Rounds Presentation. University of Southern California. Los Angeles, California. October 1999 238. New Horizons in Depression Management. Invited Speaker. National Depressive and Manic-Depressive Association. Houston, Texas. October 1999* 239. The Mysterious Brain: What Are We Learning? Invited Speaker. The Geriatrics Center, University of Michigan. Ann Arbor, Michigan. January 2000* 240. Depression in Primary Care. Grand Rounds, Oakwood Hospital and Medical Center. Dearborn, Michigan. February 2000* 241. Depression and Neuron Atrophy: Courses, Consequences and Prevention Strategies. Invited Speaker. European Winter Conference on Brain Research. Villars Sur Ollon, Switzerland. March 2000*

John F. Greden, M.D. Page 22 Last Revised December 2019

242. Depression: New Understandings about Morbidity. Invited Speaker. Midwest Nursing Research Society. Dearborn, Michigan. April 2000 243. Making It in Research: Skills and Support. APA Committee of Young Investigators, Research Colloquium for Junior Investigators. Chicago, Illinois. May 2000 244. Why is Depression Important? Grand Rounds, Battle Creek VA Department of Psychiatry. Battle Creek, Michigan. June 2000 245. Treatment Resistant Depression. Depression over the Life Cycle. The University of Michigan Medical School Departments of Psychiatry and Family Medicine. Ann Arbor, Michigan. June 2000* 246. Depression: New Understanding, New Treatments. Psychopharmacology Update: From Bench to Bedside in Psychiatric Practice Lecture. VA Ann Arbor Healthcare System, Department of Psychiatry, University of Michigan. Ann Arbor, Michigan. July 2000* 247. Striking New Advance in Depression. Invited Speaker. Nwocik Golf Outing. Ann Arbor, Michigan. August 2000* 248. Advances in Depression: New Strategies for an Old Problem. Treatment Strategies for Depression in the Millennium Symposium. Saint Joseph Mercy Hospital Behavioral Services. Ann Arbor, Michigan. October 2000* 249. Antidepressant Medications: When to Discontinue (What Happens in the Brain if you do). American College of Osteopathic Neurologists and Psychiatrists Annual Convention in Coordination with the American Osteopathic Association 105th Annual Convention and Scientific Seminar. Orlando, Florida October 2000* 250. Mental Health/Depression. Guest Lecturer, Women’s Health Class, Department of Obstetrics and Gynecology, University of Michigan. Ann Arbor, Michigan. November 2000 251. What if We Really Cared About Depression? Symposium Chair and Speaker Advances in Psychiatry, University of Michigan Medical School Department of Psychiatry Women’s Health Resource Center. Ann Arbor, Michigan. November 2000 252. A Comprehensive Look at Depression and Anxiety in the Year 2000. Annual Health Plus Behavioral Health Conference. Flushing, Michigan. November 2000 253. Neuroscience Advances in Depression: Implications for Neurologists. Grand Rounds Presentation, University of Michigan Department of Neurology. Ann Arbor, Michigan. February 2001* 254. Understanding and Reducing Depression’s Morbidity: New Advances, New Data. Grand Rounds, University of Pennsylvania, Department of Psychiatry. Philadelphia, Pennsylvania. February 2001* 255. Advances in Depression: Exciting Future Developments. Invited Speaker, University of Michigan Health Night Out Ann Arbor, Michigan. February 2001* 256. Neuroscience Advances in Depression: Implications for Pediatricians. Grand Rounds Presentation, University of Michigan Department of Pediatrics. Ann Arbor, Michigan. February 2001* 257. Advances in Depression Research. Grand Rounds, Department of Pharmacology, University of Michigan Medical School. Ann Arbor, Michigan. April 2001* 258. Your Mysterious Brain Revisited. Invited Speaker. Ann Arbor Rotary Club. Ann Arbor, Michigan. April 2001* 259. Neuroscience Advances in Depression: Implications for Obstetricians and Gynecologists. Grand Rounds, University of Michigan, Department of Obstetrics and Gynecology. Ann Arbor, Michigan. April 2001* 260. Clinical Prevention of Recurrent Depression: The Need for Paradigm Shifts. American Psychiatric Association Annual Meeting. New Orleans, Louisiana. May 2001 261. Making it in Research: Motivation, Priorities, Skills, and Support. Sixth Annual APA Colloquium for Young Investigators. New Orleans, Louisiana. May 2001* 262. Novel Approaches to Treatment-Resistant Depression. Invited Speaker. World Congress of Biological Psychiatry. Berlin, Germany. July 2001* 263. Advances in Depression. Implications for Ophthalmologists. Grand Rounds Presentation, University of Michigan, Department of Ophthalmology. Ann Arbor, Michigan. August 2001* John F. Greden, M.D. Page 23 Last Revised December 2019

264. Corporate Partnering: The University of Michigan Comprehensive Depression Center and Wyeth-Ayerst. Ann Arbor, Michigan. August 2001* 265. Neuroscience Advances in Depression: Implications and Translations for Clinicians. Grand Rounds Presentations, The University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences. Steven C. Risse Memorial Lectures. Seattle, Washington. September 2001* 266. “Prevention” of Clinical Depression: Reality or Dream? VA Puget Sound Health Care System American Lake Division. Steven C. Risse Memorial Lectures. Seattle, Washington. September 2001* 267. Fifth Annual Update of Advances in Depression. Grand Rounds, University of Michigan. Ann Arbor, Michigan. September 2001 268. Advances in Depression: The Mosaic is Becoming a Picture. Grand Rounds, Keck School of Medicine at the University of Southern California, Department of Psychiatry. Los Angeles, California. October 2001 269. Prevention of Clinical Depression: Reality or Dream? Invited Speaker. Michigan Psychiatric Society’s Fall Scientific Meeting. Holly, Michigan. November 2001 270. Research Advances in Depression: The Mosaic is becoming a Picture. Invited Speaker. The University of Michigan School of Social Work. Ann Arbor, Michigan. November 2001 271. Treatment of Recurrent Depression: A Call to Arms. University of Michigan Medical School Department of Continuing Medical Education, Advances in Psychiatry. Ann Arbor, Michigan. November 2001* 272. Clinical Depression of Recurrent Depression: The Need for Paradigm Shifts. Symposium Chair and Speaker. University of Michigan Medical School Department of Continuing Medical Education, Advances in Psychiatry. Ann Arbor, Michigan. November 2001* 273. Neuroscience Advances in Depression. The Mosaic is Becoming a Picture. Grand Rounds Presentation, University of Michigan Department of Internal Medicine. Ann Arbor, Michigan. December 2001* 274. Remaining Unmet Needs in Depression: Achieving Remissions for the Depressed Patient. Continuing Medical Education Incorporated. Los Angeles, California. December 2001* 275. Remaining Unmet Needs in Depression: Achieving Remission for the Depressed Patient. United States Central Nervous System National Advisory Board Meeting. Paradise Island, Bahamas. January 2002* 276. Managing Patients with Generalized Anxiety Disorder and Depression. United States Central Nervous System National Advisory Board Meeting. Paradise Island, Bahamas. January 2002* 277. Managing Factors that Affect Long-Term Outcomes. Long-Term Treatment Options: Improving Outcomes in Depression Symposium. Pittsburgh, Pennsylvania. January 2002* 278. Diagnosis and Longitudinal Implications of Co morbid Depression and Pain. Achieving Depression Remission Thought Leaders Summit. Half Moon Bay, California. February 2002* 279. Research Advances in Depression: The Mosaic is becoming a Picture. Wayne State University School of Medicine, Department of Psychiatry and Behavioral Neurosciences Chairman’s Grand Rounds. Detroit, Michigan. February 2002 280. Depression in the Workplace around You. Invited Speaker. Detroit Presidents’ Organization. Detroit, Michigan. February 2002* 281. The Overwhelming Burden of Clinical Depression: Contributors and Solutions. Global Mental Health Forum The University of Michigan School of Public Health. Ann Arbor, Michigan. March 2002 * 282. Making it in Research: Skills and Support. Keynote Speaker. Research Colloquium for Junior Investigators. Philadelphia, Pennsylvania. May 2002* 283. Research Advances in Depression: The Mosaic is becoming a Picture. Grand Rounds, Hennepin County Medical Center, Department of Psychiatry. Minneapolis, Minnesota. June 2002 284. Advances in Depression: “The Mosaic is becoming a Picture.” Invited Speaker. Third Annual National Mental Health Advocacy Conference: Confronting Crisis through Collaboration. Chicago, Illinois. August 2002* 285. The Global Problem of Depression. Invited Speaker. XII World Congress or Psychiatry: World Psychiatric Association Annual Meeting. Yokohama, Japan. August 2002* John F. Greden, M.D. Page 24 Last Revised December 2019

286. Physical Symptoms of Depression: Unmet Needs. Invited Speaker. Journal of Clinical Psychiatry Planning Roundtable and Supplement. Washington, DC. September 2002* 287. Treatment Resistant Prevention: How To Prevent It From Occurring: How to Treat it When it Does. Invited Speaker. CME Dinner Program. Sponsored by Wyeth through Wayne State School of Medicine. Novi, Michigan. September 2002* 288. Depression, Treatment and Family Issues. Invited Speaker. Sixth Annual Symposium in Psychiatry: Psychiatric Disorders and Families. Sponsored by The Toledo Hospital, Flower Hospital and ProMedical Health System. Perrysburg, Ohio. November 2002* 289. Clinical Depression. We are learning so Much! Invited Speaker. First Presbyterian Church. Ann Arbor, Michigan. December 2002 290. Depression: An Essential Meeting Point between Life Sciences and Public Policy in the 21st Century. Invited Speaker. Cross Campus Dinner, Sponsored by University of Michigan Medical Center. Ann Arbor, Michigan. December 2002* 291. Depression In Primary Care: We Are Learning So Much! Invited Speaker. Medical College of Ohio and GlaxoSmithKline. Toledo, Ohio. December 2002* 292. Depressive Illness and the Depression Center at the University of Michigan. Invited Speaker. Ann Arbor Economic Club. Ann Arbor, Michigan. January 2003 293. The Mysterious Brain, Advances in Depression, and the UM Depression Center. Invited Speaker. University Commons. Ann Arbor, Michigan. February 2003* 294. Depression on College Campuses. A “Cliff Notes” Introduction. Invited Speaker. Depression on College Campuses Symposium. University of Michigan. Ann Arbor, Michigan. March 2003* 295. Treatment Resistance: Are there any New Strategies Emerging? Invited Speaker. Forensic Center, Saline, Michigan. March 2003 296. Recent Advances in Depression and Implications for Treatment. Invited Speaker. Grand Rounds Presentation sponsored by Wyeth. State University New York. Stony Brook, New York. April 2003* 297. Depression through the Lifespan. Washtenaw Community Health Organization. Ypsilanti, Michigan. April 2003* 298. Depression Initiatives in the WCHO: Let’s Create a National Model. Washtenaw Community Health Organization. Ypsilanti, Michigan. April 2003* 299. The Role of Painful Physical Symptoms in Preventing Recurrences. Invited Speaker. Neuroscience Global Medical Conference. San Francisco, California. May 2003* 300. Making it in Research. Skills and Support. Keynote Speaker. American Psychiatric Association 8th Annual Colloquium for Junior Investigators. University of California, San Francisco, Langley Porter Psychiatric Institute. San Francisco, California. May 2003 301. Advances in Depression Treatment. Invited Speaker. Psychopharmacology Update: From Bench to Bedside in Psychiatric Practice. CME presentation sponsored by Wyeth. Traverse City, Michigan. July 2003* 302. Primary Care Physicians and Aging Service Providers Specific to Late-Life Depression. Sessions Moderator. Psychopharmacology Update: From Bench to Bedside in Psychiatric Practice. Traverse City, Michigan. July 2003 303. Recent Advances in Depression: Implications for Diagnosis and Treatment. Invited Speaker. Psychopharmacology Update: From Bench to Bedside in Psychiatric Practice. Traverse City, Michigan. July 2003* 304. Getting Started in Psychiatric Residency. Invited Speaker. Duke University Medical Center CNS Summit. Naples, Florida. July 2003 305. Advances in Treatment of Depression. Invited Speaker. Sponsored by Wyeth. Farmington Hills, Michigan. July 2003 306. Pediatric Bipolar Disease. Invited Guest on National Public Radio as Scientific Reporter on All Things Considered. August 2003 John F. Greden, M.D. Page 25 Last Revised December 2019

307. Depression in Men: Let’s Start Finding and Treating it Sooner. Invited Speaker. 16th Annual Conference Depression and Bipolar Support Alliance: Charting a Course: Improving Our Lives. Long Beach, California. August 2003* 308. The ‘Fine Arts’ of Academia. The Roadmap to Success. University of Michigan. September 2003 309. Recent Advances in Depression. Implications for Diagnosis and Treatment. Invited Speaker. Advantage Health Solution Physician Symposium. Indianapolis, Indiana. September 2003* 310. Serotonin and Norepinephrine Mechanisms of Action. 2003 Cymbalta Satellite Symposium, Annual Canadian Psychiatric Association Conference. Halifax, Nova Scotia, Canada. October 2003* 311. Stress and Depression in Athletes: Let’s Start Finding and Treating Them Sooner. University of Michigan Athletic Department. Ann Arbor, Michigan. November 2003* 312. Examining Current Treatment Strategies: What Still Needs to be done? University of Michigan Depression Center, Mini-Medical School on Depressive Illnesses. Ann Arbor, Michigan. November 2003 313. Clinical Neuroscience Advances Regarding Depression. Grand Rounds Presentation, University of Michigan Department of Neurology. Ann Arbor, Michigan. November 2003 314. Chronic Depression: Morbidity and Mortality. Invited Speaker. North Oakland Psychiatric Group. Sponsored by Wyeth. Southfield, Michigan. November 2003 315. Introduction to Pharmacoresistant Depression. Invited Speaker. ACNP San Juan, Puerto Rico. December 2003* 316. New Treatment for Depression. CME presentation. Ann Arbor, Michigan. January 2004* 317. Stress, Sleep, Depression and Athletes: Where do they meet? Invited Speaker. University of Michigan Athletic Department. Ann Arbor, Michigan. January 2004* 318. Depression and Pain: Neuroscience Advancements and Treatments. Grand Rounds Presentation, Medical University of South Carolina Department of Psychiatry. Charleston, South Carolina. January 2004* 319. Clinical Depression and the University of Michigan Depression Center. Invited Speaker. Knight Wallace Journalism Fellows. Ann Arbor, Michigan. March 2004* 320. Treatment of Long Term Depression: Striving Toward a Sustained Response. CME presentation sponsored by The FCG Institute for Continuing Education and IntraMed Scientific Solutions. April 2004* 321. An Implementation Plan for: A New Generation of Psychiatrist Investigators. National Sciences Symposium. Ann Arbor, Michigan. May 2004* 322. Treacherous Triad for Depression. Invited Speaker. American Psychiatric Association Annual Meeting. New York City, New York. May 2004* 323. Perinatal Depression: Burden, Neurobiology and Treatment. Symposium Chair. American Psychiatric Association Annual Meeting. New York City, New York. May 2004 324. Accelerating Medical Discovery to Improve Health. University of Michigan Health Sciences Symposium. Ann Arbor, Michigan. May 2004* 325. Newer Antidepressant Treatments: When and How to Use; When Not to Use. Psychopharmacology Update. Traverse City, Michigan. July 2004 326. The Michigan Blueprint: Closing the Mental Health Gap. Flinn Foundation. Lansing, Michigan. September 2004* 327. Depression: Naming It, Curing It. Michigan Difference Weekend. Ann Arbor, Michigan. October 2004* 328. Stress, Genes, Neuroimaging and Antidepressant Response: Where Do They Meet? Grand Rounds Presentation, Hennepin County Medical Center, Department of Psychiatry. Minneapolis, Minnesota. October 2004 329. Stress, Genes, Neuroimaging and Antidepressant Response: Where Do They Meet? Grand Rounds Presentation, University of Louisville Department of Psychiatry. Louisville, Kentucky. October 2004 330. Depression and Suicide in Youth: Treatment and Prevention. Beijing Suicide Treatment and Prevention Center, Beijing, China. November 2004*

John F. Greden, M.D. Page 26 Last Revised December 2019

331. Depression on College Campuses: A Worldwide Perspective. Beijing Suicide Treatment and Prevention Center, Beijing, China. November 2004* 332. Pediatric Depression: The Pediatrician’s Roadmap through a Conflicted Maze. Grand Rounds Presentation, University of Michigan Department of Pediatrics. December 2004* 333. Advances in Depression: What Have We Learned? Grand Rounds Presentation, University of Michigan Department of Psychiatry. Ann Arbor, Michigan. December 2004* 334. Access to Trial Data. Study Group. ACNP. San Juan, Puerto Rico. December 2004 335. FRIENDS Depression Education Resource Center. University of Michigan. Ann Arbor, Michigan. January 2005* 336. University of Michigan Research Summary Presentation to T-FORE. University of Michigan. Ann Arbor, Michigan. January 2005* 337. Depression: Naming It, Curing It. PEO Women’s Group. Ann Arbor, Michigan. January 2005* 338. Depression and Pain: Where Do They Intersect? University of Michigan Depression Center Colloquium Series. Ann Arbor, Michigan. February 2005* 339. Stress, Sleep, Depression and Aging: Where Do They Meet? Michigan Difference Seminars. Naples and Palm Beach, Florida. February 2005* 340. Stress, Genes, Neuroimaging, and Antidepressants. Grand Rounds Presentation. University of Southern California. Los Angeles, California. March 2005* 341. Depression on College Campuses: 3Rd Annual National Conference. University of Michigan. Ann Arbor, Michigan. March 2005* 342. Stress Mechanisms and Depression: U-M Mini-Medical School. University of Michigan. Ann Arbor, Michigan. April 2005* 343. Stress, Sleep and Depression: New Advances, New Diagnoses, New Treatments? Ann Arbor Women’s City Club. Ann Arbor, Michigan. April 2005* 344. Academic Child Psychiatry’s Role in Advocacy. SPCAP/AACAP 2005 Annual Meeting. Washington, DC. April 2005* 345. Depression, Physical Symptoms and Pain: Pathophysiology and Treatment. 45th Titus Harris Society Annual Meeting. Galveston, Texas. April 2005* 346. Overcoming Traditional Dilemmas in Treating Depressive Illnesses – Evidence-Based Updates. American Psychiatric Association Annual Meeting. Atlanta, Georgia. May 2005* 347. Stress, Genes, Neuroimaging, and Antidepressants. Psychopharmacology Update. Traverse City, Michigan. July 2005* 348. Stress, Sleep, Depression, and Pain: Where Do They Meet? How Do You Treat? University of Michigan M-3 Medical Student Seminar. Ann Arbor, Michigan. July 2005* 349. Effectiveness of Antidepressant Treatments for Preventing Recurrences: Relevance for Forensic Psychiatrists. University of Michigan Forensic Center. Ann Arbor, Michigan. July 2005* 350. Grand Rounds Presentation. University of Cincinnati. Cincinnati, Ohio. November 2005. 351. Effectiveness of Different Antidepressant Treatment Approaches for Preventing Depressive Recurrences: “What Should the Clinician Do?” Grand Rounds Presentation. University of Southern California. Los Angeles, California. February 2006. 352. Depression and Chronic Medical Illnesses: Where Do They Meet? How Should We Treat? BCBSM/UMHS Depression in Chronic Medical Illness CME Program. Lyon Meadows. New Hudson, Michigan. March 2006. 353. Effectiveness of Different Antidepressant Treatment Approaches for Preventing Depressive Recurrences: “What Should the Clinician Do?" Stanford Annual Psychopharmacology Course. Stanford University. Stanford, California. March 2006. 354. Depression on College Campuses: The University’s Role in Responding to Crisis, Disaster, and Loss. Depression on College Campuses Symposium. University of Michigan. Ann Arbor, Michigan. March 2006.

John F. Greden, M.D. Page 27 Last Revised December 2019

355. Stress, Sleep, Depression, and Aging: Where Do They Meet? Medicine at Michigan: Coast to Coast. Scottsdale, Arizona and Palm Springs, California. April 2006. 356. Pediatric Depression: Pediatricians’ Roadmap Through A Conflicted Maze. Grand Rounds Presentation. Beaumont Hospital. Royal Oak, Michigan. April 2006. 357. Effectiveness of Different Antidepressant Treatment Approaches for Preventing Depressive Recurrences: What Should the Clinician Do? Grand Rounds Presentation. Ohio State University. Columbus, Ohio. May 2006 358. Stress, Sleep and Depression: Where Do They Meet? Annual Emeritus Dinner. University of Michigan. Ann Arbor, Michigan. June 2006 359. Depression Center Psychiatry Programs: Where Do We Go From Here? Grand Rounds Presentation. University of Michigan. Ann Arbor, Michigan. August 2006 360. The Depression Center and MBNI: Next Steps. MBNI Grand Rounds. University of Michigan. Ann Arbor, Michigan. September 2006 361. A National Network of Depression Centers. Joint Meeting of National Advisory Board and Scientific Advisory Board. University of Michigan Comprehensive Depression Center. Ann Arbor, Michigan. October 2006 362. Depression at Work: How It Affects Everyone. University of Michigan Depression Center. Ann Arbor, Michigan. October 2006 363. Transforming Depression and Bipolar Treatment: A National Network of Depression Centers (NNDC). Advances in Psychiatry. University of Michigan. Ann Arbor, Michigan. November 2006 364. Effectiveness of Different Antidepressant Treatment Approaches for Preventing Depressive Recurrence: What Should the Clinician Do? Grand Rounds Presentation VA. University of Michigan. Ann Arbor, Michigan. February 2007. 365. National Network of Depression Center's: The Time Has Come. Grand Rounds Presenation Wayne State University. Detroit, Michigan. March 2007. 366. National Network of Depression Center’s: The Time Has Come. WPA International Congress. Melbourne, Australia. November 2007 367. Advances in Depression and Bipolar; Translation Into Real-World Treatments. Indo Australasian Psychiatry Association. WPA International Congress. Melbourne, Australia. November 2007 368. A "22-20" Retrospective and a "20-20" Vision. Grand Rounds Presentation University of Michigan. Ann Arbor, Michigan. December 2007. 369. Mental Illness in Relation to Brain Function: Advances in Treatment. OSHER Lifelong Learning Institute, University of Michigan. Ann Arbor, Michigan. January 2008. 370. A Vision of Rhode Island’s Future of Mental Health Care. Rhode Island Foundation. Providence, Rhode Island. March 2008. 371. Tangled up in Blue: Optimizing Treatment of Depression in the Presence of Comobidities. Annual APA Conference. Walter E Washington Convention Center. Washington, DC. May 2008. 372. Mood Disorders and Cancer. Implications for Treatment. APA Tomoxifen Symposium. Washington, DC. May 2008. 373. A Conceptual Approach to DSM-V Revisions: Implications for Mood Disorders. University of Michigan Comprehensive Depression Center Colloquium. Ann Arbor, Michigan. June 2008. 374. Treatment Resistance and Major Depressive Disorder: Translating Treatment Advances Into Clinical Practice. Grand Rounds Presentation, Mayo Clinic. Rochester, Minnesota. June 2008. 375. Global Networks of Depression Centers and Cancer Centers: A New Model for Transforming Clinical Care. XIV World Congress of Psychiatry, Prague, Czech Republic. September 2008. 376. Educating a New Generation of Psychatrist-Academicians: Imperatives and Approaches Tupin Visiting Professor, UC Davis, November 2008

John F. Greden, M.D. Page 28 Last Revised December 2019

377. Treatment Resistant Depression: Roadmap for Improved Diagnosis, Treatment and Prevention Tupin Visiting Professor, UC Davis, November 2008 378. Treatment Resistant Depression: Roadmap for Improved Diagnosis, Treatment and Prevention Grand Rounds, University of Massachusetts, January 2009 379. Treatment Resistant Depression: Roadmap for Improved Diagnonsis, Treatment and Prevention Michigan Translational and Psychopathology Conference in Psychology, University of Michigan January 2009 380. Mothers, Babies, Depressions, and New Treatments: What Have We Learned? Obstetrics and Gynecology and Women’s Health Center, University of Michigan January 2009 381. Depression and Cardiovascular Disease: What Have We Learned: Cardiovascular Center, University of Michigan, January 2009 382. Treatment Resistant Depression: Roadmap for Improved Diagnosis, Treatment, and Prevention: Invited Speaker Parity Plus, Novi, MI April 2009 383. Morely Lecture Grand Rounds Case Western Reserve University, Cleveland, OH April 2009 384. Advances in Deprsesion: Turning Vision into Action, University of California, San Francisco, School of Nursing Grand Rounds May 2009 385. Treatment Resistant Depression: Roadmap for Improved Diagnosis, Treatment, and Prevention Grand Rounds, University of Illinois, Chicago, September 2009 386. Academic-Industry Partnerships: Launching a New Model Lilly Scientific Board, Chicago, October 2009 387. Personalized Medicine for the Brain, Mayflower Action Group, Washington, DC, October 2009 388. Views of Genetic and Genomic Illness, Promoting Research on Severe Mental Illness NARSAD, Banbury Center, Cold Spring Harbor NY December 2009 389. No Citizen-Soldiers Left Behind: Innovative Strategies for Overcoming Stigma and Treating Returning National Guard Veterans Association for Research in Neuro and Mental Diseases, New York City, December 2009 390. No Citizen-Soldiers Left Behind: Innovative Strategies for Overcoming Stigma and Treating Returning National Guard Veterans Department of Defense, Washington, DC. January, 2010 391. Personalized Medicine for the Brain: Role of the National Network of Depression Centers (NNDC) Grand Rounds, University of Texas Southwestern, Houston January 2010 392. Treatment Resistant Depression: What Have We Learned? Psychiatric Update, Madison, WI, March 2010 393. Progress through Partnership Cedars Sinai Grand Rounds, Los Angeles, CA, April 2010 394. Progress through Partnership ULCA Grand Rounds, Westwood, CA, April 2010 395. Progress through Partnership 24th Annual Mood Disorders Research/Education Conference, Johns Hopkins University, Baltimore, MD 2010 396. Health Education Summit, Carter Center/American College of Psychiatrists, Carter Center, Atlanta, GA October 2010 397. No Soldiers Left Behind; Key Initiatives to Counteract Veterans’ Stigma Institute of Medicine, Building a Quality Management System and Scopes of Practice for the Military Under TRICARE in Washington, D.C. October 2010 398. Understanding, Addressing and Combating Stigma Surrounding Seeking Help for Psychological Health Issues in Today’s Military Webinar Defense Centers of Excellence November 2010 399. Treatment Resistant Depression – Roadmap for Effective Care - University of Utah Grand Rounds April 2011 400. Development 101 – Humble Suggestions from a Now-believer – University of Utah April 2011 401. Treatment Resistant Depression – Roadmap for Effective Care – Utah Psychiatric Society April 2011 402. Treatment Resistant Depression – Roadmap for Effective Care – Symposium, American Psychiatric Association Annual Meeting, Honolulu, HI May 2011 403. Treatment Resistant Depression – Roadmap for Effective Care – Small Interactive Session, American Psychiatric Association Annual Meeting, Honolulu, HI May 2011 John F. Greden, M.D. Page 29 Last Revised December 2019

404. Treatment Resistant Depression – Roadmap for Effective Care – Symposium, World Congress of Psychiatry, Buenos Aires, Brazil September 2011 405. Treatment Resistant Depression – Roadmap for Effective Care – Grand Rounds, Penn State University, Hershey, PA November 2011 406. Overcoming the Crisis in Psychiatric Drug Discovery: Partner or Perish – Panel, American College of Neuropsychopharmacology, Kona, HI December 2011 407. Longitudinal Course: Key “Alert Signal” for Treatment Resistant Depression – Symposium, Society of Biological Psychiatry Annual Meeting, Philadelphia, PA May 2012 408. Treatment Resistant Depression, Small Interactive Session - American Psychiatric Association Annual Meeting, Philadelphia, PA May 2012 409. Personalized, Precision Treatments for Clinical Depressions and Bipolar Illnesses: What Have We Learned, Can We Apply Clinically (And How Can Mayo Help Improve)? Grand Rounds Mayo Clinic, Rochester, MN 2012 410. If You Don’t Take the Treatments, You Don’t Get Better: Strategies for Improving Adherence, Center For Forensic Psychiatry, Ann Arbor, MI June 2012 411. Strategies for Improving Treatment Adherence:”The Neglected Component of Good Outcomes for Depression and Bipolar” 30th Annual Psychopharmacology Update, Toledo, OH September 2012 412. Depression, Stress and Biosensors Powering up Brain Research: One Mind for Research and Guardian Angels for a Smarter Life, New York City, NY November, 2012 413. Treatment Resistant Depression: It Will Take a Collaborative Village to Develop Personalized Treatments Psychiatric Research Society, Park City, UT, February 2013 414. Treatment Resistant Depression: It Takes a Global Village. University of Michigan Psychiatry Residents, Ann Arbor, MI August 28, 2013 415. Depression and Bipolar Illness: Progress Through NNDC Partnership. Duke Psychiatry and Behavioral Sciences Inaugural Advisory Board Meeting, Durham, NC September 10, 2013 416. Research Extravaganza. University of Illinois Chicago Department of Psychiatry and Depression Center, Visiting Professor, Chicago, IL September 18, 2013 417. Depressions and Bipolar Illnesses: Inisible Disabilites – Hidden Stories. Neubacher Award Presentation, University of Michigan, Ann Arbor, MI October 25, 2013 418. University of Michigan Comprehensive Depression Center: An Update. Victors for Michigan Campaign Kick-Off, University of Michigan Hospital and Health Systems, Ann Arbor, MI November 6, 2013 419. Mood Disorders and the University of Michigan Comprehensive Depression Center: Join us in the campaign. Department of Psychiatry Retreat, University of Michigan, Ann Arbor, MI January 23, 2014 420. Funding Our Future: “Development 101” From a Faculty Perspective. Department of Psychiatry Grand Rounds, University of Michigan, Ann Arbor, MI February 26, 2014 421. Biological Markers to Help Prevent Treatment Resistant Depression. Qatar Neuroscience Meeting, Doha, Qatar, March 17, 2014 422. The Epidemiology and Public Health Consequences of Suicide: A Call to Action. The 2014 Menninger Clinic Annual Symposium: “The Problem of Suicide” Houston, TX March 28, 2014 423. Personalized, Rapid Treatment for Suicide Risk: A Call to Action. Investigators’ Meeting, Janssen Pharmaceutical, Chicago, IL April 24, 2014 424. Suicide Prevention Updates and Preceptions for Clinicians and Immergin Scholars. American Psychiatric Association Annual Meeting, New York, NY May 4, 2014 425. Treatment Resistant Depression: Importance of Biomarkers and Personalized Treatments. Psychiatry in 2014 McLean Hospital, Harvard University, Boston, MA June 13, 2014 426. Personalized, Rapid Treatment for Suicide Risk: New Treatment Approaches. GeneSight ARX1006 Investigators Meeting: A Call to Action. AssurerX, Chicago, IL July 19, 2014

John F. Greden, M.D. Page 30 Last Revised December 2019

427. Mood Disorders and Disabilities: Where Do They Meet? How Do We Treat? Services For Students With Disabilities 40th Fall Conference, University of Michigan, Ann Arbor, MI October 17, 2014 428. Mood Disorders: How Do We Treat? M-3 Medical Students, University of Michigan, Ann Arbor, MI February 9, 2015 429. Precision Treatments for Mood Disorders Require Global Network Collaborations. Canadian Depression Research Intervention Network (CDRIN) Annual Conference, Ottawa, Ontario, CANADA, February 24, 2015 430. Precision Treatments for Mood Disorders: The Time Has Come for the National Network of Depression Centers (NNDC). Grand Rounds, Florida State University, Tallahassee Medical Campus, Tallahassee, FL April 6, 2015 431. Precision Treatments for Mood Disorders. Psychiatry Grand Rounds, Western Michigan University Homer Stryker, MD School of Medicine, Kalamazoo, MI April 14, 2015 432. Can Infants and Children Be Depressed? A Look at Research and Intervention. Todd Ouida Annual Conference, Montclair State University, Montclair, NJ May 1, 2015 433. A Pre-Competitive Network to Develop Personalized, Precision Treatments for Depressions and Bipolar Illnesses. 4th Annual One Mind Summit, Arlington, VA May 28, 2015 434. Personalized, Precision Treatments for Depressions and Bipolar Illnesses: The Time Has Come. Grand Rounds, Pine Rest Christian Mental Health Services, Grand Rapids, MI June 3, 2015 435. Depressions and Bipolar Illnesses: Why “One Size” Treatment Will Never Fit All. Mark Rayport Lecture, University of Toledo, Toledo, OH, October 1, 2015 436. Personalized, Precision Treatments for Depressions and Bipolar Illnesses: The Time Has Come. The Harold Cooper Lectureship, University of Texas Houston, Houston, TX, November 11, 2015 437. Personalized Treatments For Depressions and Bipolar Illnesses: What Can We Do NOW? Michigan Psychiatric Society Annual Spring Meeting, Ann Arbor, MI, April 15, 2016 438. Stress, Sleep, Depression, Athletes and Performance: Where do they meet? University of Michigan Athletics Department, Ann Arbor, MI, April 27, 2016 439. Mood Disorders: Depressions, Bipolar Illnesses and Related Disorders. M-3 Medical Students, University of Michigan, Ann Arbor, MI, May 9, 2016 440. Personalized Treatments For Depressions and Bipolar Illnesses: The Time Has Come. Ohio State University, Columbus, OH, September 21, 2016 441. Personalized Treatments For Depressions and Bipolar Illnesses: The Time Has Come. Indiana University, Indianapolis, IN, October 14, 2016 442. Personalized, Precise Treatments For Depressions and Bipolar Illnesses: A Paradigm Shift. NNDC Visiting Professorship, Mayo Clinic, Rochester, MN, December 14, 2016 443. Seasonal Affective Disorder: Is it real? NNDC Visiting Professorship, Mayo Clinic, Rochester, MN, December 15, 2016 444. Depression Across the Lifespan: Impact on the Workplace. Steelcase Corporation, Grand Rapids, MI, December 19, 2016 445. The Nation’s Need for a Depression Center and Why The University of Michigan Was First. Rotary Club of Ann Arbor, March 15, 2017 446. Personalized, Precision Treatments for Depressions and Bipolar Illnesses: The Time Has Come! University of Louisville, Louisville, KY, November 9, 2017 447. Finding the Best Treatment for Each Person. University of Louisville, Louisville, KY, November 9, 2017 448. Workshop: Treatment Resistant Depression: It May Be Possible. University of Louisville, Louisville, KY, November 10, 2017 449. Personalized, Precision Interventions for Depression and Bipolar Illnesses: The time has come. University of Connecticut Department of Psychiatry Grand Rounds, Hartford, CT. March 2, 2018. 450. Personalized, Precision Interventions for Depression and Bipolar Illnesses: The time has come. University of Florida Department of Psychiatry Grand Rounds, Gainsville, FL. December 14, 2018. John F. Greden, M.D. Page 31 Last Revised December 2019

451. Personalized, Precision Treatments for Depression and Anxiety Disorders on College Campuses: The time has come! Depression on College Campuses Conference Key Note Speaker, University of Michigan, March 14, 2019 452. Pharmacogenomics of Depression: A tool for Precision Treatment. Pine Rest Depression Summit. Pine Rest Postma Center, Michigan State University Division of Pyschiatry and Behavioral Medicine, Pine Rest Christian Mental Health Services. Grand Rapids, MI. April 26, 2019. 453. GUIDED Pharmacogenomic Testing Improves Clinical Response and Remission in Major Depressive Disorder: Emerging Research Questions.Precision Genomics Midwest Conference. Kingsgate Conference Center, University of Cincinnati, Cincinnati, OH. May 10, 2019 454. Pharmacogenomic Testing in Psychiatric Practice: Does it Deliver What it Promises? American Society of Clinical Pharmacology Annual Meeting, Scottsdale, AZ. May 28, 2019. 455. Pharmecogenomics Panel Discussion – Palmetto GBA, LCD CAC meeting, San Francisco, CA. June 26, 2019. 456. Aging with Happiness: Replacing Depression with Wellness Later in Life. Chelsea Adult Learning Institute, Chelsea, MI. September 9, 2019 457. Precision Health for Depression and Bipolar Illnesses: What to do when One-Size Treatment Doesn’t Fit All? Sheppard Pratt Grand Rounds – Wolfe Adler Lecture, October 16, 2019. 458. Pharmacogenomic Testing For Depressions in Medical Practice: Does It Deliver What It Promises? St. Joseph Mercy Health System Psychiatry Grand Rounds – November, 2019 459. Title: TBD - Penn State Grand Rounds, March 5, 2020

Committee and Administrative Service Department of Psychiatry 1974 Subcommittee to Evaluate Extramural Psychiatric Consultation 1974-1978 Resident Education Committee 1974-1978 Resident Education Committee (Chair) 1975 Quality Assurance Committee 1975 Subcommittee to Evaluate Child and Adolescent Rotation in Psychiatry Residency (Chair) 1975-1978 Policy Committee 1975-1978 Subcommittee to Formulate Irreducible Experiential Core Curriculum for Psychiatry Residents (Chair) 1982 Committee to Formulate Research Track for Psychiatric Residents 1983-1985 Research Track Committee 1984-1985 Appointments and Promotions Committee (Chair) 1984-2007 Chair, Chairman's Advisory Committee 1985-2007 Chair of Department of Psychiatry University of Michigan 1985-2007 Mental Health Research Institute Executive Committee 2017-Present Ex-Officio Committee Member for the Eisenberg Scholars and Research Prize Committees 2017-Present Royal-Mach-Gaensslen Prize for Mental Health Research 2019-Present TRImaran Pharmaceutical, Advisory Board invitation, under discussion

Medical School/Hospital 1974-1995 Senior Medical Student Counselor 1975-1981 Neural and Behavioral Sciences (NBS) Committee 1976 Chair, Subcommittee of Committee on Academic Affairs to Evaluate Course on Reproductive Endocrinology and Sexuality

John F. Greden, M.D. Page 32 Last Revised December 2019

1976-1977 Chair, Subcommittee of Committee on Academic Affairs to Evaluate Basic Science and Clinical Phases of Neural and Behavioral Sciences (NBS) 1979-1981 Director, Neural and Behavioral Sciences (NBS) 1982-1983 Vice-Chair, Internal Medicine External Review Committee 1985-2007 Dean's Advisory Council 1985-1994 Medical Service Plan Advisory Committee 1985-Present VA Dean's Advisory Council 1987-1989 University Hospitals Executive Team Consultation and Referral Effort Committee 1989 Chair, Department of Pediatrics External Review Committee 1989-Present Internal Advisory Committee, University of Michigan Geriatric Research and Training Center 1989-1999 University Hospitals Advisory Group 1989-2002 Internal Advisory Committee, Michigan Alzheimer's Disease Research Center 1989-1991 Executive Committee of the Medical School 1989-1992 UMMC Development Advisory Committee 1990 Clinical Affairs & Financial Committee 1990-1994 Executive Committee on Clinical Affairs (ECCA) 1990 Advisory Committee, University of Michigan Clinical Research Center (CRC) 1990-1994 Hospital Executive Board 1991-1994 Medical Service Plan Executive Committee 1991-1994 Faculty Advisor, Alpha Omega Alpha (AOA) 1993-1995 Board of Directors, Chelsea-Arbor Treatment Center 1993-2003 Institutional Advisory Committee, Robert Wood Johnson Clinical Scholars Program 1993 Medical Center Focus on Achievement Program 1995 Chair, Faculty Communications Task Force 1995-1996 Medical Service Plan Advisory Committee 1996 Dean's Cabinet 1996-1998 Inaugural Chair, Faculty Group Practice Board of Directors 1996-1998 Member, Clinical Delivery System (CDS) Executive Committee (CDSEC) 1996-Present Graduate Medical Education Review Board 1996-Present Clinical Chairs' Advisory Council 1996-Present Member, Geriatric Steering Committee 1996-1999 Board Representative to Hospital and Health Centers Executive Committee (HHCEC) for Faculty Group Practice 1996-1998 Chair, Strategic Planning Committee, Faculty Group Practice 1998-2007 Executive Committee, University of Michigan Comprehensive Cancer Center 1998-Present Member, Faculty Group Practice Board of Directors 1999-Present Member, Steering Committee, Strategic Planning Committee, Faculty Group Practice 1999-2000 Member, Clinical Quality Improvement Program Lead Team 2000-Present Member, Steering Committee, University of Michigan Strategic Planning Committee 2000-2003 Member, General Clinical Research Center (GCRC) Policy Committee 2002-Present Member, Senior Leadership Council 2003-Present Member, Institutional Setting Subcommittee, University of Michigan Liaison Committee on Medical Education (LCME) 2004-Present Member, Ambulatory Care Executive Committee 2005-2010 Member, Advisory Board, Addiction Research Center and Substance Abuse Section 2006-2008 Member, Cancer Center Executive Committee

University of Michigan John F. Greden, M.D. Page 33 Last Revised December 2019

1980-1983 Neuroscience Ph.D. Program Committee 1986-1989 Chair, Committee to Establish University of Michigan Substance Abuse Research Center (UMSARC) 1990-1991 Chair, Search Committee for Dean of the Medical School 1992-Present Member, University of Michigan Substance Abuse Research Center (UMSARC) 1995 Chair, Search Committee for Directorship of the Mental Health Research Institute 1998-1999 Member, Executive Committee, Tobacco Research Consortium 2000-2003 Member, Internal Advisory Committee, Nicotine Research Consortium: Neuroscience of Nicotine Dependence and Co-Factors 2002-2003 Member, Presidential Search Committee, University of Michigan (President Mary Sue Coleman selected) 2002-2003 Member, Center for Human Growth and Development Director Search Committee 2002-2004 Member, Steering Committee, Advanced Study Center, ISR Member, Task Force on the Research Enterprise (T-FORE) Committee Member, Cancer Center Executive Committee 2010 Member,Provost’s Office Cluster Hire Programs, Interdisciplinary Junior Faculty Initiative, Review Committee 2011 Chair, Provost’s Office Cluster Hire Programs, Interdisciplinary Faculty Initiative Review Committee

Bibliography Peer-Reviewed Publications 1. Briggs PF, Laperriere R, Greden JF: Working Outside the Home and the Occurrence of Depression in Middle-Aged Women. Mental Hygiene, 49:438-442, 1965* 2. Greden JF, Morgan DW: Patterns of Drug use and Attitudes toward Treatment in a Military Population. Archives of General Psychiatry, 26:113-117, 1972* 3. Greden, Morgan DW: Amnesty’s Impact upon Drug Use: A Pre/Post Study. American Journal of Psychiatry, 129:392-397, 1972* 4. Greden JF, Morgan DW, Frenkel SI: The Changing Drug Scene: 1970-1972. American Journal of Psychiatry, 131:77-81, 1974* 5. Greden JF: Anxiety or Caffeinism: A Diagnostic Dilemma. American Journal of Psychiatry, 131:1089 1092, 1974* 6. Greden JF, Frenkel SI, Morgan DW: Alcohol Use in the Army: Patterns and Associated Behavior. American Journal of Psychiatry, 132:11-16, 1975 7. Greden JF, Casariego JI: Controversies in Psychiatric Education: A Survey of Residents’ Attitudes American Journal of Psychiatry, 132:274-277, 1975* 8. Miller, Genevieve, Waring JI, Williams WH, Blake JB, Duffy J, Cash P, Andreasen NJC, Greden JF, Saffron MH, Carlson FT, Wollock JL, Beatty WK, Beatty VL, Cowen DL: A Physician in 1776. Journal of the American Medical Association, 236:26-30, 1976 9. Greden JF: The Tea Controversy in Colonial America. Journal of the American Medical Association, 236:63- 66, 1976 10. Frenkel SI, Greden JF, Morgan DW: Heroin Use in the United States and Vietnam: A Comparison in Retrospect. International Journal of Addictions, 12:1143-1154, 1977* 11. Casariego JI, Greden JF: Perceptions of Treatment Value, Therapeutic Orientation and Actual Experiences of Psychiatric Residents. Comprehensive Psychiatry, 19:241-248, 1978* 12. Greden JF, Fontaine P, Lubetsky M, Chamberlain K: Anxiety and Depression Associated with Caffeinism among Psychiatric Inpatients. American Journal of Psychiatry, 135:963-966, 1978* 13. Greden JF: Child Psychiatry for General Residents. American Journal of Psychiatry, 136:213-216, 1979* John F. Greden, M.D. Page 34 Last Revised December 2019

14. Greden JF, Brandow M, Burpee C, Przepiorka K: Interdisciplinary Differences on General Hospital Psychiatry Unit. General Hospital Psychiatry, 1:91-97, 1979* 15. Greden JF, Carroll BJ: The Dexamethasone Suppression Test as a Diagnostic Aid in Catatonia. American Journal of Psychiatry, 136:1199-1200, 1979* 16. Frenkel SI, Greden JF, Robinson JA, Guyden TE, Miller R: Does Patient Contact Change Racial Perceptions? American Journal of Nursing, 80:1340 342, 1980* 17. Greden JF, Carroll BJ: Decrease in Speech Pause Times with Treatment of Endogenous Depression. Biological Psychiatry, 15:575-587, 1980* 18. Greden JF, Victor B: Caffeine-Withdrawal Headache: A Clinical Profile. Psychosomatics, 21:411-418, 1980* 19. Greden JF, Albala AA, Haskett RF, James NM, Goodman L, Steiner M, Carroll BJ: Normalization of Dexamethasone Suppression Test: A Laboratory Index of Recovery from Endogenous Depression. Biological Psychiatry, 15(3):449-58, 1980* 20. Albala AA, Greden JF, Carroll BJ: Serial Dexamethasone Suppression Tests in Affective Disorders. American Journal of Psychiatry, 137:383, 1980* 21. Carroll BJ, Greden JF, Haskett RF, Feinberg M, Albala AA, Martin FIR, Rubin RT, Heath B, Sharp PT, McLeod WL, McLeod MF: Neurotransmitter studies of Neuroendocrine Pathology in Depression. Acta Psychiatrica Scandinavica, 280:183-198, 1980 22. Carroll BJ, Greden JF, Feinberg M: Neuroendocrine Disturbances and the Diagnosis and Etiology of Endogenous Depression. Lancet, 1:321-322, 1980* 23. Carroll BJ, Schroeder K, Mukhopadhyay S, Greden JF, Feinberg M, Ritchie J, Tarika J: Plasma Dexamethasone Concentrations and Cortisol Suppression Response in Patients with Endogenous Depression. Journal of Clinical Endocrinology and Metabolism, 51:433-437, 1980* 24. Carroll BJ, Greden JF, Feinberg M: Neuroendocrine Dysfunction in Genetic Subtypes of Primary Unipolar Depression. Psychiatry Research, 2:251-258, 1980* 25. Carroll BJ, Feinberg M, Greden JF: Diagnosis of Endogenous Depression: Comparison of Clinical, Research, and Neuroendocrine Criteria. Journal of Affective Disorders, 2:177-194, 1980* 26. Greden JF and Domino L: Caffeine Withdrawal Headache. New England Journal of Medicine, 303(4):221, 1980 27. Carroll BJ, Feinberg M, Greden JF, James NM, Haskett RF, Steiner M, Albala AA, DeVigne JP, Tarika J: Neuroendocrine Diagnostic Criteria for Depression. Psychopharmacology Bulletin, 16:42-44, 1980 28. Victor B, Greden JF: Somatic Manifestations of Caffeinism. Journal of Clinical Psychiatry, 42:185-188, 1981* 29. Carroll BJ, Feinberg M, Smouse PE, Rawson SF, Greden JF: The Carroll Rating Scale for Depression I. Development, Reliability, and Validation. British Journal of Psychiatry, 138:194-200, 1981* 30. Feinberg M, Greden JF, Zis AP, Carroll BJ: Effect of Dextroamphetamine on Plasma Cortisol in Endogenously Depressed and Non- Endogenously Depressed Patients. Psychosomatic Medicine 43:82-83, 1981* 31. Greden JF, Carroll BJ: Psychomotor Function in Affective Disorders: An Overview of New Monitoring Techniques. American Journal of Psychiatry, 138:1441-1448, 1981* 32. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, DeVigne JP, Young, E: A Specific Laboratory Test for the Diagnosis of Melancholia. Standardization, Validation, and Clinical Utility. Archives of General Psychiatry, 38:15-22, 1981* 33. Albala AA, Greden JF, Tarika J, Carroll BJ: Changes in Serial Dexamethasone Suppression Tests among Unipolar Depressives receiving Electroconvulsive Treatments. Biological Psychiatry, 16:551-560, 1981* 34. Greden JF, Albala AA, Smokler IA, Gardner R, Carroll BJ: Speech Pause Time: A Marker of Psychomotor Retardation among Endogenous Depressives. Biological Psychiatry, 16:851-859, 1981* 35. Kronfol Z, Greden JF, Carroll BJ: Psychiatric Aspects of Diabetes Mellitus: Diabetes and Depression. British Journal of Psychiatry, 139:171-172, 1981* John F. Greden, M.D. Page 35 Last Revised December 2019

36. Greden JF, Procter A, Victor B: Caffeinism Associated with Greater Use of Other Psychotropic Agents. Comprehensive Psychiatry, 22:565-571, 1981* 37. Garcia-Sevilla JA, Zis AP, Hollingsworth PH, Greden JF, Smith CB: Platelet Alpha-2 Adrenergic Receptors in Major Depressive Disorders. Archives of General Psychiatry, 38:1327-1333, 1981* 38. Greden JF, Kronfol Z, DeVigne JP, Albala AA, Gardner R, Carroll BJ: Dexamethasone Suppression Test and Selection of Antidepressant Medications. Journal of Affective Disorders, 3:389-396, 1981* 39. Feinberg M, Gillin JC, Carroll BJ, Greden JF, Zis AP: EEG Studies of Sleep in the Diagnosis of Depression. Biological Psychiatry, 17:305-315, 1982* 40. Greden JF, DeVigne JP, Albala AA, Tarika J, Buttenheim P, Eiser A, Carroll BJ: Serial Dexamethasone Suppression Tests Among Rapidly Cycling Bipolar Patients. Biological Psychiatry, 17:455-462, 1982* 41. Greden JF: Biological Markers of Melancholia and Reclassification of Depressive Disorders. Encephale, 8:193-202, 1982* 42. Privitera MR, Greden JF, Gardner RW, Ritchie JR, Carroll BJ: Interference by Carbamazepine with the Dexamethasone Suppression Test. Biological Psychiatry, 17:611-621, 1982* 43. Kronfol Z, Greden JF, Condon M, Feinberg M, Carroll BJ: Application of Biological Markers in Depression Secondary to Thyrotoxicosis. American Journal of Psychiatry, 138:1319-1322, 1982* 44. Proctor AW and Greden JF: Caffeine and Benzodiazepines. American Journal of Psychiatry, 139:132, 1982 45. Feinberg M, Greden JF, Carroll BJ: The Effect of Amphetamine on Plasma Cortisol in Patients with Endogenous and Non-Endogenous Depression. Psychoneuroendocrinology, 6:355-357, 1982* 46. Matthews J, Akil H, Greden JF, Watson SJ: Plasma Measures of Beta-Endorphin-Like Immunoreactivity in Depressive and other Psychiatric Subjects. Life Sciences, 31:1867-1870, 1982* 47. Feinberg M, Carroll BJ, Greden JF, Zis AP: Sleep EEG, Depression Rating Scales, and Diagnosis. Biological Psychiatry, 17:1453-1458, 1982* 48. Kronfol Z, Greden JF, Gardner R, Carroll BJ: Suicidal Behavior and the DSTs: Lack of an Association. American Journal of Psychiatry, 139:1214-1215, 1982* 49. Greden JF, Gardner R, King LD, Grunhaus L, Carroll BJ, Kronfol Z: Dexamethasone Suppression Tests in Antidepressant Treatment of Melancholia: The Process of Normalization and Test- Retest Reproducibility. Archives of General Psychiatry, 40:493-500, 1983* 50. Grunhaus L, Greden JF, Carroll BJ: Dexamethasone Suppression Test in Primary Degenerative Dementia. American Journal of Psychiatry. 140(8):1098-9, 1983 51. Kronfol Z, Greden JF, Zis AP: Imipramine-Induced Tremor. Description, Course, and Effects of a Beta Adrenergic Blocking Agent. Journal of Clinical Psychiatry, 44:225-226,1983* 52. Dilsaver S, Kronfol Z, Sackellares C, Greden JF: Antidepressant Withdrawal Syndromes: Evidence Supporting the Cholinergic Overdrive Hypothesis. Journal of Clinical Psychopharmacology, 3:157-164, 1983* 53. Grunhaus L, Dilsaver S, Greden JF, Carroll BJ: Depressive Pseudodementia: A Suggested Diagnostic Profile. Biological Psychiatry, 18:215-225, 1983* 54. Baer RK, Muecke MM, Nasr S, Laymeyer HW, Gaviria FM, Dysken MW, Akiskal HS, Dilsaver SC, Greden JF: Biological and Family Indicators in Depression. Journal of Clinical Psychiatry, 44:372-378, 1983* 55. Kroll P, Palmer C, Ritchie J, Greden JF: The Dexamethasone Suppression Test in Patients with Alcoholism. Biological Psychiatry, 18:441-450, 1983* 56. Kronfol Z, Greden JF: The Dexamethasone Suppression Test in Patients with Thyroid Disease. Journal of Clinical Psychopharmacology, 3:282-283, 1983 57. Dilsaver SC, Feinberg M, Greden JF: Antidepressant Withdrawal Symptoms Treated with Anticholinergic Agents. American Journal of Psychiatry, 140:249-251, 1983* 58. Grunhaus L, Greden JF, Carroll BJ, Shein H: The Dexamethasone Suppression Test in Repeated Hospitalizations. Biological Psychiatry, 18:1497-1503, 1983*

John F. Greden, M.D. Page 36 Last Revised December 2019

59. Kronfol Z, Silva J, Greden JF, Dembinski S, Gardner R, Carroll BJ: Impaired Lymphocyte Function in Depressive Illness. Life Sciences, 33:241-247, 1983* 60. Dilsaver SC and Greden JF: The DST in Borderline Patients. American Journal of Psychiatry, 140:1540-1541, 1983* 61. Dilsaver SC and Greden JF: Possible Cholinergic Mechanism in Reserpine and Tardive Dyskinesia. American Journal of Psychiatry, 141:151-152, 1984 62. Dilsaver SC and Greden JF: Antidepressant Withdrawal Phenomena: A Review. Biological Psychiatry, 19:237-256, 1984* 63. Cameron OG, Kronfol Z, Greden JF, Carroll BJ: Hypothalamic-Pituitary-Adreno-Cortical Activity in Patients with Diabetes Mellitus. Archives of General Psychiatry, 41:1090-1095, 1984 64. Feinberg M, Carroll BJ, King D, Greden JF: The Effect of Dexamethasone on Sleep: Preliminary Results in Eleven Patients. Biological Psychiatry, 19:771-775, 1984* 65. Greden JF, Price HL, Genero N, Feinberg M, Levine S: Facial EMG Activity Levels Predict Treatment Outcome in Depressives. Psychiatry Research, 13:345-352, 1984* 66. Dilsaver SC and Greden JF: Antidepressant Withdrawal-Induced Activation (Hypomania and Mania): Mechanisms and Theoretical Significance. Brain Research Reviews, 7:29-48,1984* 67. Grunhaus L, King D, Greden JF, Flegel P: Depression and Panic in Patients with Borderline Personality Disorder. Biological Psychiatry, 20:688-692, 1985* 68. Grunhaus L, Tiongco D, Roehrich H, Eiser A, Feinberg M, Greden JF: Serial Monitoring of Antidepressant Response to Electroconvulsive Therapy with Sleep-EEG Recordings and Dexamethasone Suppression Tests. Biological Psychiatry, 20:805-808, 1985* 69. Kumar A, Greden JF, Eiser A: Sleep Onset REM Period in Chronic Paranoid Schizophrenia. Biological Psychiatry, 20:815-816, 1985* 70. Dilsaver SC, Greden JF: Effects of Antidepressant Withdrawal on the Dexamethasone Suppression Test. Psychiatry Research, 14:111-122, 1985* 71. Grunhaus L, Flegel P, Carroll BJ, Greden JF: Self-Reported Diurnal Mood Changes, Early Morning Awakening and the Dexamethasone Suppression Test in Endogenous Depression. Journal of Affective Disorders, 8:1-7, 1985* 72. Lee M, Cameron OG, Greden JF: Anxiety and Caffeine Consumption in People with Anxiety Disorders. Psychiatry Research, 15:211-217, 1985* 73. Greden J, Genero N, Price HL: Agitation Increased Activity in the Corrugator Muscle Region: A Possible Explanation of the “Omega Sign”? American Journal of Psychiatry, 142:348-351. 1985* 74. Rihmer Z, Arato M, Greden JF: Possible Dexamethasone Influences on Subsequent Serial DST Results. American Journal of Psychiatry, 142:519-520, 1985 75. Stoutemire B and Greden JF: Hypothalamic-Pituitary-Adrenal Axis and Thyroid Testing. American Journal of Psychiatry, 142:622, 1985 76. Grunhaus L, Rabin D, Greden JF: Simultaneous Panic and Depressive Disorder: Response to Antidepressant Treatments. Journal of Clinical Psychiatry, 47:4-7, 1986* 77. Greden JF, Genero N, Price HL, Feinberg M, Levine S: Facial Electromyography in Depression: Subgroup Differences. Archives of General Psychiatry, 43:269-274, 1986* 78. Kronfol Z, House JD, Silva J, Greden JF, Carroll BJ: Depression, Urinary-Free Cortisol Excretion and Lymphocyte Function. British Journal of Psychiatry, 148:70-73, 1986* 79. Kumar A, Alcser K, Grunhaus L, Greden JF: Relationships of the Dexamethasone Suppression Test to Clinical Severity and Degree of Melancholia. Biological Psychiatry, 21:436-444, 1986* 80. Grunhaus L, Rabin D, Harel V, Greden JF, Feinberg M, Herman R: Simultaneous Panic and Depressive Disorders: Clinical and Sleep EEG correlates. Psychiatry Research, 17:251-259, 1986*

John F. Greden, M.D. Page 37 Last Revised December 2019

81. Matthews J, Akil H, Greden JF, Charney D, Weinberg V, Rosenbaum A, Watson SJ: Beta-Endorphin/Beta Lipotropin-Like Immunoreactivity in Endogenous Depression: Effect of Dexamethasone. Archives of General Psychiatry, 43:374-381, 1986* 82. Greden JF, Flegel P, Dilsaver S, Carroll BJ, Grunhaus L, Haskett RF, Genero N: Age Effects in Serial Hypothalamic-Pituitary-Adrenal Monitoring. Psychoneuro-endocrinology, 11:195-204, 1986* 83. Dilsaver SC, Greden JF, Snider RM: Antidepressant Withdrawal Syndromes: Phenomenology and Pathophysiology. International Clinical Psychopharmacology, 2(1):1-19, 1987 84. Grunhaus L, Flegel P, Haskett RF, Greden JF: Serial Dexamethasone Suppression Tests in Simultaneous Panic and Depressive Disorders. Biological Psychiatry, 22:332-338, 1987* 85. Grunhaus L, Tiongco D, Haskett RF, Greden JF: Dexamethasone Suppression Test in Inpatients with Panic Disorder or Agoraphobia with Panic Attacks. Biological Psychiatry, 22:517-521, 1987* 86. Murphy D, Gardner R, Greden JF, Carroll BJ: Lymphocyte Numbers in Endogenous Depression. Psychol Med. 17(2):381-5, 1987* 87. Meador-Woodruff J, Gurguis G, Grunhaus L, Haskett RF, Greden JF: Multiple Depressive Episodes and Plasma Post-Dexamethasone Cortisol Levels. Biological Psychiatry, 22:583-592, 1987* 88. Tandon R, Greden JF: Schneiderian First Rank Symptoms: Reconfirmation of High Specificity for Schizophrenia. Acta Psychiatrica Scandinavica, 75:392-396, 1987* 89. Dilsaver SC, Greden JF, Snider RM: Antidepressant Withdrawal Syndromes: Phenomenology and Pathophysiology. Journal of Clinical Psychopharmacology. 2:1-19, 1987* 90. Tandon R and Greden JF: Trihexiphenidyl Treatment of Negative Schizophrenic Symptoms. Acta Psychiatrica Scandinavica, 76:732, 1987 91. Tandon R, Grunhaus L, Greden JF: Tinnitus in Imipramine Therapy. Journal of Clinical Psychiatry, 48:109- 111, 1987* 92. Meador-Woodruff JH, Haskett RF, Grunhaus L, Akil H, Watson SJ, Greden JF: Post-Dexamethasone Plasma Cortisol and B-endorphin Levels in Depression: Relationship to Severity of Illness. Biological Psychiatry, 22:1137-1150, 1987* 93. Grunhaus L, Zelnik T, Albala AA, Rabin D, Haskett RF, Zis A, Greden JF: Serial Dexamethasone Suppression Tests in Depressed Patients Treated only with Electroconvulsive Therapy. Journal of Affective Disorders, 13:233-240, 1987* 94. Coyne JC, Kessler RC, Tal M, Turnbull J, Wortman CB, Greden JF: Living with a Depressed Person. Journal of Consulting and Clinical Psychology, 55:347-352, 1987* 95. Tandon R, Grunhaus L, Greden JF: Mechanism of Tricyclic-Induced Tinnitus. Journal of Clinical Psychiatry, 48:496-497, 1987 96. Meador-Woodruff JH, Greden JF: Effects of Psychotrophic Medications on Hypothalamic-Pituitary-Adrenal Regulation. In Brown WA (editor): Endocrinology of Neuropsychiatric Disorders. Neurologic Clinics, 6:225- 234, 1988 97. Pande AC, Krugler T, Haskett RF, Greden JF, Grunhaus LJ: Predictors of Response to Electroconvulsive Therapy in Major Depressive Disorders. Biological Psychiatry. 24(1):91-3, 1988 98. Tandon R and Greden JF: Schneiderian First Rank Symptoms in Schizophrenia and Multiple Personality Disorder. Acta Psychiatric Scandinavica, 77:237-238, 1988 99. Tandon R, Greden JF, Silk KR: Treatment of Negative Schizophrenic Symptoms with Trihexiphenidyl. Journal of Clinical Psychopharmacology, 8:192-195, 1988* 100. Hariharan M, VanNoord T, Greden JF: A High-Performance Liquid-Chromatographic Method for Routine Simultaneous Determination of Nicotine and Cotinine in Plasma. Clinical Chemistry, 34:724-729, 1988* 101. Tandon R, Grunhaus L, Haskett RF, Krugler T, Greden JF: Relative Efficacy of Unilateral and Bilateral Electroconvulsive Therapy in Melancholia. Convulsive Therapy, 4:153-159, 1988* 102. Tandon R, Channabasavanna SM, Greden JF: CSF Biochemical Correlates of Mixed Affective States. Acta Psychiatrica Scandinavica, 78:289-297, 1988* John F. Greden, M.D. Page 38 Last Revised December 2019

103. Lee MA, Flegel P, Greden JF, Cameron OG: Anxiogenic Effects of Caffeine on Panic and Depressed Patients. American Journal of Psychiatry, 145:632-635, 1988* 104. Pande AC, Krugler T, Haskett RF, Greden JF, Grunhaus LJ: Predictors of Response to Electroconvulsive Therapy in Major Depressive Disorder. Biological Psychiatry, 24:91-93, 1988* 105. Meador-Woodruff JH, Greden JF, Grunhaus L, Haskett RF: Dexamethasone Suppression Status and Severity of Depression. Biological Psychiatry, 24:693-696, 1988* 106. Lee MA, Flegel P, Cameron OG, Greden JF: Chronic Caffeine Consumption and the Dexamethasone Suppression Test in Depression. Psychiatry Research, 24:61-65, 1988* 107. Grunhaus L, Greden JF, et al.: Monitoring of Antidepressant Response to ECT with Polysomnography Recordings and the Dexamethasone Suppression Test. Psychiatry Research, 24:177-185, 1988 108. Meador-Woodruff JH, Greden JF, Grunhaus L, Haskett RF: Plasma Postdexamethasone Cortisol Levels in Schizoaffective Disorder. Psychiatry Research, 26:35-42, 1988* 109. Modell JG, Mountz JM, Curtis GC, Greden JF: Neurophysiologic Dysfunction in Basal Ganglia/Limbic Striatal and Thalamo Cortical Circuits as Pathogenetic Mechanism of Obsessive-Compulsive Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 1:27-36, 1989* 110. Tandon R, Silk KR, Greden JF, Goodson, Hariharan M, Meador-Woodruff JH, Kronfol Z: Positive and Negative Symptoms in Schizophrenia and the Dexamethasone Suppression Test. Biological Psychiatry, 25:788-792, 1989* 111. Tandon R, Dutchak D, Greden JF: Cholinergic Syndrome Following Anticholinergic Withdrawal in Schizophrenic Patient Abusing Marijuana. British Journal of Psychiatry, 154:712-714, 1989* 112. Tandon R and Greden JF: Cholinergic Hyperactivity and Negative Schizophrenic Symptoms: A Model of Cholinergic/Dopaminergic Interactions in Schizophrenia. Archives of General Psychiatry, 46:745-753, 1989* 113. Tandon R and Greden JF: Positive/Negative Syndrome Distinction in Schizophrenia. American Journal of Psychiatry, 146:407, 1989 114. Tandon R, Shipley JE, Eiser A, Goodson J, Greden JF: Association Between Abnormal Rapid Eye Movement Sleep and Negative Symptoms in Schizophrenia. Psychiatry Research, 27:359-361, 1989* 115. Tandon R, Shipley JE, Greden JF: Electroencephalographic Sleep Abnormalities in Schizophrenia: Relationship to Positive/Negative Symptoms and Ventricular Enlargement. Schizophrenia Research, 2:80, 1989 116. Nair MN, Schwartz SA, Kronfol ZA, Heimer EP, Pottathil R, Greden JF: Immunoregulatory Effects of Alcohol in Lymphocyte Responses to Human Immunodeficiency Virus Proteins. Progress in Clinical and Biological Research. 325:221-230, 1990 117. Naylor M, Greden JF, Alessi NE: Plasma Dexamethasone Levels in Children Given the Dexamethasone Suppression Test. Biological Psychiatry. 27:592-600, 1990* 118. Gurguis GN, Meador-Woodruff JH, Haskett RF, Greden JF: Multiplicity of Depressive Episodes: Phenomenological and Neuroendocrine Correlates. Biological Psychiatry, 27:1156-1164, 1990* 119. Tandon R, Goldman R, Goodson J, Greden JF: Mutability and Relationship between Positive and Negative Symptoms during Neuroleptic Treatment in Schizophrenia. Biological Psychiatry, 27:1323-1326, 1990* 120. Meador-Woodruff JH, Greden JF, Haskett RF, Grunhaus L: Severity of Depression and Hypothalamic- Pituitary-Adrenal Axis Dysregulation: Identification of Contributing Factors. Acta Psychiatrica Scandinavica, 81:364-371, 1990* 121. Pande AC, Grunhaus LJ, Haskett RF, Greden JF: Electroconvulsive Therapy in Delusional and Non- delusional Depressive Disorder. Journal of Affective Disorders, 19:215-219, 1990* 122. Young EA, Watson SJ, Kotun J, Haskett RF, Greden JF, Grunhaus L, Murphy-Weinberg V, Vale W, Rivier J, Akil H: Beta-Lipotropin-Beta-Endorphin Response to Low-dose oCRF Releasing Factor in Endogenous Depression. Archives of General Psychiatry, 47:449-457, 1990*

John F. Greden, M.D. Page 39 Last Revised December 2019

123. Pande AC, Grunhaus L, Haskett RF, Greden JF: Effect of Imipramine versus Desipramine on Body Weight in Major Depression. Annals of Clinical Psychiatry, 2:259-261, 1990* 124. Panzer M, Tandon R, Greden JF: Treatment of Catatonia with an Anticholinergic Agent: A Case Report. Biological Psychiatry, 28:178-179, 1990 125. Tandon R, Cardona D, Haskett RF, Alcser K, Greden JF: Menstrual Cycle Effects on the Dexamethasone Suppression Test in Major Depression. Biological Psychiatry, 29:485-488, 1990* 126. Tandon R and Greden JF: Abnormal Phosphoinositide Turnover in Schizophrenia. Biological Psychiatry, 29:295-308, 1991* 127. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R, Greden JF: Dexamethasone Suppression Test in Schizophrenia: Relationship to Symptomatology, Ventricular Enlargement, and Outcome. Biological Psychiatry, 29:953-964, 1991* 128. Tandon R, Haskett RF, Cardona D, Alcser K, Greden JF: Menstrual Cycle Effects on the Dexamethasone Suppression Test In Major Depression. Biological Psychiatry. 29(10):953-64, 1991* 129. Tandon R and Greden JF: Negative Symptoms of Schizophrenia: Need for Conceptual Clarity. Biological Psychiatry, 30:321-325, 1991* 130. Demitrack MA and Greden JF: Chronic Fatigue Syndrome: The Need for an Integrative Approach. Biological Psychiatry, 30: 747-752, 1991* 131. Tandon R, Shipley JE, Greden JF, Mann N, Eisner W, Goodson J: Muscarinic Cholinergic Hyperactivity in Schizophrenia: Relationship of Positive and Negative Symptoms. Schizophrenia Research, 4:23-30, 1991* 132. Goldman R, Tandon R, Goodson J, Liberzon I, Greden JF: Stability of Positive and Negative Symptom Constructs During Neuroleptic Treatment in Schizophrenia. Psychopathology, 24:247-252, 1991* 133. Tandon R, Shipley J, Taylor S, Greden JF, Eiser A, DeQuardo J, Goodson J: Electroencephalograph Sleep Abnormalities in Schizophrenia: Relationship to Positive/negative Symptomatology and CT Findings. Archives of General Psychiatry, 49:185-194, 1992* 134. Pande AC, Haskett RF, Greden JF: Seasonality in atypical depression. Biological Psychiatry, 31:965-967, 1992* 135. Goldman R, Tandon R, Liberzon I, Greden JF: Measurement of Depressive and Negative Symptoms in Schizophrenia. Psychopathology, 25:49-56, 1992* 136. Ribeiro SCM, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF: Clinical Predictors of 1-Year Outcome in Schizophrenia. Psychopathology, 25:331-334, 1992* 137. Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF: Effect of Anticholinergics on Positive and Negative Symptoms in Schizophrenia. Psychopharmacology Bulletin, 28:297-302, 1992* 138. Greden JF, Pande AC: Treatment of Resistant Depression with 5-HT Uptake Inhibitors. Clinical Neuropharmacology. 15 Suppl PT A: 442A-443A, 1992. 139. Tandon R, Greden JF, Haskett RF: Behavioral Effects of Physostigmine in Normal Subjects: Possible Model for Negative Schizophrenic Symptoms. Schizophrenia Research, 9:19-23, 1993 140. Akil H, Haskett R, Grunhaus L, Kotun J, Young EA, Weinberg G, Greden JF, Watson SJ: Multiple HPA Profiles in Endogenous Depression: Effect of Age and Sex on Cortisol and Beta-Endorphin, Biological Psychiatry, 33:73-85, 1993* 141. Kronfol Z, Nair MPN, Hill E, Kroll P, Brower K, Greden JF: Immune Function in Alcoholism: a Controlled Study. Alcoholism: Clinical and Experimental Research. 17: 279-283, 1993* 142. Young EA, Kotun J, Haskett RF, Grunhaus L, Greden JF, Watson SJ, Akil H: Dissociation between Pituitary and Adrenal Suppression to Dexamethasone in Depression. Archives of General Psychiatry, 50:395-403, 1993* 143. King C, Naylor MW, Hill EM, Shain BN, Greden JF: Dysthymia Characteristic of Heavy Alcohol use in Depressed Adolescents. Biological Psychiatry, 33:210-212, 1993*

John F. Greden, M.D. Page 40 Last Revised December 2019

144. Naylor MW, King CA, Lindsay KA, Evans T, Armelagos J, Shain BN, Greden JF: Sleep Deprivation in Depressed Adolescents and Psychiatric Controls. Journal of the American Academy of Child and Adolescent Psychiatry, 32:753-759, 1993 145. Schwartz JA, Speed NM, Brunberg JA, Brewer TL, Brown M, Greden JF: Depression in Stroke Rehabilitation. Biological Psychiatry, 33:694-699, 1993* 146. Tandon R, Ribeiro SCM, DeQuardo JR, Goldman RS, Goodson RS, Greden JF: Covariance of Positive and Negative Symptoms during Neuroleptic Treatment in Schizophrenia: a Replication. Biological Psychiatry, 34:495-497, 1993* 147. Ribeiro SCM, Grunhaus L, Tandon R, Greden JF: The DST as a Predictor of Outcome in Depression: A Meta- Analysis. American Journal of Psychiatry, 150:1618-1629, 1993* 148. Nair MPN, Schwartz SA, Kronfol ZA, Saravolatz LA, Heimer EP, Pottathil R, Greden JF: Inhibition of Cellular Immune Responses of Lymphocytes from Healthy Donors and AIDS Patients by Alcohol. Advances in the Biosciences, 86: 103-114, 1993 149. Kronfol Z, Nair M, Goel K, Sufalko D, Greeley C, Greden JF: Lymphocyte Subsets and Natural Killer Cytotoxicity in Alcoholism. Advances in the Biosciences, 86: 115-119, 1993 150. Greden JF: Antidepressant Maintenance Medications: When to Discontinue and How to Stop. Journal of Clinical Psychiatry, 54: 39-45, 1993* 151. Greden JF: Psychomotor Monitoring: A Promise Being Fulfilled? Journal of Psychiatric Research, 27(3):285- 287, 1993* 152. Nair MPN, Kumar NM, Kronfol ZA, Saravolatz LA, Pottathil R, Greden JF, Schwartz SA: Selective Effect of Alcohol on Cellular Immune Responses of Lymphocytes from AIDS Patients. Alcohol. 11:85-90, 1994* 153. Grunhaus L, Pande AC, Brown MB, Greden JF: Clinical Characteristics of Patients with Concurrent Major Depressive Disorder and Panic Disorder. American Journal of Psychiatry. 151: 541-546, 1994* 154. Grunhaus L, Shipley JE, Eiser A, Pande AC, Tandon R, Remen A, Greden JF: Shortened REM Latency Post ECT is Associated with Rapid Recurrence of Depressive Symptomatology. Biological Psychiatry. 36: 214- 222, 1994* 155. Grunhaus L, Shipley JE, Eiser A, Remen A, Pande A, Tandon R, Greden JF: Sleep Electroencephalographic Studies after ECT. Age and Clinical Response. American Journal of Geriatric Psychiatry. 2: 39-51, 1994* 156. Nair MPN, Kronfol ZA, Greden JF, Chadha KC, Dumaswala U, Sweet AM, Schwartz, SA: Selective Inhibition by Alcohol and Cortisol of Natural Killer Cell Activity of Lymphocytes from Cord Blood. Prog. Neuropsychopharmacology and Biological Psychiatry. 18: 1293-1305, 1994* 157. Nair MP, Schwartz SA, Kronfol ZA, Hill EM, Sweet AM, Greden JF: Suppression of Tumor Necrosis Factor Production by Alcohol in Lipopolysaccharide-Stimulated Culture. Alcoholism, Clinical & Experimental Research, 18(3):602-607, 1994 158. Greden JF and Tandon R: Long-term Treatment for Lifetime Disorders? Archives of General Psychiatry. 52:197-200, 1995* 159. Ghaziuddin M, Alessi NE, Greden JF: Life Events and Depression in Children with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders. 25:495-502, 1995* 160. Nair MPN, Kumar NM, Kronfol ZA, Greden JF, Lwebuga-Mukasa JS, and Schwartz SA: Alcohol Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Gene Expression by Peripheral Blood Mononuclear Cells as Measured by Reverse Transcriptase PCR in Situ Hybridization. Clinical and Diagnostic Laboratory Immunology, 3:392-398, 1996 161. Ghaziuddin N, King C, Naylor M, Ghaziuddin M, Chaudhary N, Giordani B, DeQuardo JR, Tandon R, Greden JF: Electroconvulsive Treatment in Adolescents with Pharmacotherapy Refractory Depression. Journal of Child and Adolescent Psychopharmacology, 6:259-271, 1996 162. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF: Fluoxetine versus Phenelzine in Atypical Depression. Biological Psychiatry, 40(10):1017-20, 1996

John F. Greden, M.D. Page 41 Last Revised December 2019

163. Grunhaus L, Shipley JE, Eiser A, Pande AC, Tandon R, Remen A, Greden JF: Polysomnographic Studies in Patients Referred for ECT: Pre-ECT studies. Convulsive Therapy, 12(4):224-31, 1996 164. Grunhaus L, Shipley J, Eiser A, Pande AC, Tandon R, Krahn DD, Demitrack MA, Remen A, Hirschmann S, Greden JF: Sleep-Onset Rapid Eye Movement after Electroconvulsive Therapy is more Frequent in Patients who Respond Less Well to Electroconvulsive Therapy. Biological Psychiatry, 42(3):191-200, 1997* 165. Ghaziuddin M and Greden JF: Depression in Children with Autism/Pervasive Developmental Disorders: A Case-Control Family History Study. Journal of Autism and Developmental Disorders, 28:2:111-115, 1998* 166. Maixner S and Greden JF: Extended Antidepressant Maintenance and Discontinuation Syndromes. Depression and Anxiety, 1:43-53, 1998* 167. Greden JF: Do Long-Term Treatments Alter Lifetime Course? Lessons Learned Actions Needed. Journal of Psychiatric Research, 32(3-4): 197-9, 1998 168. Greden JF: Serotonin: How Much We Have Learned! So Much to Discover... Biological Psychiatry, 44(5):309-12, 1998 169. Marcus SM, Barry KL, Flynn HA, Tandon R, Greden JF: Treatment Guidelines for Depression in Pregnancy: A Review of Critical Issues. International Journal of Obstetrics and Gynecology, 72(1):61-70, 2001 170. Greden JF and Agranoff BA: In Memoriam: Seymour S. Kety. Journal of Psychiatric Research. 34(4-5):263, 2000 171. Ghaziuddin N, King CA, Zaccagnini J, Weidmer-Mikhail E, Mellow A, Ghaziuddin M, Greden JF: Serotonin Dysregulation in Adolescents with Major Depression: Hormone Response to meta-Chlorophenylpiperazine (mCPP) Infusion. Psychiatry Research. 95: 183-194, 2000 172. Brower KJ, Aldrich MS, Robinson EAR, Zucker RA, Greden JF: Insomnia, Self-Medication, and Relapse to Alcoholism. American Journal of Psychiatry. 158: 399-404, 2001 173. Greden JF: Burden of Disease for Treatment Resistant Depression: Journal of Clinical Psychiatry, 62(16):26- 31, 2001* 174. Greden JF: The Burden of Recurrent Depression: Causes, Consequences, and Future Prospects: Journal of Clinical Psychiatry, 62(22):5-9, 2001* 175. Ghaziuddin M, Ghaziuddin N, Greden JF: Depression in Persons with Autism: Implications for Research and Clinical Care. The Journal of Autism and Developmental Disorders. 32(4): 299-306, 2002 176. Korszun A, Young E, Engleberg NC, Crofford L, Greden JF: Use of Actigraphy for Monitoring Sleep and Activity Levels in Patients with Fibromyalgia and Depression. The Journal of Psychosomatic Research, 52(6): 439-443, 2002 177. Hirschfeld RMA, Russell J, Buatti M, Croghan T, Dunner DL, Fulop G, Grudzinski AN, Hess G, Hylan T, Keller MB, Lieberman JA, Meyer RE, Miceli R, Revicki D, Rosenbaum JF, Schatzberg AF, van Loon J, Greden JF: Development of Methodological Standards in CNS Pharmacoeconomic Research. Report of an ACNP Task Force. Neuropsychopharmacology, 25(5): 621-623, 2001 178. Greden JF: Unmet Need: What Justifies the Search for a New Antidepressant? The Journal of Clinical Psychiatry, 63(2):3-7, 2002* 179. Ghaziuddin N, Welch K, Greden JF: Central Serotonergic Effects of m-Chlorophenylpiperazine (mCPP) among Normal Control Adolescents. Neuropsychopharmacology. 28:133-139, 2003 180. Brower KJ, Kim, HM, Karam-Hage MA, Zucker RA, Greden JF: A Double-Blind Randomized Clinical Trial of Gabapentin vs. Placebo for Treating Alcohol Dependence. Biological Psychiatry, 53(8S): 84S-85S, 2003 181. Greden JF: Physical Symptoms of Depression: Unmet Needs. Journal of Clinical Psychiatry. 64 Suppl 7:5-11 Review, 2003* 182. Yager J, Greden JF, Abrams M, Riba M: The Institute of Medicine’s Report on Research Training in Psychiatry Residency: Strategies for Reform–Background, Results, and Follow Up. Academic Psychiatry. 28:4, 267-274, 2004 183. Greden JF: Diagnosing and Treating Depression Earlier and Preventing Recurrences: Still Neglected After All These Years. Current Psychiatry Reports, 6(6):401-2, 2004 John F. Greden, M.D. Page 42 Last Revised December 2019

184. Riolo SA, Nguyen TA, Greden JF, King CA: Prevalence of Depression by Race/Ethnicity: Findings From the National Health and Nutrition Examination Survey III. American Journal of Public Health, 95:6, 5-7, 2005. 185. Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC: What Happened to Lithium? Antidepressant Augmentation in Clinical Settings. American Journal of Psychiatry, 163:1219-1225, 2006 186. Saunders EFH, M, Greden JF: Evidence for the Need for Long-Term Treatment of Major Depression. Primary Psychiatry, 14(6): 60-65, 2007 187. Greist J, Greden JF, Jefferson JW, Trivedi MH: Depression and Pain. Academic Highlights Report prepared by the CME Institute of Physicians Postgraduate Press, Inc. The Journal of Clinical Psychiatry, 69 (12), 2008 (In Press). 188. Zivin K, Nosowsky R, Difranco D, Valenstein M; Kales HC, Greden JF. Criminal Background Checks for Psychiatry? Michigan’s Mental Health Exceptionalism". Journal of the American Academy of Psychiatry and the Law. 2008; 36: 6-9. 189. Boyd A, Saxman P, Hunscher D, Smith K, Morris T, Kasten M, Bayoff F, Rogers B, Hayes P, Namrata R, Kline- Rogers E, Eagle K, Clauw D, Greden JF, Green L, Athey B, The University of Michigan: Honest Broker: A Web-based Service for Clinical and Translational Research and Practice. BAA/MCRC 2009;16:784 –791 190. Meyer R, Salzman C, Youngstrom E, Clayton P, Mann J, Goodwin F, Alphs L, Baldessarini R, Broich K, Goodman W, Greden JF, Meltzer H, Normand S, Posner K, Revicki D, Shaffer D, Trivedi M, Turecki G, Zito J, Beasley C , Beautrais A, Bridge J, Brown G, Oquendo M, Pearson J, Ryan N, Sheehan D, Sherrill J, Stanley B. Suicidality and Risk of Suicide: Definition, Drug Safety Concerns and A Necessary Target for Drug Development: A brief report. J Clin Psychiatry. 2010 Aug; 71(8):1040-6. PMID:20673551 191. Greden, JF Does Antidepressant Step Therapy Fuel the Law of Unintended Consequences? American Journal of Psychiatry 2010 Oct;167(10):1148-51 192. Greden JF, Valenstein M, Spinner J, Blow A, Gorman LA, Dalack GW, Marcus S, Kees M: Buddy-to-Buddy, a citizen soldier peer support program to counteract stigma, PTSD, depression, and suicide. Ann N Y Acad Sci. 2010 Oct;1208:90-7. PMID:20955330 193. Dalack GW, Blow A, Valenstein M, Gorman L, Spinner J, Marcus S, Kees M, McDonough S, Greden JF, Ames B, Francisco B, Anderson JR, Bartolacci J, Lagrou R: Public-academic partnerships: Working Together to Meet the Needs of Army National Guard Soldiers: An Academic-Military Partnership. Psychiatric Services 2010 Nov; 61(11):1069-71. PMID:21041342 194. Greden JF, The National Network of Depression Centers: Progress Through Partnership. Depression and Anxiety 28:615-621 2011 195. Weiner R, Lisanby SH, Husain MM, Morales OG, Maixner DF, Hall SF, Beeghly J, Greden JF, National Network of Depression Centers. Electroconvulsive Therapy Device Classification: Response to FDA Advisory Panel Hearing and Recommendations. J Clin Psychiatry. 2013 Jan;74(1):38-42 196. Greden, JF. Workplace Depression: Personalize, Partner, or Pay the Price. Am J Psychiatry. 2013 Jun 1; 170(6):578-81. PMID:23732962 197. Kennedy PJ, Greden JF, Riba M. The next 50 years: A new vision of Community of Mental Health. Am J Psychiatry. 2013 Oct 1:170(10): 1097-8. PMID:24084813 198. McInnis MG, Greden JF. Longitudinal studies: An essential component for complex psychiatric disorders. Neursci Res. 2015 Jun 5 pii: S0168-0102(15)00152-2. PMID: 26051908 199. Parikh, SV, Taubman DS, Antoun C, Cranford J, Ewell-Foster C, Grambeau M, Hunter J, Jester J, Konz K, Meyer T, Salazar S, Greden JF. (2018). "The Michigan Peer-to-Peer Depression Awareness Program: School-Based Prevention to Address Depression Among Teens." Psychiatr Serv 69(4): 487-491. PMID: 29493416 200. Lopez D, Vande Voort JL, Frye M, Bobo W, Goes F, Achtyes E, Goddard A, McCullumsmith C, Maixner D, Watson B, Drake K, Greden JF, Parikh SV, and Bio-K Study Team. (2018). “Developing a Ketamine Clinic for Treatment Resistant Depression”. Under Review - Pharmacology Bulletin.

John F. Greden, M.D. Page 43 Last Revised December 2019

201. Parikh SV, Taubman DS, Antoun C, Cranford J, Grambeau M, Hunter J, Jester J, Konz K, Meyer T, Salazar S, Greden JF. (2018). "The Michigan Peer-to-Peer Depression Awareness Program: School-Based Prevention to Address Depression Among Teens." Psychiatr Serv 69(4): 487-491. 202. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattisa C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechario B: Impact of pharmacogenomics on clinica outcomes in major depressive disorder in the GUIDED trial: A large, patient-and rater-blinded, randomized, controlled study. Journal of Psychiatric Research 111 (2019) 59-67. 203. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattisa C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechario B: Letter to the Editor Response to: Goldberg et al. and Severance et al Letters to the Editor: The Clinical Significance of Improving Remission over Standard of Care – The Reality of Treatment Resistant-Based Therapies. Journal of Psychiatric Research, 114 (2019) 211-213. 204. Thase ME, Parikh SV, , Rothschild AJ, Dunlop BW, DeBattisa C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Brown L, Jablonski MR, Greden JF: S36 Combinatorial Pharmacogenomic Testing Improces Outcomes For Patients Taking Medications with Gene-Drug Interactions in a Randomized, Controlled Trial. European Neuropsychopharmacology 29:S132-S133. DOI: 10.1016/j.euroneuro.2019.08.037

Non-Peer-Reviewed Publications 1. Greden JF and Morgan DW: Illicit Drug Use in The Military District of Washington (Technical report prepared for Chief Surgeon, Military District of Washington), 1971 2. Greden JF, Morgan DW, Frenkel SL: Illicit Drug Use in the Military District of Washington: 1971 vs. 1972. (Technical report prepared for Chief Surgeon, Military District of Washington), 1972 3. Greden JF: Terminal Care. Journal of the American Medical Association, 223:924, 1973 4. Greden JF: Marijuana Medical Papers: 1939-1972. (Book Review). Journal of the American Medical Association , 228:506-507, 1974 5. Greden JF: Effects of Caffeine on Sexual Function. Medical Aspects of Human Sexuality, 9:46, 1975 6. Greden JF: Marijuana Medical Papers: 1839-1972. (Book Review). Clio Medica, 9:256-257, 1976 7. Greden JF: Tissue Responses to Addictive Drugs. American Journal of Psychiatry, 135:144, 1978 8. Greden JF: Caffeinism. Behavioral Medicine, 5:7, 1978 9. Greden JF: Coffee, Tea, and You. The Sciences, 19:6-11, 1979 10. Greden JF: Caffeine and Cocoa. The Sciences, 19:6-11, 1979 11. Carroll BJ, Greden JF, Feinberg M: Neuroendocrine Diagnosis of Endogenous Depression. Neuroendocrinology Letters, 2:100, 1980 12. Carroll BJ, Greden JF, Feinberg M: Disinhibition of Cortisol Secretion in Depression. Neuroendocrinology Letters, 2:100, 1980 13. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young E: Standardization of the Dexamethasone Suppression Test for the Diagnosis of Melancholia. Advances in Biological Psychiatry, 7:1-13, 1981 14. Grunhaus L, Greden JF, Carroll BJ: Dexamethasone Suppression Test in Primary Degenerative Dementia. (Letter). American Journal of Psychiatry, 140:1098, 1983 15. Dilsaver SC, and Greden JF: Antidepressant Withdrawal Syndromes: Evidence for Super Sensitivity of Cholinergic System as an Etiologic Factor. Journal of Clinical Psychopharmacology, 3:330, 1983 16. Dilsaver SC, Leckrone JG, Greden JF: Cholinergic Syndrome from Psychotropic Withdrawal in a Marijuana Abuser. Psychosomatics, 25:8, 1984

John F. Greden, M.D. Page 44 Last Revised December 2019

17. Dilsaver SC, Greden JF: Antidepressant Withdrawal-Induced Activation (Hypomania and Mania): Is Withdrawal-Induced Cholinergic Overdrive Causally Significant? Journal of Clinical Psychopharmacology, 4(3):174-175, 1984 18. Greden JF: Depression: A 1984 Outlook. Michigan Hospitals. December, 1984 19. Greden JF: Clinical Applications of Serial Dexamethasone Suppression Tests. Psychiatry Letter, 3:1-5, 1985 20. Dilsaver SC, Domino L, Greden JF: Meige’s Syndrome or Tardive Dyskinesia? Journal of Clinical Psychopharmacology, 5:362-364, 1985 21. Dilsaver SC, Greden JF: Mania Induced by Antidepressant Withdrawal. Psychosomatics, 27(11):798-9, 1986 22. Martin D, Shipley JE, Genero N, Greden JF, Flegel P, Eiser A, Grunhaus L, Haskett RF: Association of EEG Sleep Measures on Facial Electromyography in Depression. Sleep Research, 16:285, 1987 23. Cameron OG, Thomas B, Tiongco D, Hariharan M, Greden JF: Hypercortisolism in Diabetes Mellitus. Diabetes Care, 10:662-663, 1987 24. Meador-Woodruff JH, Greden JF: Clinician-Researchers in Psychiatry. American Journal of Psychiatry. 144:535, 1987 25. Newman J, Zelnik T, Greden JF: Depression as an Adverse Medication Reaction. A Prevention Project of the University of Michigan and the Prevention Services Unit, Michigan Department of Mental Health. Lansing, Michigan. Produced by Biomedical Communications, Office of Educational Resources and Research, The University of Michigan Medical Center; 1988 26. Tandon R, Mazzara C, Silk KR, Greden JF: Dexamethasone Suppression Test, Positive and Negative Symptoms in Schizophrenia. Biological Psychiatry, 26:858, 1989 27. Panzer M, Tandon R, Greden JF: Benzodiazapines and Catatonia. Biological Psychiatry, 28:178-179 28. Tandon R and Greden JF: Abnormal Phosphoinositide Turnover in Schizophrenia. Biological Psychiatry, 29:295-6, 1991 29. Tandon R, Goldman R, Greden JF: Positive and Negative Symptoms during Neuroleptic Treatment. Biological Psychiatry, 29:621, 1991 30. Tandon R, Shipley JE, Taylor S, Greden JF: Sleep Abnormalities in Schizophrenia: Cholinergic Contribution. Clinical Neuropharmacology. 15 Supplement:294-295, 1992 31. Greden JF: In Memoriam: Daniel X. Freedman. Journal of Psychiatric Research, 27:233-234, 1993 32. Greden JF: Psychomotor Monitoring: A Promise Being Fulfilled? Journal of Psychiatric Research, 27:285- 287, 1993 33. Greden JF: New Agents for the Treatment of Depression. Journal of Clinical Psychiatry, 55:32-33, 1994 34. Greden JF: Introduction, Part III. New Agents for the Treatment of Depression. Journal of Clinical Psychiatry, 55 Supplement:32-33, 1994 35. Greden JF: Maintenance Antidepressant Treatment. Progress Notes, 6:28-34, 1995 36. Greden JF: Michigan: A new plan for the 21st Century. Academic Clinical Practice, 11(2):1-12, Spring 1998 37. Pies R; Contributors: Greden JF and Kaplan E: Treatment Challenges in Depressive Disorders. Advances in Psychiatric Medicine: Supplement to Psychiatric Times, May 1998 38. Psychiatric Research Report: The Fine Art of Academia: An Interview with John Greden. Psychiatric Research Report, 14(1):1, 8-12, Winter 1998 39. Greden JF: ACNP Scientific Publications. New Challenges, New Strategies. ACNP Bulletin, (2):6-7, August 1999 40. Amsterdam J, Greden JF, Nierenberg A, Thase M: Treatment Resistant Depression, Depression Insights Series. The Intercom, Newsletter of the Journal of Clinical Psychiatry, August 2000 41. Greden JF: ACNP Nobel Celebration, Knowledge Heals. ACNP Bulletin, 7(3):3-4, August 2001 42. Greden JF: News from the Council on Research, ACNP Honors Nobel Laureates. Psychiatric Research Report, 17(2):4-5, Summer 2001 43. Greden JF: Will DSM-V Criteria for Depression be More Research Based? Psychiatric Research Report. 18(3):4-6,23, Fall 2002 John F. Greden, M.D. Page 45 Last Revised December 2019

44. Eisenberg D, Greden JF, Meyer T, Soet J, Sevig T, Vasquez J: University of Michigan’s Approach to Student Mental Health. Student Affairs Leader. 35(19), 1-2. October 2007. 45. DiFranco D, Greden JF, Kales H, Nosowsky R, Valenstein M, Zivin K: Criminal Background Checks for Psychiatry? Michigan’s Mental Health Exceptionalism. Journal of the American Academy of Psychiatry and the Law, 36(1), March 2008 46. Boyd AD, Saxman PR, Hunscher DA, Smith KA, Morris T, Kaston M, Bayoff F, Rogers B, Shensky B, Hayes P, Rajeev N, Moscucci M, Kline-Rogers E, Eagle K, Clauw D, Greden JF, Green LA, Athey BD: The University of Michigan Honest Broker: A Web-based service for clinical and translational research and practice. Journal of American Medical Informatics Association, submitted August 2008.

Publications Under Review

Books 1. Greden JF and Tandon R (Editors): Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. American Psychiatric Press, Washington, D.C., 1991 2. Grunhaus L and Greden JF (Editors): Severe Depressive Disorders. American Psychiatric Press, Washington, D.C., 1994 3. Greden JF (Editor): Treatment of Recurrent Depression. Review of Psychiatry Volume 20 American Psychiatric Press Inc., Washington, DC, 2001 4. Greden JF, Riba M, McInnis M, (Editors): Treatment Resistant Depression: A Roadmap for Effective Care. American Psychiatric Press, Washington, D.C., 2011 5. Riba M, Greden JF, Parikh, SV: Mental Health in the Workplace - Strategies and Tools to Optimize Outcomes. Springer Publications, Integrating Psychiatry and Primary Care, New York, New York, 2018. Chapters in Books 1. Greden JF: Caffeine and tobacco disorders. In, Comprehensive Textbook of Psychiatry, III (Third Edition). Edited by HI Kaplan, AM Freedman, BJ Sadock. The Williams and Wilkins Company, Baltimore: pp. 1021- 1024, 1980 2. Greden JF Caffeinism and caffeine withdrawal. In, Substance Abuse in the United States: Problems and Perspectives. Edited by Lowinson J, Ruiz P: The Williams and Wilkins Company, Baltimore: pp. 715-730, 1980 3. Greden JF: Caffeine. In Behavior in Excess: A Guide to the Volitional Disorders. Edited by S Joseph Mule. The Free Press, Macmillan Publishing, New York: pp. 164-189, 1981 4. Carroll BJ, Greden JF, Feinberg M: Suicide, Neuroendocrine Dysfunction and CSF 5-HIAA Concentrations in Depression. In, Recent Advances in Neuropsychopharmacology. Proceedings of the 12th CINP Congress. Edited by Angrist B. Pergamon Press, Oxford: pp. 307-313, 1981 5. Carroll BJ, Greden JF, Feinberg M, Lohr N, James NM, Steiner M, Haskett RF, Albala AA, DeVigne JP, Tarika J: Neuroendocrine Evaluation of Depression in Borderline Patients. In The Borderline Patient: Diagnosis and Management. Edited by Friedel RO. Biomedical Information Corporation: pp. 19-23, 1981 6. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, DeVigne JP, Young E: Standardization of the dexamethasone suppression test for the diagnosis of melancholia. In Advances in Biological Psychiatry. Edited by Mendlewicz J, Van Praag HM. Basel: 1-13, 1981 7. Greden JF, Kronfol Z, Gardner R, Feinberg M, Carroll B: Neuroendocrine evaluation of schizoaffectives with the dexamethasone suppression test. In Biological Psychiatry. Edited by Perris C, Struwe G, and Jansson B. Elsevier/North Holland Biomedical Press: pp. 469-472, 1981 8. Greden JF: The dexamethasone suppression test: An established biological marker of melancholia. In Biological Markers in Psychiatry and Neurology. Edited by Usdin E, Hanin I. Pergamon Press, Oxford: 1982

John F. Greden, M.D. Page 46 Last Revised December 2019

9. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, DeVigne JP, Young E: Standardization of the dexamethasone suppression test for the diagnosis of melancholia. In, Advances in Psychiatry, Vol. 7: pp. 1-13, 1982 10. Greden JF: The dexamethasone suppression test as a research variable. In, Frontiers in Neuropsychiatric Research. Edited by Usdin E, Goldstein M. Macmillan Press, New York: 1983 11. Greden JF: Minds in despair. Medical Update, World Book Encyclopedia Inc, Chicago, pp. 146-158, 1983 12. Albala AA, Haskett RF, Greden JF, Carroll BJ: The use of neuroendocrine markers in the practice of ECT.In, ECT: Basic Mechanisms. Edited by R. Belmaker, B. Lerer, R.D. Weiner. John Libbey and Company, London: 1983 13. Greden JF, DeVigne JP, Albala AA, Tarika J, Buttenheim M, Eiser A, Carroll BJ: Postdexamethasone plasma cortisol levels among lithium-treated rapid cycling bipolar patients. In Predictors of Lithium Response. Edited by Dufour H. Economica, Paris: 1983 14. Greden JF: Tests of psychomotor function. In Handbook of Psychiatric Diagnostic Procedures. Edited by Hall RCW, Beresford TP. Spectrum Publication, Jamaica, New York: 1984 15. Greden JF: Biological laboratory tests in psychiatry. In Comprehensive Textbook of Psychiatry, IV (Fourth Edition). Edited by Sadock BJ, Kaplan HI. The Williams and Wilkins Company, Baltimore: pp. 2028- 2033, 1985 16. Greden JF: Caffeine and tobacco disorders. In Comprehensive Textbook of Psychiatry, IV (Fourth Edition). Edited by Sadock BJ, Kaplan HI. The Williams and Wilkins Company, Baltimore: pp. 1026-1033, 1985. 17. Arato M, Banki CM, Tothfalusi L, Nemeroff CB, Bisette G, Akil H, Watson, SJ, Greden JF: Post-mortem CSF measurements as a new research tool. In, Clinical Neuropharmacology Vol. 9(4). Raven Press, New York, 1986 18. Greden JF: The hypothalamic-pituitary-adrenal system in depression: Paradigms and problems in research and practice. In Hormones and Depression. Edited by Halbriech U. Raven Press, New York, pp. 59-76, 1987 19. Meador-Woodruff JH and Greden JF: Effects of Psychotropic Medications on Hypothalamic-Pituitary- Adrenal Regulation. In Endocrinology and Metabolism Clinics of North America. Edited by Brown WA, Saunders WB. Company, Philadelphia, Pennsylvania, vol. 17, pp. 225-234,1988 20. Nair MPN, Schwartz SA, Kronfol ZA, Pottathil R, Heimer, EP, Greden JF: Suppressive effect of alcohol on normal lymphocyte proliferative response to immunodeficiency virus (HIV) antigens. In Viruses, Immunity and Mental Health. Edited by E. Kurstad. Quebec, Canada. 1989 21. Nair MPN, Schwartz SA, Kronfol ZA, Pottathil R, Heimer EP, Greden JF: Suppressive effect of alcohol and normal lymphocyte proliferative response to HIV antigens. In Psychiatry and Biological Factors. Edited by E. Kurstad. pp. 269-273, 1991 22. Cardona D, Tandon R, Haskett RF, Greden JF: Menstrual effects on neuroendocrine measures. In Menstruation, Health, and Illness. Edited by N. Woods, D. Taylor, Matteo S. Hemisphere Publishing Corporation, Washington, D.C.: pp. 41-48, 1991 23. Tandon R and Greden JF: Cholinergic excess and the negative schizophrenic syndrome. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Edited by Greden JF and Tandon R. American Psychiatric Press, Washington, D.C.: pp. 99-111, 1991 24. Tandon R and Greden JF: Conclusion: Is integration possible? In Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Edited by JF Greden, R Tandon. American Psychiatric Press, Washington, D.C.: pp 235-239, 1991 25. Tandon R, Greden JF, Shipley JE, Mann NA, Eisner WH: Cholinergic activity and schizophrenic symptoms. In Biological Psychiatry, Edited by G. Racagni. Elsevier, Amsterdam: pp. 520-522, 1991 26. Greden JF and Walters AM: Caffeine. In, Substance Abuse: A Comprehensive Textbook, 2nd edition. Lowinson, Ruiz, Millman, Eeds. Williams & Williams, Baltimore: pp. 357-370, 1992

John F. Greden, M.D. Page 47 Last Revised December 2019

27. Greden JF, and Pomerleau O: Caffeine and Nicotine. In Comprehensive Textbook of Psychiatry, VI (Sixth Edition). Edited by B.J. Sadock, H.I. Kaplan. The Williams and Wilkins Company, Baltimore: pp. 799-810, 1995 28. Greden JF and Schwenk T: Major Mood Disorders. In, Primary Care Psychiatry. Edited by D. Knesper, M. Riba, and T. Schwenk. W. B. Saunders Company, Philadelphia: pp. 107-131, 1997 29. Greden JF and Walters AM: Caffeine. In Substance Abuse: A Comprehensive Textbook (Third Edition). Edited by Lowinson, Ruiz, Millman, and Langrod. Williams and Wilkins, Baltimore: pp. 294-307, 1997 30. Greden JF and Lopez J: Treatment of Major Depression. In, Current Psychiatric Therapy II. Edited by D. L. Dunner. W. B. Saunders, Philadelphia: pp. 221-232, 1997 31. Greden JF: Antidepressant Maintenance Medications. In, Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders. Edited by U Halbreich and S Montgomery, Washington, D.C.: pp.315-330, 2000 32. Greden JF: Recurrent Depression and Mania: Their Overwhelming Burden, Treatment of Recurrent Depression, American Psychiatric Press Review of Psychiatry, p. 1-18, Vol. 20, American Psychiatric Press, Inc., Washington, DC, 2001 33. Greden JF: Clinical Prevention of Recurrent Depression: The Need for Paradigm Shifts, Treatment of Recurrent Depression, American Psychiatric Press Review of Psychiatry, p. 143-170, Vol. 20, American Psychiatric Press, Inc., Washington, DC, 2001 34. Greden JF: Classes of Psychiatric Treatments: Animal and Human Pharmacology, Antidepressants and Anxiolytics, Duloxetine and Milnacipran, Textbook of Psychopharmacology, American Psychiatric Publishing, p. 361-370, Third Edition, Washington, DC, 2004 35. Webster MC, Kerr DCR, Ghaziuddin N, Greden JF, King CA: A Clinical Monitoring System for Depressed Adolescents: A Randomized Controlled Trial, 2008. 36. McInnis MG, Riba M, Greden JF: Depressive Disorders. In Eds: Hales RE,Yudofsky SC, Roberts LW: The American Psychiatric Publishing Textbook of Psychiatry, Sixth Edition, American Psychiatric Press, Inc., 353-389, 2014 37. Parikh, SV, Riba MB, Greden JF: Depressive Disorders, Ch. 12. Hales RE,Yudofsky SC, Roberts LW: The American Psychiatric Publishing Textbook of Psychiatry, Seventh Edition, American Psychiatric Press, Inc., 2019

Abstracts, Posters and Panel Discussions 1. Greden JF, Morgan DW: Amnesty’s Impact upon Drug Use: A Pre/Post Study. Scientific Proceedings of the 125th Annual Meeting of the American Psychiatric Association. Dallas, Texas. May 1972 2. Morgan DW, Greden JF, Frenkel SI: Patterns of Alcohol use Among Soldiers. Proceedings of the Second International Conference on Alcoholism and Drug Dependence. Liverpool, England. April 1973 3. Greden JF, Morgan DW, Frenkel SI: The Changing Drug Scene: 1969-1972. Scientific Proceedings of the 126th Annual Meeting of the American Psychiatric Association. Honolulu, Hawaii. May 1973 4. Morgan DW, Greden JF, Frenkel SI, Ream NW: Heroin Use: “Contagious Disease” or “Psychosocial Phenomenon”. Scientific Proceedings of the 126th Annual Meeting of the American Psychiatric Association. Honolulu, Hawaii. May 1973 5. Greden JF, Morgan DW, Pinsen J, Trick G: Panel: “Problems of Addicted Veterans, Servicemen or Dependents” Moderator: Alex Richman, M.D., Beth Israel Medical Center, New York, New York. Conducted at the Annual Meeting of the Orthopsychiatric Association, New York, New York. May 1973 6. Greden JF, Nelson KE, McLaughlin AE, Morgan DW, Robinson JA: Panel: “Emerging Alcohol Treatment Programs”. Scientific Proceedings of the 127th Annual Meeting of the American Psychiatric Association. Detroit, Michigan. May 1974 7. Greden JF: Anxiety or Caffeinism: A Diagnostic Dilemma. Scientific Proceedings of the 127th Annual Meeting of the American Psychiatric Association. Detroit, Michigan. May 1974

John F. Greden, M.D. Page 48 Last Revised December 2019

8. Greden JF, Casariego JI: Psychiatry Residents View Education Controversies. Scientific Proceedings of the 127th Annual Meeting of the American Psychiatric Association. Detroit, Michigan. May 1974 9. Frenkel SI, Greden JF, Morgan DW: Alcohol use in the Army: Patterns and Associated Behaviors. Proceedings of International Conference on Psychological Stress and Adjustment in Time of War and Peace. Tel Aviv, Israel. January 1975 10. Greden JF, Guyden T, Miller R: Doctors and Race Relations: A Consultation Quandary. Scientific Proceedings of the 128th Annual Meeting of the American Psychiatric Association. Anaheim, California. May 1975 11. Greden JF: Caffeinism. Today in Psychiatry Audiotape Services. Systems, 1975 12. Greden JF: Suicide. Audio-Digest, 1976 13. Greden JF: Child Psychiatry for General Residents. Scientific Proceedings of the 129th Annual Meeting of the American Psychiatric Association. Miami Beach, Florida. May 1976 14. Greden JF, Brandow M, Burpee C, Przepiorka K: Staff Perceptions of General Hospital Psychiatry. Scientific Proceedings of the 129th Annual Meeting of the American Psychiatric Association. Miami Beach, Florida. May 1976 15. Greden JF, Willett AB, Voth H, Romano J: Panel: Pros and Cons of Physical Exams by Psychiatrists. Scientific Proceedings of the 129th Annual Meeting of the American Psychiatric Association. Miami Beach, Florida. May 1976 16. Blank R, Hartman J, Ash P, Greden JF: Critical Issues in Psychiatry Residency Education. Panel presented at the Scientific Proceedings of the 130th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. May 1977 17. Greden JF, Fontaine P, Lubetsky M, Chamberlain K: Caffeinism: An Emerging Clinical Profile. Scientific Proceedings of the 130th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. May 1977 18. Greden JF, Schnackenberg R, Cobb S, Gilbert R: Caffeine and Psychiatric Manifestations. Panel presented at the Scientific Proceedings of the 130th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. May 1977 19. Lippman D, Nesse R, Persad E, Clark E, Greden JF, Carli T, Nicks BRC: Psychiatry Residency Training in United States and Canada. Panel presented at the Scientific Proceedings of the 130th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. May 1977 20. Albala AA, Barton G, Greden JF, Clark NW: The after Care Clinic in the Psychiatric Resident’s Education. Panel presented at the Scientific Proceedings of the 131st Annual Meeting of the American Psychiatry Association. Atlanta, Georgia. May 1978 21. Greden JF: Needed: A Curriculum of Experiences for Psychiatry Residents. Scientific Proceedings of the 131st Annual Meeting of the American Psychiatric Association. Atlanta, Georgia. May 1978 22. Carroll BJ, Greden JF, Haskett R, Feinberg M, Albala AA, Martin FIR, Rubin RT, Heath B, Sharp PT, McLeod WL: Neurotransmitter Studies of Neuroendocrine Pathology in Depression. Presented at symposium “Biogenic Amines and Affective Disorders.” London, England. January 1979 23. Greden JF, Albala AA, Haskett RF, James NM, Goodman L, Steiner M, Carroll BJ: Normalization of Dexamethasone Suppression Tests: A Probable Index of Recovery among Endogenous Depressives. Scientific Proceedings of the 132nd Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1979 24. Greden JF, Victor B, Fontaine P, Lubetsky M: Caffeine Withdrawal Headache: A Neglected Psychiatric Syndrome. Scientific Proceedings of the 132nd Annual Meeting of the American Psychiatric Association. Chicago Illinois. May 1979 25. Greden JF and Carroll BJ: Decrease in Speech Pause and Phonation Times with Treatment of Endogenous Depression. Scientific Proceedings of the Annual Meeting of the Society of Biological Psychiatry. May 1979

John F. Greden, M.D. Page 49 Last Revised December 2019

26. Greden JF, Albala AA, Carroll BJ: Speech Pause Times among Endogenous Depressives: An Objective Measure of Diurnal Variation. Proceedings of the 5th World Congress of the International College of Psychosomatic Medicine. Jerusalem, Israel. September 1979 27. Carroll BJ, Greden JF, Feinberg M, James N MCI, Lohr N: Neuroendocrine Disinhibition in “Borderline Syndrome”. Psychiatric Research Society. Madison, Wisconsin. September 1979 28. Carroll BJ, Greden JF, Feinberg M, et al.: The Evaluation of Depression. Scientific Proceedings of the 133rd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1980 29. Greden JF: Antidepressant Drugs: Past, Present and Future. Scientific Proceedings of the 133rd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1980 30. Greden JF, Tarika JS, DeVigne JP: Dexamethasone Suppression Test Predicts Treatment Response. Scientific Proceedings of the 133rd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1980 31. Greden JF, DeVigne JP, Albala AA, Tarika J, Buttenheim M, Eiser A, Carroll BJ: Effects of Lithium upon Hypothalamic Pituitary Adrenal Functioning among Rapid Cycling Bipolar Patterns. Proceedings of International Colloquium on “The Criteria of Response to Lithium Salts”. Marseilles, France. June 1980 32. Albala AA, Greden JF, Tarika J, Carroll BJ: Changes in Serial Dexamethasone Suppression Tests among unipolar depressives receiving electroconvulsive treatments. Scientific proceedings of the Society of Biological Psychiatry. Boston, Massachusetts. September 1980 33. Greden JF, Albala AA, Smokler IA, Carroll BJ: Speech pause time among endogenous depressives: A follow- up report. Scientific proceedings of the Society of Biological Psychiatry. Boston, Massachusetts. September 1980 34. Greden JF, DeVigne JP, Albala AA, et al: Serial Dexamethasone Suppression Tests among Rapid Cyclers. Scientific Proceedings of the Society of Biological Psychiatry. Boston, Massachusetts. September 1980 35. Feinberg M, Carroll BJ, Gillin JC, Greden JF: Diagnosis of Depression using Sleep EEG. Scientific proceedings of the Society of Biological Psychiatry. Boston, Massachusetts. September 1980 36. Feinberg M, Carroll BJ, Greden JF: Comparison of Two Neuroendocrine Markers for Endogenous Depression. Scientific proceedings of the Society of Biological Psychiatry. Boston, Massachusetts. September 1980 37. Feinberg M, Gillin JC, Carroll BJ, Greden JF, Zis AP: EEG Studies of Sleep and the Dexamethasone Suppression Test in the Diagnosis of Depression. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. December 1980 38. Greden JF: Pharmacology of Neuroendocrine Control: Possible Role of Cholinergic System. Winter Conference on Brain Research. Keystone, Colorado. February 1981 39. Carroll BJ, Feinberg M, Greden JF, Zis AP: Neuroendocrine Diagnosis of Endogenous Depression. Scientific Proceedings of the 134th Annual Meeting of the American Psychiatric Association. New Orleans, Louisiana. May 1981 40. Garcia-Sevilla J, Smith CB, Hollingsworth P, Zis A, Greden JF: Alpha-2 Adrenergic Receptor Function in Endogenous Depression. Scientific proceedings of the 134th Annual Meeting of the American Psychiatric Association. New Orleans, Louisiana. May 1981 41. Greden JF: The Dexamethasone Suppression Test: An Established Biological Marker of Melancholia. Scientific proceedings of the 134th Annual Meeting of the American Psychiatric Association. New Orleans, Louisiana. May 1981 42. Privitera M, Greden JF, Gardner R, Carroll BJ: Carbamazepine Interference with the Dexamethasone Suppression Test. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. New Orleans, Louisiana. May 1981 43. Albala AA, Greden JF, Zis A, Young E: Sleep Deprivation Effects upon the Dexamethasone Suppression Test. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. New Orleans, Louisiana. May 1981 John F. Greden, M.D. Page 50 Last Revised December 2019

44. Greden JF, DeVigne JP, Kronfol Z, Tarika J, Albala AA, Feinberg M, Carroll BJ: Dexamethasone Suppression Test Classifications and Prediction of Treatment Response. Proceedings of the 3rd World Congress of Biological Psychiatry. Stockholm, Sweden. June 1981 45. Greden JF, Kronfol Z, Gardner R, Feinberg M, Carroll BJ: Neuroendocrine Evaluation of Schizoaffectives with the Dexamethasone Suppression Test. Proceedings of the 3rd World Congress of Biological Psychiatry. Stockholm, Sweden. June 1981 46. Feinberg M, Carroll BJ, Greden JF, Zis AP: Neuroendocrine Diagnosis of Depression using Sleep EEG and the Dexamethasone Suppression Test. Presented at the 6th World Congress of Psychosomatic Medicine. Montreal, Quebec, Canada. September 1981 47. Kronfol Z, Carroll BJ, Dembinski S, Silva J, Gardner R, Greden JF: Impaired Immunity in Endogenous Depression. World Psychiatric Association, New York, New York. 1981 48. Kronfol Z, Silva J, Greden JF, Dembinski S, Carroll BJ: Cell Mediated Immunity in Melancholia. American Psychosomatic Society. Denver, Colorado. 1982 49. Greden JF: The Dexamethasone Suppression Test. Audio-Digest, Psychiatry, 1982 50. Greden JF: Affective Disorders: Diagnosis and Treatment. Audio-Digest, Psychiatry, 1982 51. Haskett RF, Carroll BJ, Greden JF, Albala AA: Neurotransmitter Mechanism Associated with Cortisol Escape from Dexamethasone Suppression. Integrative Neurohumoral Mechanisms. Budapest, Hungary. March 1982 52. Kronfol Z, Silva J, Gardner R, Greden JF, Carroll BJ: Lymphocyte Function in Melancholia. Scientific Proceedings of the 135th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. May 1982 53. Haskett RF, Carroll BJ, Greden JF, Albala AA: Neurotransmitter Mechanism Associated with Cortisol Escape from Dexamethasone Suppression. Integrative Neurohumoral Mechanisms. Budapest, Hungary. March 1982. 54. Kronfol Z, Silva J, Gardner R, Greden JF, Carroll BJ: Lymphocyte function in melancholia. Scientific proceedings of the 135th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. May 1982. 55. Feinberg M and Greden JF: Twice is not Enough: First Night Effect on Sleep Recordings in Depressed Inpatients and Outpatients. Scientific Proceedings of the Annual Meeting of Society of Biological Psychiatry. Toronto, Ontario, Canada. May 1982 56. Greden JF, Kronfol Z, Gardner R, Carroll BJ: Serial Dexamethasone Suppression Tests. Scientific proceedings of the Annual Meeting of Society of Biological Psychiatry. Toronto, Ontario, Canada. May 1982 57. Grunhaus L, Dilsaver S, Greden JF, Carroll BJ: The Dexamethasone Suppression Test in Dementia and Pseudodementia. Scientific proceedings of the Annual Meeting of Society of Biological Psychiatry. Toronto, Ontario, Canada. May 1982 58. Kroll P, Ritchie J, Palmer C, Greden JF: Dexamethasone Suppression Test in Alcoholics. Scientific Proceedings of the Annual Meeting of Society of Biological Psychiatry. Toronto, Ontario, Canada. May 1982 59. Matthews JD, Akil H, Greden JF, Watson SJ: Plasma Measures of Beta-Endorphin like Immunoreactivity in Depressives and Normal Subjects. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Toronto, Ontario, Canada. May 1982 60. DeVigne JP, Greden JF, Feinberg M, Carroll BJ: Depression Classification and Dexamethasone Suppression Test. Les marqueurs Biologiques et les Disorders Affectifs. Luxembourg. 1982 61. Greden JF: The Dexamethasone Suppression Test as a Research Variable. Frontiers in Neuropsychiatric Research Symposium. Corfu, Greece. 1982

John F. Greden, M.D. Page 51 Last Revised December 2019

62. Albala AA, Haskett RF, Zis AP, Greden JF, Carroll BJ: Serial Dexamethasone Test during Electroconvulsive Therapy. Abstracts of the 13th Collegium International Neuro-Psychopharmacologium (CINP). Jerusalem, Israel. 1982 63. Greden JF: New Applications of the Dexamethasone Suppression Test. Abstracts of the 13th Collegium International Neuro-Psychopharmacologium (CINP). Jerusalem, Israel. 1982 64. Greden JF, Kronfol Z, Gardner RW, Carroll BJ: Serial Monitoring of Endogenous Depressives with Weekly Dexamethasone Suppression Tests. Abstracts of the 13th Collegium International Neuropsychopharmacology (CINP). Jerusalem, Israel. 1982 65. Greden JF: The Dexamethasone Suppression Test in Neuroendocrine Dysfunction in the Hypothalamic- Pituitary- Adrenal Axis Dysfunction: Search for the Lesion. Symposium at the Winter Conference on Brain Research (WCBR). Keystone, Colorado. February 1983 66. Cameron OG, Kronfol K, Greden JF, Carroll BJ: The Dexamethasone Suppression Test in Diabetes American Psychosomatic Society. New York, New York. March 1983 67. Cameron OG, Kronfol Z, Greden JF, Carroll BJ: The Dexamethasone Suppression Test (DST) in Diabetes. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. New York, New York. 1983 68. Grunhaus L, Shein H, Greden JF, Carroll BJ: The Dexamethasone Suppression Test in Patients with repeated Hospitalizations. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. New York, New York. 1983 69. Kronfol Z, Silva J, Greden JF, Carroll BJ: Immune Function in Depressive Illness: Preliminary Findings. Scientific Proceedings of the Annual Meeting of the Society of Biological Psychiatry. New York, New York. 1983 70. Greden JF: Clinical Interpretation of Dexamethasone Suppression Test Results. Scientific Proceedings of the 136th Annual Meeting of the American Psychiatric Association. New York, New York. 1983 71. King D, Greden JF, Carroll BJ: Diagnosis and Serial Dexamethasone Suppression Test Results in Borderlines. Scientific proceedings of the 136th Annual Meeting of the American Psychiatric Association. New York, New York. 1983 72. Kronfol Z, Slymen D, Dembinski S, Silva J, Greden JF, Carroll BJ: Lymphocyte Function in Subtypes of Depression. Scientific proceedings of the 136th Annual Meeting of the American Psychiatric Association. New York, New York. 1983 73. Watson SJ, Matthews JD, Greden JF, Akil H: Pituitary Peptides in Depression. Scientific proceedings of the 136th Annual Meeting of the American Psychiatric Association. New York, New York. 1983 74. Greden JF, Lenox RH, Reus VI, Risch SC: Multiple Neuroendocrine Abnormalities in Patients with Affective Disorders. Symposium at the Winter Conference on Brain Research (WCBR). Steamboat Springs, Colorado. January 1984 75. Greden JF, Bendz H: A Serum Cortisol "Profile" of Hypothalamic-Pituitary- Adrenal Axis Dysregulation. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Los Angeles, California. May 1984 76. Greden JF, Genero N, Price HL: The "Omega Sign" of Melancholia: EMG Results. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Los Angeles, California. May 1984 77. Grunhaus L, Rabin D, Greden JF, Feinberg M, Herman R: Simultaneous Panic and Depressive Disorders. Neuroendocrine and Depressive Disorders: Neuroendocrine and Sleep EEG Correlates. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Los Angeles, California. May 1984 78. Lopez JF, Watson SJ, Young E, Knobloch M, Weinberg G, Vale W, Rivier J, Greden JF, Akil H: CRF Releases Beta-Endorphin/beta-LPH in Normal Humans. Society for Neuroscience. October 1984 79. Greden JF: Serial Monitoring of Depressed Patients with Hypothalamic-Pituitary-Adrenal Tests. Annual Meeting of the Psychiatric Research Society. Tampa, Florida. March 1985 John F. Greden, M.D. Page 52 Last Revised December 2019

80. Greden JF: Strategies for the Development of Psychiatric Laboratory Tests: A Review for Consumers. Scientific Proceedings of the Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 81. Greden JF, Haskett RF, Zelnik T, Grunhaus L, Tiongco D: Serial Hypothalamic-Pituitary- Adrenal Monitoring in Depressed Patients. Scientific Proceedings of Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 82. Grunhaus L, Alcser K, Haskett RF, Greden JF, Zelnik T: Clinical and DST Correlates of ECT Response. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 83. Kumar A, Alcser K, Carroll BJ, Greden JF: The Dexamethasone Suppression Test: Does it Reflect Endogeneity? Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 84. Tandon R, Flegel P, Greden JF: CSF Biochemical Correlates of Mixed Affective States. Scientific proceedings of the Annual Meeting of the Society Biological Psychiatry. Dallas, Texas. May 1985 85. Tandon R, Alcser K, Greden JF: Effects of Menstrual Cycle on the Dexamethasone Suppression Test. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 86. Tiongco D, Feinberg M, Grunhaus L, Greden JF: Serial Monitoring of Sleep EEGs and Dexamethasone Suppression Tests during Electroconvulsive Therapy. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 87. Zelnik T, Albala AA, Haskett RF, Grunhaus L, Greden JF: Serial Neuroendocrine Patterns in Depressives Treated only with Electroconvulsive Therapy. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Dallas, Texas. May 1985 88. Greden JF, Dilsaver S, Haskett RF, Grunhaus L: The Cholinergic-Neuroendocrine Connection. Symposium. Scientific proceedings of the 138th Annual Meeting of the American Psychiatric Association. Dallas, Texas. May 1985 89. Lake CR, Greden JF, Cohen S, Smith D, Wender PH: CNS Stimulant use vs. Abuse: Clinical Aspects. A Symposium. Scientific Proceedings of the 138th Annual Meeting of the American Psychiatric Association. Dallas, Texas. May 1985 90. Greden JF: Adrenergic Influences on HPA Regulation. 4th World Congress of Biological Psychiatry. Philadelphia, Pennsylvania. September 1985 91. Greden JF: Age Effects on HPA Regulation: A serial Monitoring Strategy. Annual Meeting of the American College of Psychopharmacology. Maui, Hawaii. December 1985 92. Greden JF: Antidepressant Withdrawal Syndromes. Winter Conference on Brain Research. Keystone, Colorado. January 1986 93. Genero N, Haskett R, Kotun J, Newman J, Tiongco D, Warner E, Greden JF: Melancholia: Proposed DSM-III Revisions. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 94. Greden JF, Haskett RF, Grunhaus L, Bendz H, Flegel P: Does Severity Explain Melancholia? A neuroendocrine perspective. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 95. Greden JF, Tiongco D, Haskett RF, Grunhaus L, Kotun J: Interactions Between Depression and Aging in HPA Dysregulation. Scientific Proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 96. Gurguis G, Meador-Woodruff J, Haskett RF, Greden JF: Relationship between Number of prior Episodes and Persistent HPA Dysregulation in Responsive Patients with Major Depressive Disorders. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986

John F. Greden, M.D. Page 53 Last Revised December 2019

97. Lee MA, Flegel P, Cameron OG, Greden JF: Caffeine and the Dexamethasone Test (DST) in Depressed Patients. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 98. Lee MA, Flegel P, Greden JF, Cameron OG: Caffeine as an Anxiogenic Agent: Comparison of Panic and Depressed Patients. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 99. Meador-Woodruff J, Grunhaus L, Haskett RF, Greden JF: Post- Dexamethasone Cortisol Levels in Major Depressive Disorder: Relationship to Severity of Illness. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 100. Meador-Woodruff JH, Gurguis G, Grunhaus L, Haskett RF, Greden JF: Effect of Chronicity of Illness on Pre- treatment Hypothalamic-Pituitary-Adrenal (HPA) Dysregulation in Major Depressive Disorder. Presented at the 41st Annual Meeting of the Society of Biological Psychiatry, Washington D.C. May 1986 101. Meador-Woodruff J, Haskett RF, Akil H, Watson SJ Greden JF: B- Endorphin Levels in Major Depressive Disorder: Relationship to Severity of Illness. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 102. Shipley JE, Kumar A, Eiser A, Feinberg M, Flegel P, Greden JF: EEG Sleep and DST Correlates of Sleep onset REM Periods. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 103. Tandon R, Flegel P, Greden JF: Comparison of Hamilton and Carroll Rating Scales for Depression. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 104. Tandon R, Grunhaus L, Krugler T, Greden JF: Efficacy of Unilateral versus Bilateral Electroconvulsive Therapy in Endogenous Depression. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 105. Tiongco DD, Hariharan M, Haskett RF, Greden JF: Age effects on HPA Regulation and Dexamethasone Plasma Levels in Normal Subjects. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 106. Young EA, Akil H, Kotun J, Haskett RF, Greden JF, Rivier J, Watson SJ: Response to CRF Infusion in Normal Controls and Endogenous Depression (ED). Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1986 107. Greden JF, Hasket RF, Grunhaus L, Bendz H, Flegel P: Does Severity Explain Melancholia? A DST Validation. Scientific proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986 108. Greden JF, Tiongco D, Haskett RF, Grunhaus L, Kotun J: Aging Increases HPA Dysregulation in Depressives. Scientific proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986 109. Haskett RF, Tandon R, Greden JF, McEwen BS, Halbriech U, Endicott J: Psychobiology of the Menstrual Cycle. A Symposium. Scientific proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986 110. Lee MA, Flegel P, Cameron OG, Greden JF: Caffeine effects on Anxiety and DST in Depression. Scientific Proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986 111. Meador-Woodruff J, Haskett RF, Akil H, Watson SJ, Grunhaus L, Greden JF: Severity of Depression and Multiple HPA Measures. Presented at the 139th Annual Meeting of the American Psychiatric Association, Washington, D.C. May 1986 112. Shipley JE, Kumar A, Eiser A, Feinberg M, Flegel P, Greden JF: Psychobiology of Sleep onset REM Periods. Scientific Proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986

John F. Greden, M.D. Page 54 Last Revised December 2019

113. Tandon R, Flegel P, Greden JF: Carroll and Hamilton Rating Scales for Depression. Scientific proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986 114. Tandon R, Grunhaus L, Krugler T, Greden JF: Unilateral versus Bilateral ECT in Melancholia. Scientific proceedings of the 139th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1986 115. Greden JF, Tiongco DD, Haskett RF, Hariharan M, Grunhaus L: Interactions among Aging Plasma Dexamethasone Levels and Hypothalamic-Pituitary-Adrenal Dysregulation. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Washington, D.C. December 1986 116. Kronfol Z, Schwartz S, Greden JF: Depression and Immune Function: The Role of Corticosteroids. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Washington, D.C. December 1986 117. Aerator M, Banki C, Tothfalusi CB, Nemeroff G, H, Watson SJ, Greden JF: Post-Mortem CSF Measurements as a New Research Tool. 15th Annual Meeting of the Collegium Internationale Neuropsychopharmacologicum. San Juan, Puerto Rico. December 1986 118. Greden JF: Laboratory Tests in Psychiatry: Is there a Clinical Future? Presented at the First Annual Symposium on Psychiatric Medicine. Orlando, Florida. March 1987 119. Grunhaus L, Flegel P, Pande A, Kotun J, Greden JF, Haskett RF: Dexamethasone non- Suppression Predicts Outcome in Major Depressive Disorder (MDD). Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 120. Grunhaus L, Harel Y, Krugler T, Haskett RF, Greden JF: MDD and Panic Disorder: Effects of Comorbidity on Treatment Outcome. Scientific proceedings of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 121. Kotun J, Haskett RF, Grunhaus L, Greden JF: Predictors of HPA Dysfunction in Depression. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 122. Pande A. Hariharan M, Grunhaus L, Greden JF, Haskett RF: Relationship of Plasma Dexamethasone to Plasma Cortisol in Major Depressive Disorder (MDD). Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 123. Pande A, Krugler T, Haskett RF, Greden JF, Grunhaus L: Predictors of Response to Electroconvulsive Therapy (ECT) in Major Depressive Disorder (MDD). Scientific Proceedings of the Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 124. Shipley JE, Genero N, Martin DK, Greden JF, Haskett RF: EEG Sleep and Facial EMG’s in Major Depressive Disorder. Scientific proceedings of the Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 125. Grunhaus L, Harel Y, Krugler T, Haskett RF, Greden JF: MDD and Panic Disorder: Effects of Comorbidity on Treatment Outcome. Scientific Proceedings of the 140th Annual Meeting of the American Psychiatric Association. Chicago, Illinois. May 1987 126. Kotun J, Haskett RF, Grunhaus L, Greden JF: Predictors of HPA Axis Dysfunction in Depression. Scientific Proceedings of the 140th Annual Meeting of the American Psychiatric Association. Chicago, Illinois. May 1987 127. Meador-Woodruff JH, Haskett RF, Grunhaus L, Greden JF: Psychosis, Severity of Illness, and Post- Dexamethasone Cortisol Levels. Scientific proceedings of Annual Meeting of the Society of Biological Psychiatry. Chicago, Illinois. May 1987 128. Martin D, Shipley JE, Genero N, Greden JF, Flegel P, Eiser A, Grunhaus L, Haskett R: Association of EEG Sleep Measures and Facial Electromyography in Depression. 5th International Congress of Sleep Research. Copenhagen, Denmark. June 1987 129. Grunhaus L, Flegel P, Pande AC, Kotun J, Greden JF, Haskett RF: Dexamethasone non-Suppression Predicts Outcome in Major Depressive Disorder. ISPNE XVIII International Society of Psychoneuroendocrinology. Durham, North Carolina. June 1987 John F. Greden, M.D. Page 55 Last Revised December 2019

130. Haskett RF, Grunhaus L, Greden JF, Weinberg V, Knobloch M, Watson S, Akil H: Changes in B-Endorphin Response to Dexamethasone during Treatment of Depression. ISPNE XVIII International Society of Psychoneuroendocrinology. Durham, North Carolina. June 1987 131. Pande AC, Hariharan M, Grunhaus LJ, Greden JF, Haskett RF: Relationship of Plasma Dexamethasone to Plasma Cortisol in Major Depressive Disorder. ISPNE XVIII International Society of Psychoneuroendocrinology. Durham, North Carolina. June 1987 132. Greden JF: New Laboratory and Treatment Advances for Adult Depression. Presented at the World Psychiatric Association Regional Symposium, Buenos Aries, Argentina. August 1987 133. Greden JF, Tandon R, Haskett RF: Physostigmine-induced Cholinergic Excess: A Proposed Model for Negative Schizophrenia Symptoms. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. December 1987 134. Tandon R and Greden JF: Validity of Negative Schizophrenic Syndrome: Temporal Stability and Biological Markers. Presented at the Annual Meeting of the American Psychopathological Association. New York, New York. March 1988 135. Genero N, Greden JF, Pande A, Haskett RF: Facial EMG’s: Severity Differences in Depression. Scientific Proceedings of the Annual Meeting of the Society for Biological Psychiatry. Montreal, Quebec. May 1988 136. Haskett RF, Young EA, Greden JF: Natural History of ß Endorphin Response to Dexamethasone during Depression. Scientific Proceedings of the Society for Biological Psychiatry. Montreal, Quebec. May 1988 137. Krahn D, Gosnell B, Drewnowski A, Canum K, Lemmen C, Greden JF: Effects of Naloxone and Butorphanol on the Consumption of Palatable Food by Females. Scientific proceedings of the Annual Meeting of the Society for Biological Psychiatry. Montreal, Quebec. May 1988 138. Meador-Woodruff JF, Greden JF, Grunhaus L, Haskett RF: Severity of Depression and Hypothalamic- Pituitary-Adrenal Axis Dysregulation: Identification of Contributing Factors. Scientific Proceedings of the Annual Meeting of the Society for Biological Psychiatry. Montreal, Quebec. May 1988 139. Tandon R, Goodson J, Silk KR, Kronfol Z, Hariharan M, Greden JF: Positive and Negative Symptoms in Schizophrenia and the Dexamethasone Suppression Test. Scientific Proceedings of the Annual Meeting of the Society for Biological Psychiatry. Montreal, Quebec. May 1988 140. Tandon R, Shipley J, Eiser A, Goodson J, Greden JF: Association between Abnormal Rapid Eye Movement Sleep and Negative Symptoms in Schizophrenia. Scientific Proceedings of the Annual Meeting of the Society for Biological Psychiatry. Montreal, Quebec. May 1988 141. Greden JF: Symposium Chair: Pathophysiology of Negative Schizophrenic Symptoms. Scientific Proceedings of the 141st Annual Meeting of the American Psychiatric Association. Montreal, Quebec. May 1988 142. Hariharan M, VanNood T, Cameron OG, Curtis GC, Ostrow D, Greden JF: Free Plasma MHPG (3-methoxy-4- hydroxyphenylglycol) Determination by HPLC using an Electrochemical (EC) Detector. Presented at the Annual Meeting of AACC. Washington, D.C. 1988 143. Greden JF: Laboratory Testing in Psychiatry. ND MDA Audiotape Series, 1988 144. Greden JF: Underlying Mechanisms of Negative Schizophrenia. Presented at the Annual Meeting of the World Psychiatric Association Regional Symposium. Washington, D.C. October 1988 145. Greden JF: Prolonged Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Aged Depressives. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. December 1988 146. Newman J, Zelnik, T, Greden JF: Depression: As an Adverse Medication Reaction. A Guide for the Mental Health Professional. Sponsored and published by the State of Michigan Department of Mental Health. 1989 147. Hsu T, Shipley JE, Greden JF, Eiser AS, Douglass AB, Haskett RF, Grunhaus LJ, Pande A: Weight Change and Sleep Continuity in Major Depressive Disorder. Presented at the Annual Meeting of the Society of Biological Psychiatry. San Francisco, California. May 1989

John F. Greden, M.D. Page 56 Last Revised December 2019

148. Krahn D, Canum K, Flegel P, Drewnowski A, Greden JF: Caffeinism in Eating Disordered Patients. Presented at the Annual Meeting of the Society of Biological Psychiatry. San Francisco, California. May 1989 149. Naylor MW, Greden JF, Alessi NE: Plasma Dexamethasone Levels in Children Given the Dexamethasone Suppression Test. Presented at the Annual Meeting of the Society for Biological Psychiatry. San Francisco, California. May 1989 150. Pande A, Grunhaus L, Haskett RF, Greden JF: Response to Electroconvulsive Therapy in Psychotic Non- Psychotic Depression. Presented at the Annual Meeting of the Society of Biological Psychiatry. San Francisco, California. May 1989 151. Pande A, Grunhaus L, Haskett RF, Greden JF: Weight Change with Antidepressant Treatment Presented at the Annual Meeting of the Society of Biological Psychiatry. San Francisco, California. May 1989 152. Greden JF: The Omega Sign of Depression. Presented at the 142nd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1989 153. Hsu T, Shipley JE, Greden JF, Haskett RF, Grunhaus L, Eiser A: Weight Change and EEG Sleep in MDD. Presented at the 142nd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1989 154. Hsu T, Shipley JE, Greden JF, Haskett RF, Grunhaus L, Pande A: Age-Related Changes in Major Depressive Disorder. Presented at the 142nd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1989 155. Tandon R, Silk K, Shipley J, Greden JF: Cholinergic Excess and Negative Schizophrenia. Presented at the 142nd Annual Meeting of the American Psychiatric Association. San Francisco, California. May 1989 156. Hsu T, Shipley JE, Greden JF, Eiser A, Douglass AB, Haskett R, Grunhaus L, Pande A: Effect of Weight Change on Sleep in Major Depressive Disorder. Presented at the 3rd Annual Meeting of the Association of Professional Sleep Societies. Washington, D.C. June 1989 157. Shipley JE, Kumar A, Eiser A, Jacobs B, Haskett RF, Grunhaus L, Pande A, Greden JF: The Effect of In or Out Patient Status on the Association of EEG Sleep Data with Post-Dexamethasone Cortisol Levels in Depressed Patients. Presented at the 3rd Annual Meeting of the Association of Professional Sleep Societies. Washington, D.C. June 1989 158. Tandon R, Shipley JE, Greden JF: Electroencephalographic Sleep Abnormalities in Schizophrenia: Relationship to Positive Negative Symptoms and Ventricular Enlargement. Presented at the 2nd International Congress on Schizophrenia Research. San Diego, California. 1989 159. Tandon R, Shipley JE, Greden JF: Cholinergic Excess and Negative Schizophrenic Symptoms: Cholinergic Excess and Cerebral Atrophy. Presented at the 8th World Congress of Psychiatry. Athens, Greece. October 1989 160. Tandon R, Mann NA, Eisner WH, Greden JF: Effect of Anticholinergic Medication on Positive and Negative Symptoms in Medication-free Schizophrenic Patients. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Maui, Hawaii. December 1989 161. Tandon R, Shipley JE, Eiser A, Goodson J, DeQuardo, Greden JF: Sleep-EEG Abnormalities in Schizophrenia: Relationship to Positive/Negative Symptoms and Ventricular Enlargement. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Maui, Hawaii. December 1989 162. Tandon R, Greden JF: Muscarinic Cholinergic Hyperactivity in Schizophrenia: Relationship to Positive and Negative Symptoms. Presented at the Annual Meeting of the American Psychopathological Association. New York, New York. March 1990 163. Tandon R, Greden JF, Shipley JE: Muscarinic Hyperactivity in Schizophrenia: Relationship to Positive and Negative Symptoms. Presented at the Annual Meeting of the Society for Biological Psychiatry. New York, New York. May 1990 164. Kronfol Z, Nair MPN, Schwartz SA, Goel K, Modell S, Greden JF: Alcohol effects on Lymphocyte Natural Killer Cell Activity. Presented at the Annual Meeting of the Research Society on Alcoholism. June 1990

John F. Greden, M.D. Page 57 Last Revised December 2019

165. Kronfol Z, Nair MPN, Goel K, Haskett R, Greden JF: Depression, Cortisol, and Natural-Killer Cell Activity. First International Congress, International Society for Neuroimmunomodulation, Florence, Italy. June 1990 166. Tandon R, Greden JF, Shipley JE: Increased Cholinergic Activity in Schizophrenia: Relationship to Positive and Negative Symptoms. Presented at Schizophrenia 1990, An International Conference. Vancouver, British Columbia. July 1990 167. Cameron OG, Greden JF: Clinical Consequences of Glucocorticoid Excess or Deficiency. Presented at the XXI International Congress of the International Society of Psychoneuroendocrinology (ISPNE). Buffalo, New York. August 1990 168. Tandon R, Mazzara C, Greden JF: Dexamethasone Suppression Test in Schizophrenia: Relationship to Outcome, and Positive, Negative, and Depressive Symptoms. Presented at the XXI International Congress of the International Society of Psychoneuroendocrinology (ISPNE). Buffalo, New York. August 1990 169. Greden JF: The Changing Horizon in the Treatment of Depression and Related Disorders. Chantilly, Virginia. November 1990 170. Tandon R, Shipley JE, Taylor S, Eiser A, DeQuardo J, Greden JF: Clinical Correlates of EEG Sleep Abnormalities in Schizophrenia: Comparison of Drug- Naive and Previously-Medicated Patients with Health Controls. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 1990 171. Nair MPN, Schwartz SA, Kronfol ZA, Greden JF: Recreational Drugs, Immune Response and HIV Infection. World Congress of AIDS. Bombay, India. December 1990 172. Greden JF: Neglected Concepts in Psychiatric Research. Keynote Address. Annual Meeting of the Psychiatric Research Society. Park City, Utah. February 1991 173. Greden JF: Atypical Depression: New Perspectives on Etiology and Treatment. Presented at New Visions of the Brain II: Update: Anxiety and Mood Disorders. Scottsdale, Arizona. March 1991 174. Greden JF: A Crisis for Educators in Psychiatry: Earn-As-You- Go Pressures versus Teaching. Keynote Address. Presented at the Annual Meeting of the Association for Academic Psychiatry. Tampa, Florida. March 1991 175. Greden JF: How Chairpersons can hold Workshops to help their Faculty Teach despite Earning Pressures. Presented at the Annual Meeting of the Association for Academic Psychiatry. Tampa, Florida. March 1991 176. Greden JF: Techniques for Academic Success of Junior Faculty. Presented at the Annual Meeting of the Association for Academic Psychiatry. Tampa, Florida. March 1991 177. Greden JF: Symposium Chair: Neurotransmitters in Schizophrenia. Presented at the Fifth World Congress of Biological Psychiatry. Florence, Italy. June 1991 178. Greden JF: Aging-2 Glucocorticoid Interactions and Vulnerability to Depression. 5th World Congress of Biological Psychiatry. Florence, Italy. June 1991 179. Kronfol Z, Nair MPN, Haskett R, Tandon R, Greden JF: Natural Killer Cell Activity in Depression and Schizophrenia. Presented at the Fifth World Congress of Biological Psychiatry, Florence, Italy, June 1991 180. Tandon R, DeQuardo JR, Goodson J, Greden JF: Effect of Anticholinergics on Positive and Negative Symptoms in Schizophrenia. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 1991 181. Greden JF: Recurrent Depression: A Lifetime Disorder. Video Communications.1992 182. Nair MN, Schwartz SA, Kronfol ZA, Pottathil R, Greden JF: Immunoregulations of Lymphocyte Functions in AIDS and Normal Subjects by Alcohol. Presented at the International Conference on Alcohol Micronutrients and Cell Function. Kerala, India. February 1992 183. Greden JF: Developmental Neurobiology in Course of Depression: Implications for Clinicians. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 184. King CA, Naylor MW, Hill EM, Shain BN, Greden JF: Alcohol Use and Depressive Symptoms in Depressed Adolescents. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 John F. Greden, M.D. Page 58 Last Revised December 2019

185. Kronfol Z, Nair M, Greden JF: Alcohol and Age: Effects on Natural Killer Cell Activity. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 186. Nair M, Kronfol Z, Schwartz SA, Greden JF: Effect of Cortisol on Natural Killer Cell Activity of Lymphocytes from Normal Subjects and AIDS Patients. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 187. Pande AC, Haskett RF, Greden JF: Fluoxetine versus Phenelzine in Atypical Depression. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 188. Ribeiro SCM, Grunhaus L, Greden JF: Course of Illness and Biological Measures in Affective Disorders: A Critical Review of the DST Literature. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 189. Ribeiro SCM, Tandon R, Goldman RS, Goodson J, Greden JF: Covariance of Positive and Negative Symptoms during Initial Neuroleptic Treatment in Schizophrenia. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 190. Tandon R, Melnick P, DeQuardo JR, Meador-Woodruff JH, Goldman R, Greden JF: Premorbid Adjustment and Ventricular Enlargement in Schizophrenia. Presented at the Annual Meeting of the Society of Biological Psychiatry. Washington, D.C. May 1992 191. Greden JF: Symposium Chair. Is depression a lifetime disorder? Presented at the 145th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1992 192. Greden JF: Depression Medication: When to Maintain, How to Stop. Presented at the 145th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1992 193. Pande AC and Greden JF: Co-Chair Symposium. Diagnosis and Treatment of Atypical Depression. Presented at the 145th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1992 194. Pande AC, Haskett RF, Greden JF: Fluoxetine Treatment of Atypical Depression. Presented at the 145th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1992 195. Tandon R, Goldman R, Greden JF: Negative Symptoms: A Longitudinal Perspective. Presented at the 145th Annual Meeting of the American Psychiatric Association. Washington, D.C. May 1992 196. Nair MN, Schwartz SA, Kronfol Z, Greden JF: Selective Inhibition by Alcohol and Cortisol of Natural Killer Cell Activity of Lymphocytes from Cord Blood. Presented at the 18th Congress of CINP. Nice, France. June 1992 197. Kronfol Z, Nair MPN, Greden JF: Natural and Lymphokine-Activated Killer Cell Activities in Depression and Schizophrenia. Proceedings, 18th Congress of CINP. Nice, France. 1992 198. King CA, Naylor MW, Hill ED, Shain BN, Greden JF: Alcohol Use and Depression in Adolescent Inpatients. Presented at the annual meeting of the Research Society on Alcoholism. San Diego, California. June 1992 199. Nair MPN, Schwartz SA, Kronfol ZA, Greden JF: Suppression of Tumor Necrosis Factor by Alcohol in LPS Stimulated Human Whole Blood. Presented at the annual meeting of the Research Society on Alcoholism. San Diego, California. June 1992 200. Naylor MW, Kaminski KM, King CA, Ghaziuddin N, Greden JF: The Effect of Sleep Deprivation on Depression in Adolescents. 39th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington D.C. October 1992 201. Tandon R, DeQuardo JR, Mann N, Eisner W, Goodson J, Greden JF: Effects of Antimuscarinics on Positive and Negative Symptoms (in Schizophrenia). Panel discussion at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. December 1992 202. Tandon R, Shipley JE, Taylor S, Goodson J, Greden JF: Sleep Abnormalities in Schizophrenia: Cholinergic Contribution. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. December 1992 203. Tandon R, Ribeiro SCM, Perez M, Goodson J, Greden JF: Covariance of Positive and Negative Symptoms in Schizophrenia during Treatment with Typical Neuroleptics and Clozapine. Presented at the Annual Meeting of the College of Neuropsychopharmacology. San Juan, Puerto Rico. December 1992 John F. Greden, M.D. Page 59 Last Revised December 2019

204. Naylor MW, Kaminski K, King CA, Ghaziuddin N, Shipley JE, Greden JF: Predictors of Antidepressant Response to Sleep Deprivation in Depressed Adolescents. Poster presentation at the American Academy of Child & Adolescent Psychiatry 40th Annual Meeting. San Antonio, Texas. October 1993 205. Tandon R, Shipley JE, Taylor SF, Douglass A, Goodson J, Greden JF: Effects of Clozapine on Sleep-EEG Measures in Schizophrenia. Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, Hawaii. December 1993 206. Greden JF: Major Depression: A Lifetime Disorder. Symposium presentation at the American Psychiatric Association Annual Meeting. Philadelphia, Pennsylvania. May 1994 207. Greden JF: Caffeine Intake in Psychiatric Patients. Symposium presentation at the American Psychiatric Association Annual Meeting. Philadelphia, Pennsylvania. May 1994 208. Greden JF: Preparing to be a 21st Century Researcher. Component Workshop presentation at the American Psychiatric Association Annual Meeting. Philadelphia, Pennsylvania. May 1994 209. Greden JF: Continuation and Maintenance Treatment. Roundtable: Antidepressant Treatment: The State of the Art. Invited participant in American Society of Clinical Psychopharmacology (ASCP) Roundtable. Boston, Massachusetts. July 1995 210. Greden JF: Antidepressant Maintenance Strategies: Neglected Research Questions. Invited speaker for the Psychiatric Research Society annual meeting. Park City, Utah. February 1996 211. Greden JF: The New Psychiatry. Keynote address for the Psychiatric Society for Informatics annual meeting. New York, New York. May 1996 212. Ghaziuddin N, King C, Zaccagnini J, Weider-Mikhail E, Mellow A, Ghaziuddin M, Greden JF: Response to Serotonergic probe (mCPPMCPP) in Depressed Adolescents and Controls. Proceedings of the 52nd meeting of the Society of Biological Psychiatry. May 1997 213. Tandon R, Greden JF, Murray R, Waddington, J, Wyatt R, Lieberman J: Impact of Antipsychotic Treatment on Long- Term Course of Schizophrenic Illness. Symposium presentation at the 6th World Congress of Biological Psychiatry. June 1997 214. Rush J, Greden JF, Kornstein S, Nierenberg A, Sackeim H: Recognizing Treatment-Resistant Depression. Physicians Postgraduate Press Audiotape Series. Volume 4, Number 3, March 2001 215. DiFranco DF, Valenstein M, Kavanagh J, Shriberg R, Young EA, Greden JF, Blow FC: Managed Care Organizations Can Help Identify Potential Research Recruits. Institute on Psychiatric Services. October 2002 216. Brower KJ, Kim HM, Strobbe, SS, Karam-Hage MA, Zucker RA, Greden JF: A Randomized, Double Blind Pilot Trial of Gabapentin vs. Placebo to Treat Alcohol Dependence. Silverman Research Conference. May 2003 217. Brower KJ, Kim, HM, Karam-Hage MA, Zucker RA, Greden JF: A Double-Blind Randomized Clinical Trial of Gabapentin vs. Placebo for Treating Alcohol Dependence. Society of Biological Psychiatry’s Annual Convention and Scientific Program. May 2003 218. Brower KJ, Kim HM, Karam-Hage MA, Zucker RA, Greden JF: Pharmacotherapy of Alcoholism and Comorbid Insomnia. RSA Symposium on Alcohol and Sleep, 2003 219. Affective Disorders Consultation Panel. Invited Guest. Sponsored by Bristol-Myers Squibb. ACNP. San Juan, Puerto Rico. December 2003 220. Boyd AD, Hunscher DA, Kramer AJ, Hosner C, Saxman P, Athey BD, Greden JF, Clauw DC: The “Honest Broker” Method of Integrating Interdisciplinary Research Data. Poster presentation at the AMIA Annual Symposium. Washington, DC. October 2005 221. Rush AJ, Weissman MM, Fava M, McMahon FJ, Greden JF: STAR*D Outcomes: Acute and Longer-Term. American Psychiatric Association Annual Meeting. San Diego, CA. May 2007 222. Trivedi M, Tandon R, Ketter T, Glazer W, Greden JF: Florida Medicaid Drug Therapy Management Program for Behavioral Health: Expert Panel Meeting to Update the Florida Adult Mental Health Guidelines. University of South Florida. Tampa, Florida. July 2007.

John F. Greden, M.D. Page 60 Last Revised December 2019

223. Burns T, Greden JF, Tanielian T, Lester P, Karnik N, Simon, NM, Spinner J. Enhancing Capacity to Address Mental Health Needs of Veterans and Their Families: The Welcome Back Veterans (WVB) Initiative. Symposia, American Psychiatric Association Annual Meeting, Toronto, ON, Canada May 19, 2015 224. Parikh SV, Taubman DS, Antoun C, Cranford J, Foster CE, Grambeau M, Hunter J, Jester J, Konz K, Myer T, Salazar S, Greden JF. (2018). "The Michigan Peer-to-Peer Depression Awareness Program: School-Based Prevention to Address Depression Among Teens." Psychiatr Serv 69(4): 487-491. 225. DePaulo JR, Wang P, Greden JF. Learning Health Care Systems: Clinical Registries and Networks in Psychiatry. Presidential Symposium. American Psychiatric Association Annual Meeting, New York, NY May 7, 2018. 226. Greden JF, Parikh SV, Rosthschild AJ, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechario B. Combinatorial pharmacogenomics significantly improves response and remission for major depressive disorder: A double- blind, randomized control trial. American Psychiatric Association Annual Meeting, New York, NY. May 7, 2018. 227. Greden JF, Parikh SV, Rosthschild AJ, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechario B. Combinatorial pharmacogenomics to guide treatment selection for major depressive disorder (MDD): congruency matters. Society of Biological Psychiatry Annual Meeting, New York, NY. May 9, 2018. 228. Parikh SV, Salazar L, Salazar S, Taubman DH, Greden JF: The Michigan Peer-to-Peer Depression Awareness Campaign: School-Based Prevention to Reduce the Impact of Depression Among Adolescents. 9th Biennial Conference of the International Society for Affective Disorders in partnership with 2018 Houston Mood Disorders Conference- From Treatment Resistance to Recovery in Affective Disorders. Houston, TX. September 20-22, 2018. 229. Parikh SV, Salazar L, Salazar S, Taubman DH, Greden JF: The Michigan Peer-to-Peer Depression Awareness Campaign: School-Based Prevention to Reduce the Impact of Depression Among Adolescents. Poster presentation at National Network of Depression Centers 10th Annual Conference Baltimore, MD. October 17-19, 2018. 230. Greden JF, Parikh SV, Rosthschild AJ, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechario B. Combinatorial Pharmacogenetic Testing-Informed Medication Switching from Genetically Incongruent to Congruent Medications Leads to Decreased Side Effect-Burden for Patients with Depression. 57th Annual American College of Neuropsychopharmacology Meeting. Hollywood, FL. December 9-13, 2018. 231. Greden JF, Parikh SV, Rosthschild AJ, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechario B. HAM-D6 outcomes in a randomized, controlled trial evaluating the utility of combinatorial pharmacogenomics in depression. American Psychiatric Association Annual Meeting Poster Presentation. San Francisco, CA. May 18-22, 2019. 232. Greden JF, Parikh SV, Rosthschild AJ, Thase M, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Li J, Gilbert A, Burns L, Jablonski M, Dechario B. Pharmacogenomic Testing in Psychiatric Practice: Does it deliver what it promises? American Society of Clinical Psychopharmacology. Scottsdale, AZ. May 28, 2019. 233. Stanley BH, Greden JF. Fast Acting, Brief Interventions for Suicidal Patients. Mini Panel American College of Neuropscyhopharmacology 2019 Annual Meeting, Orlando, FL, December 8, 2019. (Submitted) 234. Parikh SV, Fiedorowicz J, thase ME, Rothschild AJ, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Brown L, Jablonski MR, Greden JF. Weight gain in patients with depression taking antipsychotics. American College of Neuropscyhopharmacology 2019 Annual Meeting, Orlando, FL, December 8, 2019. (Submitted)

John F. Greden, M.D. Page 61 Last Revised December 2019

235. Parikh SV, Bobo W, Vande Voort J, Lopez D, Rico J, Goes F, Singh B, Greden JF and the Biomarkers-of- Ketamine (BIO-K) Team. Comparison of Different Duration Regimens for Intravenous Racemic Ketamine: 100-minute versus 40-minute infusions for Refractory Depression. American College of Neuropscyhopharmacology 2019 Annual Meeting, Orlando, FL, December 8, 2019. (Submitted) 236. Greden JF. Pharmacogenomic Testing in Psychiatric Practice: Progress in Overcoming Conceptual Barrier for Clinicians. Anxiety and Depression Association in America, Anxiety and Depression Conference 2020, San Antonio, TX. March 19-22, 2020. (Submitted) 237. Parikh SV, Dunlop BW, Rothschild AJ, Thase ME, DeBattista C, Conway CR, Forester BP, Shelton RC, Macaluso M, Li J, Brown K, Jablonski MR, Dechairo B, Greden JF. Safety of Utilizing a Combinatorial Pharmacogenomic Test for Patients with MDD in the GUIDED trial. 173 American Psychiatric Association Annual Meeting, Philideplphia, PA, April 25 – 29, 2020. (Submitted) 238. Morganstein J, Riba M, Parikh SV, Pinals D, Blazes C, Wright J, Greden JF. Workplace Mental Health: Behavioral and Psychological Issues. 173 American Psychiatric Association Annual Meeting, Philideplphia, PA, April 25 – 29, 2020. (Submitted) 239. Shelton RC, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Macaluso M, Law RA, Hain DT, Lews DJ, Jablonski M, Greden JF. Combinatorial pharmacogenomic algorithm is significantly more predictive of citalopram and escitalopram metabolism than CYP2C19 phenotype alone. 173 American Psychiatric Association Annual Meeting, Philideplphia, PA, April 25 – 29, 2020. (Submitted)

Recent Articles, Interviews and Media 1. Depression and Bipolar Awareness: From Diagnosis to Remission, American Foundation for Suicide Prevention, Film; November 2011 2. MI Healthy Mind, Television Episode, February 8, 2016 air date 3. Let’s Fight Depression How We Fight Cancer: With Data, Michigan Radio (WUOM), Article & Interview; March 7, 2016. 4. Ask the Doctor: Making the Most of Your Medication, John F. Greden, Esperanza Magazine; August 1, 2016 5. Curious Minds: Ford Motor Company Media Cast; September 28, 2017. 6. The Wall Street Journal: Which Anti-Depressant is Right for You? Your DNA can Shed some light; May 6, 2018 7. CBS News, New York: Pharmacogenomics Interview Scheduled; May 7, 2018 8. TIME Magazine: A Genetic Test Could Help Predict the Right Antidepressant For YOU; May 7, 2018 9. MD Magazine: Genetic Testing Improves Short-and Long-Term Remission, Response Rates in MDD; May 7, 2018 10. Xconomy: Will New Study Cut Guesswork for Depression Medicine Prescriptions? May 7, 2018 11. Medscape: Genetic Test Identifies Best Antidepressant; May 7, 2018 12. GenomeWeb: Personlized Psychiatry; May 7, 2018 13. Fox 2 News, Detroit: Mental Health, Stigma and Precision Health: Brain linkages. Air-date: TBD (Fall, 2019)

John F. Greden, M.D. Page 62 Last Revised December 2019